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SUMMARY
Clironic bronchitis was first recognised as a disabling disorder in 1808. It is often a 
feature of chronic obstructive pulmonary disease, and recent studies have shown that the 
neutrophil and in particular neutrophil elastase, released by activated neutrophils, is 
implicated in the pathogenesis of chronic bronchitis including the facilitation of bacterial 
colonisation. The degree of neutrophil influx has been shown to be associated, not only 
with worse lung function, but also the rate of progression of airflow obstruction. Many 
patients with chronic bronchitis are colonised with bacteria in the stable clinical state but 
it is not known how this affects upper airways inflammation, disease progression, 
frequency of exacerbations, or quality of life.
Secretory leukoprotease inliibitor is thought to be the most critical anti-elastase in the 
upper airways whereas alpha-1-antitrypsin is thought to be less important, although 
more important at the alveolar level protecting against the development of emphysema. 
Patients with homozygous PiZ alpha-1-antitrypsin deficiency have decreased circulating 
(15-20% normal) and alveolar concentrations of alpha-1-antitrypsin which facilitate the 
development of early onset and rapidly progressive emphysema. About 30-40 % of these 
patients also have chronic bronchitis although the natme of the upper airways 
inflammation has not been studied.
There have been few studies assessing the complex interplay of inflammatoiy cells and 
appropriate mediators in patients with chronic bronchitis. The first study in this thesis 
investigated patients with chronic bronchitis and a wide spectrum of neutrophil influx to
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assess the relationships between: neutrophil influx (as reflected by sputum 
myeloperoxidase concentration) and the chemoattractants interleukin 8 and leulcotriene 
B4; active neutrophil elastase and the chemoattractants (interleukin 8 and leukotriene 
B4), its own inliibitor secretory leukoprotease inhibitor, and bronchial protein leak 
(leakage of albumin from serum into the airways); and finally FEVi (% predicted) and 
myeloperoxidase, interleukin 8 and leukotriene B4, secretory leukoprotease inhibitor, 
and bronchial protein leak.
The results showed that both interleukin 8 and leukotriene B4 correlate with the degree 
of neutrophil influx and elastase activity, although the relationship with interleukin 8 and 
neutrophil influx appeared to be curvilinear. Elastase activity that exceeded 50nM was 
associated with decreased levels of secretory leukoprotease inliibitor and increased 
levels of bronchial protein leak. Patients with chionic bronchitis without alpha-1- 
antitrypsin deficiency showed a negative correlation between FEVi (% predicted) and 
myeloperoxidase, interleukin 8 and leukotriene B4, and bronchial protein leak. Although 
the interrelationships were often significant, they were complex, and further 
understanding the interaction of various mediators will require the development of 
specific antagonists and appropriately designed intervention studies.
The second study investigated the effect of bacterial colonisation, bacterial load, and 
bacteria themselves on upper airways inflammation in patients with chronic bronchitis. 
This study highlighted that bacterial colonisation of sputum exceeding 10^  colony 
forming units/ml was associated with neutrophil influx in the upper airways, which 
increased with increasing bacterial load. Patients with a bacterial load of less than 10^
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colony forming units/ml had a similar degree of upper airways inflammation to samples 
where no pathogen or only mixed normal flora was isolated. Finally the study revealed 
that patients colonised with Pseudomonas aeruginosa had a more intense upper airways 
inflammatory response than patients colonised with Moraxella catarrhalis or non- 
typeable Haemophilus influenzae.
The third study assessed upper airways inflammation in patients with chronic bronchitis 
with and without PiZ alpha-1-antitrypsin deficiency in the stable clinical state, to 
determine the importance of alpha-1-antitrypsin in the upper airways and the effects of 
continued smoking. Patients with alpha-1-antitryspin deficiency had excessive upper 
airways inflammation despite being younger, including a greater proportion of ex­
smokers and more being on inhaled steroids (all of which would tend to limit the degree 
of inflammation). The results highlight the importance of alpha-1-antitrypsin in the 
upper airways. Ex smokers had lower levels of interleukin 8 compared to current 
smokers and was associated with less neutrophil influx (as determined by 
myeloperoxidase). The results suggest that the reduction in interleukin 8 levels was 
responsible for the reduced neutrophil influx and this mechanism may explain the slower 
rate of progression of lung disease compared to continuing smokers.
The final study assessed upper airways inflammation in patients with and without alpha- 
1-antitrypsin deficiency during an acute exacerbation. This study revealed that there was 
excessive upper airways inflammation in patients with alpha-1-antitrypsin deficiency 
which was probably due to the low baseline alpha-1-antitrypsin levels and the reduced 
acute phase response.
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1. INTRODUCTION
1.1 THE NORMAL BRONCHIAL TREE
The airways have important functions beyond gas conduction. This includes the 
warming and humidification of inhaled air, and acts as the primary host defence system 
cleansing inlialed air of potentially harmful dust particles and micro-organisms. The 
primary host defence system is relatively non-specific and includes:
1. nervous reflexes that cause bronchoconstriction and cough.
2. integrity of the bronchial epithelium and the efficiency of the mucociliary escalator, 
that prevent bacterial adherence, penetration, and facilitate their removal.
3. lung secretions proteins including lysozyme and laetofemn that prevent bacterial 
replication (Jacquot et al, 1987)(Ellison et al, 1991), as well as Immunoglobulin A 
(IgA) that prevent epithelial adherence of bacteria and viruses (Stockley, 1997).
4. cellular immune reactions to remove allergenic particles from the airways.
5. airway macrophages, the resident phagocytes that facilitate bacterial and particulate 
removal (Stockley, 1995).
The normal bronchial tree is kept sterile and animal experiments have shown that these 
defences are able to clear bacterial loads of up to 2x10^ colony forming units per ml 
(cfu/ml) (Onofrio et al, 1983) with little or no activation of the secondary host defences.
1.1.1 Development of the airways
On the 26^ *^  day after ovulation, the lung first appears as an epithelial bud (Boyden, 
1977), which is derived fr om endoderm, and will form the epithelium of the airways and 
the acini. As it elongates, it becomes invested in mesenchyme derived from mesoderm 
(Thurlbeck, 1981) which develops into the connective tissue, cartilage, smooth muscle 
and vessels of the lung. In the first few weeks of development, nerve fibres arising from 
ectoderm migrate into the mesenchyme to give the lung its motor and sensoiy 
connections (Longman, 1975). The developing lung bud divides into 2 halves and 
elongates, growing caudally on either side of the oesophagus. By about the 3 3"^  ^ day the 
trachea has become separated from the foregut, and pouches representing the 5 lobes are 
apparent. Subsequent dichotomous division leads to the development of the full adult 
complement of segments by the 41®^ day and to completion of the bronchial tree as far as 
the terminal bronchioles by the 16^ '^  week (Bucher et al, 1961).
1.1.2 Secretion of the airways
The bulk of the bronchial secretions is secreted by the serous and mucous cells of the 
bronchial glands, with important contributions from the goblet cells as well as from the 
serous and clara cells of the airway epithelium. Even in the normal airways, however, 
the bronchial secretions are contaminated by surfactant from alveoli and by fluid 
transudate from plasma. Sputum is a pathological secretion and consists of a mixture of 
bronchial secretions, cells and cellular debris, cleared organisms and saliva that is 
spontaneously expectorated.
1,1.2.1 Airway mucus
The functions of bronchial mucus include: waterproofing, diminishing water loss from 
the respiratory tract; protecting the bronchial epithelium by forming a baiTier between it 
and particles in the inhaled air; and defence both by removing inlialed particles as a 
result of ciliary activity, and by acting as a vehicle for immunoglobulins and other 
protective proteins.
Mucus is present over the bronchial epithelium as a continuous sol layer (or periciliary 
liquid), in which cilia beat, and a gel layer (on the surface of the cilia) (Richardson et al, 
1992) which is not continuous at the bronchiolai* level, but forms almost a complete 
covering of the epithelium in the larger airways.
The depth of the sol layer is about 5-10pm, which is just sufficient for the cilia during 
their effective stroke enabling them to propel the gel layer over the surface with their 
tips. The thickness of the gel phase is uncertain but values are between 2 and 20 pm. 
The gel is moved by mucociliary transport, being faster in the larger airways (human 
trachea is about 10mm min'^ with that in the bronchioles about 10 times slower). It is 
thought that the sol layer is probably derived largely from the clara cells at the 
bronchiolar level in the airway epithelium with some contribution from a fluid 
transudate (serum proteins including albumin, fibrinogen, alpha-l-antitrypsin, and 
immunoglobulins "leak" from the blood vessels in the mucosa due to transudation 
during airway inflammation (Persson, 1992)). The mucus gel phase of secretion is 
derived from several sources including goblet cells and serous cells in the airway
epithelium (Kim, 1994), clai'a cells at the bronchiolar level (Widdicombe et al, 1982), 
and the submucosal glands (Richardson et al, 1992)(Shimura et al, 1994).
There are many proteins identified in sputum sol phase (some of which include albumin, 
lysozyme, lactoferrin, immunoglobulins, alpha-l-antitrypsin, alpha-1-chymotrypsin, and 
secretory leukoprotease inhibitor (Stockley, 1997)). The gel phase consists of about 95% 
water, 1% salt, 1-3% proteins and mucoglycoproteins, and 1-3% proteoglycans and 
lipids (Boat et al, 1994).
The physical properties of mucus are provided mainly by mucins, which are high 
molecular mass (up to 15 MDa) mucoglycoproteins (King et al, 1994), although 
proteoglycans of lower molecular mass also contribute to viscosity. Phospholipids may 
be important in weakening adhesion of the mucus to the epithelium (Rubin et al, 
1992)(Puchelle et al, 1992).
Immunoglobulin A is an important component of bronchial mucus and predominates in 
the upper respiratory tract (Morgan et al, 1980), with Immunoglobulin G (IgG) and M 
contributing little (Burnett, 1986). In the lung most of the IgA is dimeric (linked by a 
peptide called the J chain), 70% is of the IgAl subclass and the remainder IgA2 
subclass. The dimeric form can prevent the epithelial adherence of bacteria and viruses 
but in addition other studies have shown that secretory IgA can interact with other arms 
of the immune system (enhancing macrophage phagocytosis (Richards et al, 1985) and 
facilitating antibody dependent cell mediated cytotoxicity in synergism with IgG (Shen
et al, 1981)). ïn addition it also plays a role in increasing the strength and stability of the 
mucus itself.
The immunoglobulins are relatively large molecules and transudation from plasma is 
therefore limited. Thus most of the immunoglobulins detected in lung secretions 
represent those made locally (secreted originally by B lymphocytes and plasma cells 
around the bronchial glands (Soutar, 1976)), facilitated by a special transport system for 
the passage of dimeric IgA into the lumen of the lung. The secretory component (N 
terminal sequence of a transmembrane Fca receptor) (Mostov et al, 1980) is expressed 
on the basal surface of bronchial epithelial cells and strongly binds dimeric IgA (to form 
an irreversible complex) and some unbound receptor. The complex is internalised by 
endocytosis, sorted in an endosomal compartment and incorporated into transcytotic 
vesicles. These vesicles translocate to the apical surface (Breitfeld et al, 1989), fuse with 
the membrane and the amino terminus, with the IgA attached, is cleaved (Musil et al, 
1987), and the secretory IgA molecule or ft'ee secretory component (both identified in 
lung secretions) is released (Stockley et al, 1981). The remainder of the polymeric IgA 
receptor (transmembrane segment and cytosol tail) is then transported to lysozomes for 
degradation (Stockley et al, 1981).
Other proteins such as lysozyme and lactoferrin participate in airway bacterial defence 
(Jacquot et al, 1987)(Ellison et al, 1991), whereas molecules such as catalase and 
glutathione that are detected in the lower respiratory tract may play a role in the oxidant 
and anti-inflammatory properties of airways secretions (Cantin et al, 1990). The anti-
protease secretory leukoprotease inliibitor is produced locally in the lung by epithelial 
cells (Maruyama et al, 1994), and is present in serous glands (De Water et al, 
1986)(Mooren et al, 1983) and clara cells (Sallenave et al, 1993). It acts as the main 
bronchial inhibitor against neutrophil elastase (Kramps et al, 1988), but in addition has 
broad spectrum antibiotic activity that includes anti-retroviral, bactericidal, and 
antifungal activity (Tomee et al, 1998).
1.1.2.2 Mucus and bacteria
The mucus gel acts as a barrier for bacteria, which adhere to it and can then 
subsequently multiply witliin it (Puchelle et al, 1992). Mucins have chemical receptors 
that can bind to the adhesins on many bacteria but other mucus receptors that may be 
active in binding to bacterial adhesins include glycolipids, which are found in airway 
secretions. The adhesins on common respiratory pathogens include the pilin proteins in 
fimbriae, mucoid exopolysaccharride, haemagglutinins, internal lectins, exoenzyme S 
and non pilus protein components (Widdicombe et al, 1990)(Girod et al, 1992). The 
respiratory pathogens that bind strongly to mucus include Streptococcus pneumoniae, 
Haemophilus influenzae. Staphylococcus aureus and Pseudomonas aeruginosa.
Colonised bacteria may also promote further mucus secretion (Adler et al, 
1986)(Somerville et al, 1992). This increase has been shown in response to several 
bacterial species Haemophilus influenzae. Staphylococcus aureus. Streptococcus 
pneumoniae and Pseudomonas aeruginosa, and the active secretory agents have been 
established as proteases and rhamnolipids (Adler et al, 1986)(Somerville et al,
1992).This process could be advantageous to the host if it promotes greater cleai'ance of
7
mucus from the airway by cough (although this could also lead to bacterial spread) but a 
disadvantage of the increased mucus secretion would be blockage of the smaller airways 
and a further nidus for bacterial multiplication.
1.1.3 Mucociliary clearance
1.1.3.1 Cilia
The ciliated cell predominates in the tracheo-bronchial epithelium, although reduced 
numbers are present at the bronchiolar level (Shimura et al, 1994)(Widdicombe et al, 
1995). There are approximately 200-300 cilia per cell, each is 4-6 pm long and about 
0.1-0.2 pm in diameter, and beats at 1000 beats per minute with co-ordination between 
adjacent cells (Sleigh et al, 1988). Microvilli project between the cilia and are thought to 
play a role in fluid absorption and therefore control the depth of the periciliary fluid 
layer with in which the cilia beat.
The tips of the cilia end in small claws that engage the overlying mucus gel, enabling it 
to be transported (Jeffery et al, 1975). In the cross section of the cilium there are 9 outer 
microtubular doublets and two central single microtubules linked by dynein arms 
(consist of an ATPase protein), nexin links, and spokes (Figure 1-1). The bending of the 
cilia depends on the active sliding of the peripheral microtubules relative to each otlier, 
based on the dynein bridges. ATP is the soiu’ce of energy for this process and dynein 
acts as an ATPase protein.
In man the ciliary beat frequency appears uniform in the large and small airways (15- 
18Hz). The ciliary beat cycle has 2 components: movement towards the larynx which is 
the effective stroke followed by a recovery stroke in the opposite direction when the 
cilia disengage from the mucus and bend as they recover (Sleigh et al, 1988). The action 
of the cilia both in a single cell and between adjacent cells is co-ordinated in health 
(Sanderson et al, 1981).
Central pair of 
microtubules
Outerdoublet
microtubules
Interdoublet 
nexin connection
Inner dynein arm
Outer dynein arm
Plasma 
membrane
Radial
spoke
Projections from 
central pair
Figure 1-1: Diagrammatic cross section of a cilium.
The intracellular control of ciliary action depends on ATP, cATP, cGMP, and protein 
kinase C, in addition to ionic calcium (Wanner, 1994). All increase ciliary beat 
frequency except for protein Kinase C which decreases it. Baseline ciliary activity does 
not seem to be under nervous control, but acetylcholine and beta] adrenoceptor agonists 
increase ciliary beat frequency. Vasoactive intestinal polypeptide stimulates ciliary 
movement and may coact with acetylcholine as both are released from parasympathetic 
nerves. The sensory neuropeptides, for example substance P, stimulates ciliary activity.
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so this action may be a feature of neurogenic inflammation when the sensory nerves are 
excited.
Most inflammatory mediators affect ciliary activity. It is increased by prostaglandins El 
and E2, leukotrienes C4 and D4, and bradykinin whereas platelet activating factor is said 
to inhibit ciliary beating (Wanner, 1994).
Some of the proteases, including neutrophil elastase and the elastases from 
Pseudomonas aeruginosa inhibit cilia (Widdicombe et al, 1990)(Wilson et al, 1987). 
Other bacterial products such as rhamnolipid and pyocyanin (Wilson et al, 1987) also 
inliibit cilia as do oxygen radicals. Some of these effects are due to activation of protein 
kinase C.
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1.1.3.2 Mucociliary transport a
The clearance of mucus with any entrapped material depends, in part, only on ciliary n
activity (Hasani et al, 1989)(Pucheile et al, 1980)(Yeates et al, 1975)(Pavia, 1984). 
Other factors include cough, amount of mucus present, viscoelasticity of the mucus, and 
adhesiveness to the airway epithelium. Mucociliary transport (Hasani et al, 1989)(Pavia, 
1984) has 2 phases, a fast phase taking a few hours in healthy people due to clearance by 
cilia and cough and a slower phase with a half life of weeks or months that represents 
alveolar clearance.
Inflammatory mediators may have actions that are different for ciliary beat frequency 
and mucociliary transport (Wanner, 1994). For example histamine increases mucociliary 
transport in man, but has little action on the ciliary beat.
1i
i
In airway diseases, structural damage to the epithelium and secretion of mucus with 
increased adhesiveness may be more important factors in determining mucociliary 
transport than changes in ciliary beat frequency (Puchelle et al, 1992)(Girod et al, 1992) 
(mucociliary transport is impaired in chronic bronchitis when the ciliaiy beat of
individual epithelial cells may be normal).
#.ipi
;
!
:#
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1.1.4 The airway wall
This comprises epithelial, lymphoid, miisculai’, vascular, and nervous elements 
interspersed in a connective tissue support arranged as a) a lining mucosa of surface 
epithelium, basement membrane, and supporting elastic lamina propria; b) the 
submucosa in which lie the glands, muscle and cartilage; c) adventitial coat.
If the layer of the mucus overlying the epithelium is inadequate to protect the mucosa, 
the airway epithelium presents the next important barrier (Laitinen et al, 
1991)(Mmiakata et al, 1991). Smooth muscle becomes 3-5 times more responsive to 
contractile drugs such as luminal acetylcholine, histamine and 5 hydroxytryptamine 
(Munakata et al, 1991)(Barnes, 1991) following removal of the epithelium. Experiments 
with B] adrenoceptor agonists are far more effective when applied to the serosal side of 
the airway wall than when presented at the mucosal side (Munakata et al, 1991). This 
difference in sensitivity disappears when the epithelium is removed suggesting the 
epithelium is acting as a barrier. Measiuement of the permeability of radiolabelled 
tracers through the epithelium or the airway mucosa supports the view that the 
epithelium can be a major barrier (Hanafi et ai, 1994)(Wells et al, 1995) especially for 
hydrophilic molecules. In isolated ferret trachea, epithelial damage by platelet activating 
factor increases the permeability coefficient about 8 fold (Hanafi et al, 1994). In vivo 
where penetration has only to be through the epithelium to reach the copious vascular 
network , the coefficient of permeability to DTPA is increased 50 fold (Morikawa et al, 
1991) by epithelial destruction. With lipophilic agents, on the other hand, destruction of 
the epithelium makes no difference to the permeability (Hanafi et al, 1994). The 
epithelium is also a strong barrier to macromolecules and, in healthy airways,
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horseradish peroxidase penetrates the epithelium only up to the tight junctions between 
cells (Hogg, 1990). If tight junctions are opened by the effect of histamine or cigarette 
smoke for example, the peroxidase penetrates through the epithelium to the basement 
membrane (Hogg, 1990)(Hulbert et al, 1981).
1.1.4.1 Bacterial-epithelial interaction
Many bacteria adhere more to mucus than to undisrupted epithelium provided the latter 
is healthy (Puchelle et al, 1992)(Widdicombe et al, 1990)(Girod et al, 1992). Most 
respiratory pathogens, apart from Mycoplasma pneumoniae and Bordatella pertussis 
will not adhere to epitheliiun until it has been damaged by toxins or proteases 
(Tuomanen et al, 1983)(Bredt et al, 1982). Airway pathogens such as Non typeable 
Haemophilus influenzae. Streptococcus pneumoniae, and Staphylococcus aureus adhere, 
however, powerfully to damaged cells, both ciliated and non ciliated (Widdicombe et al, 
1990)(Plotkowski et al, 1989)(Feldman et al, 1992). Bacteria use a wide range of 
adherence mechanisms, examples include lectin like substances which are found 
embedded in the outer membrane, the secretion of exopolysaccharide, or the expression 
of hair like outgrowths called fimbriae (Wilson et al, 1997).
1.1.4.2 Surface epithelium
This includes the surface lining of the airway epithelium and submucosal glands. The 
epithelium consists of pseudostratified, ciliated, columnar cells. There are many 
different epithelial cell types including the ciliated cell (described above), goblet cell, 
serous cell, clara cell, endocrine, basal and brush cells, and finally transitional forms 
(Jeffery et al, 1975)(Breeze et al, 1977)(Jeffery, 1983). There are also cells involved in
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the immune response that may migrate through the epithelial basement membrane, some 
of which remain within the surface epithelium whereas some pass into the aiivvay lumen 
(McDermott et al, 1982). The terminal processes of nerve fibres whose cell bodies lie 
deep to the epithelium, also pierce the epithelial basement membrane and are thought to 
initiate airway reflexes such as cough and bronchoconstriction (Richardson et al, 1981).
1.1.4.3 Migratorv cells
In health, neutrophils are rarely found in the airways but are rapidly recruited in 
inflammatory states. In the normal healthy epithelium the following mononuclear 
migrating cells are found: a) intraepithélial lymphocytes and b) intraepithélial mast cells. 
The intraepithélial lymphocyte may occui' alone or in groups (McDermott et al, 1982) 
and functions to remove allergenic particles from the airways. They maybe either T or B 
cells, although few B lymphocytes are found in this compartment (Pabst, 1997). The T 
cell surface markers normally identified in the bronchial epithelium include the universal 
lymphocyte marker CD3+ cells, as well as the more specific CD4+ and CD8+ cells 
(preponderance of CD8+ cells compared with CD4+ cells in the epithelium (Bradley et 
al, 1976) but conversely the CD4+ cells predominate over CD8+ cells in the lamina 
propria (Azzawi et al, 1990)). The immunostimulation of resting T lymphocytes is 
thought to require the initial presentation of antigen in association with class II major 
histocompatibility complex (la) molecules expressed by normal dendritic cells (Holt,
1993). It appears that T cell immunity is regulated by a balance of signals from resident 
la positive dendritic cells and macrophages (Holt et al, 1989)(Holt et al, 1990).
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The intraepitheiial mast cell and subepithelial mast cell is morphologically and 
functionally distinct from the mast cell present in the connective tissue (Enerback,
1986). Both are capable of releasing mediators of inflammation which affect epithelial 
and vascular permeability. A greater number of these cells are found in the lung tissues 
of smokers (Lamb et al, 1982).
1.1.4.4 Submucosal glands
These are numerous (4000 glands are present in the human trachea (Tos, 1970)) and are 
probably the major source of tracheobronchial mucus. Each gland unit is of the 
tubuloalveolar type and in humans it is composed of 4 regions, the lumina of which are 
continuous (Meyrick et al, 1969)(Meyrick et al, 1970): a) the ciliated duct is continuous 
with the surface epithelium; b) a wider collecting duct of cells of indeterminate 
morphology or of eosinophilic cells packed with mitochondria c) mucous tubules and 
acini; 4) serous acini. Although mucins of both acidic and neutral type ai’e produced, 
other secretions such as lysozyme (Bowes et al, 1977), lactoferrin (Bowes et al, 1981), 
secretory component of IgA (Brandtzaeg, 1974) and low molecular weight 
antiproteinase secretory leukoprotease inhibitor (Kramps et al, 1981) are also found in 
submucosal glands, particularly in serous acini. In addition lymphocytes and plasma 
cells which are responsible for the production of IgA (Soutar, 1976) are found in the 
gland. The submucosal gland mass increases in chronic bronchitis, which is the result of 
cell proliferation within each secretory acinus rather than of increase in the number of 
gland imits (Douglas, 1980).
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1.2 CHRONIC BRONCHITIS
1.2.1 General background
1.2.1.1 Historical background
The recognition of chronic bronchitis as a common and often gravely disabling disorder 
dates from the early nineteen century. Bronchitis was first described by Badham in 1808 
(Badham, 1808) and then subsequently by Mackintosh in 1831 (Mackintosh, 1831) and 
Laennec in 1834 (Laennec, 1834). In 1923 a detailed review of morbidity and mortality 
statistics was undertaken by Collis (Collis, 1923). He commented that despite records in 
England and Wales showing that bronchitis was the most important of all diseases when 
morbidity and mortality were taken together, “those called upon to treat it do not find it 
sufficiently interesting to study closely”. Renewed interest in bronchitis however came 
after a severe smog in 1952 (5^ *^  to 9^  ^December). Within 1 week, there were 4000 extra 
deaths which occurred mainly in people already suffering from cluonic respiratory or 
cardiovascular disease. Since this period there has been intensive research into the 
epidemiology, aetiology, and natural history of chronic bronchitis.
Until 1959, there was diagnostic confusion between the use of the terms chronic 
bronchitis and emphysema. In 1959 a group of British workers (Ciba Guest Symposium 
(Symposimn, 1959)) proposed that the diagnostic confusion could be alleviated by 
defining emphysema on an anatomical basis and chronic bronchitis on a clinical basis. 
They defined emphysema as enlargement of air spaces with destructive changes in their 
walls and chi'onic bronchitis as chronic or recurrent excessive mucus production in the 
bronchial tree that was not attributable to other lung diseases. Although this gained wide 
acceptance, the term chronic bronchitis continued to be used without qualification to
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indicate on one extreme of regular production of small quantities of sputum without any 
abnormality of lung function and at the other extreme severe airflow obstruction. In 
1965, the Medical Research Council (Medical Research Council, 1965) addressed this 
issue, and proposed that chronic bronchitis be classified into "simple" chronic bronchitis 
with mucoid hypersecretion, chronic or recurrent mucopurulent bronchitis 
(expectoration that has occurred on most days during at least 3 consecutive months for 
more than two successive years), and cluonic obstructive bronchitis.
1.2.1.2 Prevalence
The college of general practitioners conducted a survey of sample practices through 
Britain aged 40-64 yeai's (Practitioners, 1961), and found that the prevalence of chronic 
bronchitis was 17% for males and 8% for females. These figures were similar to figures 
from New Hampshire, USA, where the prevalence was 22% for males and 9% for 
females (Ferris et al, 1962). A much lower prevalences has been found in parts of Africa 
where there are low rates of smoking (Cookson et al, 1978).
1.2.1.3 Burden
Cluonic bronchitis and emphysema is the fourth leading cause of mortality in the USA 
with age adjusted death rate of 21 per 100,000 (Ventiua et al, 1997) (UK (1994) around 
12/100,000 mortality rate (Organisation, 1996)). Mortality statistics are, however, based 
on the underlying cause of death listed on death certificates, and because chronic 
bronchitis and emphysema are often not listed as the underlying cause of death, 
mortality statistics may underestimate the true burden of disease (Mannino et al, 1997). 
Mortality is related to the number of cigarettes smoked per day with more than a twofold
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difference between light (<15 cigarettes per day) and heavy (>25 cigarettes per day) 
smokers in the British physicians study (Doll et al, 1976). In the Seven Countries study 
clironic bronchitis and emphysema was found to be a clear predictor of excess all cause 
mortality in the populations studied (Menotti et al, 1997).
1.2.1.4 Demogranhic characteristics
Men have a higher prevalence of chronic bronchitis in most population based studies, 
and this difference persists after adjustment for smoking but not after adjustment for 
occupational exposures (Sherrill et al, 1996). It is not clear whether men or women are 
more susceptible to cigarette smoke. A recent finding, however, from two population 
studies of nearly 14,000 Danish adults, followed for up to 16 years, revealed that female 
smokers had greater losses in lung function and were at significantly increased risk of 
being hospitalised for chronic bronchitis than male smokers (Prescott et al, 1997).
Prevalence and mortality data for chronic bronchitis based on race and ethnicity, 
suggests that blacks, Hispanics, and Asian/Pacific Islanders are at lower risk than whites 
for developing chronic bronchitis (Petty et ai, 1997). Many potential factors could 
account for these racial disparities including differences between the age structure, 
smoking habits, occupational exposures, education, income, and genetic make up of the 
population.
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1.2.1.5 Aetiology of chi'onic bronchitis
1.2.1.5,1 Smoking
Chronic bronchitis has been mainly associated with the inhalation of cigarette smoke
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(pipe and cigar smokers have a much lower prevalence of the disease and less
impairment of function (Olsen et al, 1960)(Higgins, 1959)). A sample survey in urban
and rural populations in Britain found, that the prevalence of chronic bronchitis in males |
aged 55-64 was 17.7% for heavy smokers, 13.9% for light smokers, 4.4% for ex­
smokers, and nil for non smokers (Higgins, 1959). Prevalence studies in at least 10 
countries have confirmed the association between smoking and chronic bronchitis 
(Fletcher, 1968). |
The most important evidence relating smoking and mortality was published by Doll and 
Peto (Doll et al, 1976). They found that the death rate for chronic bronchitis was |
significantly higher for cigarette smokers than non smokers and increased with the 
amount smoked (bronchitis mortality per 100,000 British male doctors was 3 for non
smokers and 114 for subjects smoking > 25 cigarettes per day). Recent population based y
■studies in China have provided further evidence of a causal link between smoking and 
death from chronic bronchitis. Lam et al (Lam et al, 1997) found, in a cohort study of 
factory workers followed up over 20 years, an adjusted relative risk of chronic bronchitis
'mortality of 4.1 in male and 26.6 in female ever smokers compared with never smokers. 
Another prospective study of factory workers in Shanghai followed up for 16 years 
indicated a relative risk for chronic bronchitis mortality of 2.5 for male smokers 
compared with never smokers, and a strong dose response relationship (Chen et al.
1997). j
Pathogenesis
Smoke induces mucosal gland hypertrophy (Megahed et al, 1967)(Greenberg et al, 
1967)(Thurlbeck et al, 1967) and increased mucus secretion. This, together with the 
inhibitory effect of cigarette smoke on the bronchial ciliary blanket (Goodman et al, 
1978), predisposes to the accumulation of mucus in the bronchial tree.
Cigarette smoke recruits inflammatory cells in the lungs and studies have shown 
increased numbers of neutrophils in broncho-alveolar lavage fluid from smokers 
(Reynolds et al, 1974)(Huiminghake et al, 1983). In addition the lungs of smokers with 
airflow obstruction contain more neutrophils than smokers without airflow obstruction 
(Stanescu et al, 1996)(Di Stefano et al, 1998) and the number of neutrophils recovered 
are related to the amount smoked (Bosken et al, 1992). These observations are consistent 
with a major role for the neutrophil in the pathogenesis of chi’onic bronchitis. In vitro 
and in vivo work have demonstrated that neutrophil elastase, released from the activated 
neutrophil, can cause epithelial damage (Amitani et al, 1991), reduce ciliary beat 
frequency (Smailman et al, 1984), produce mucus gland hyperplasia (Snider et al, 1985), 
stimulate mucus secretion (Sommerhoff et al, 1990), and inactivate many critical lung 
host defences (Solomon, 1978)(Tosi et al, 1990). Thus neutrophil elastase alone can 
reproduce most of the typical features of clironic bronchitis.
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There may be several ways in which cigarette smoke could increase neutrophil traffic 
into the lungs and hence release of neutrophil elastase (Janoff et al, 1983):
a) neutrophil chemotaxis
Cigai*ette smoke has been shown to stimulate bronchial epithelial cells to produce 
interleukin 8, an important neutrophil chemoattractant (Mio et al, 1997), and indeed 
current smokers have been found to have raised interleukin 8 levels (Keatings et al,
1997). Nicotine itself has been shown to be a neutrophil chemoattractant in vitro (Totti 
et al, 1984), and finally cigarette smoke can stimulate alveolar macrophages to release 
neutrophil chemoattractants (Humiinghake et al, 1983).
b) upregulation of adhesion molecules
Smokers with airflow obstmction, have increased expression of adhesion molecules 
including E selectin on submucosal vessels (Di Stefano et al, 1994), intercellular 
adhesion molecule-1 (ICAM-1) in bronchial epithelium (Di Stefano et a), ) 994), and 
sputum leukocyte beta 2 integrins (GDI lb and CD 18) (MaestrelH et al, 1996). All of 
these adhesion molecules are critical in the process of neutrophil migration from the 
vascular space into the lung.
c) reduction in neutrophil transit time
In vitro studies have demonstrated that oxidants (Drost et a f 1992), but not nicotine 
(Aoshiba et al, 1994), from cigarette smoke reduce nev^bophc aefomiability. The 
reduced deformability would reduce the neutrophils ability to pass tlnough the
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pulmonary circulation. This possibility is supported by in vivo studies confirming a 
delay in transit time in lungs immediately after smoking (Bosken et al, 1991).
d) inactivation of alpha-1-antitrvosin
Cigarette smoke can inactivate alpha-1-antitrypsin in vitro probably by oxidation of the 
active site methionine (Carp et al, 1978), and indeed a 40% reduction of functional 
alpha-1-antitrypsin has been demonstrated in broncho-alveolar lavage fluids of human 
smokers (Gadek et al, 1979). Local inactivation of alpha-1-antitrypsin could also be the 
result of oxidants released from activated neutrophils and macrophages (Claik et al, 
1981)(Harris et al, 1970). It has been proposed that this process may increase the f
likelihood of lung damage due to proteinase release. Other studies, however, have not 
confirmed a reduction in functional alpha-1-antitrypsin (Boudier et al, 1983)(Stone et al, 
1983)(Stockley et al, 1984), except perhaps transiently (Abboud et al, 1985) and this 
mechanism remains unproven.
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1.2.1.5.2 Atmospheric pollution
Atmospheric pollution has been implicated as an aetiological factor. Studies in Britain 
demonstrated an increased prevalence of and mortality from chronic bronchitis with 
increased inbanisation (Practitioners, 1961)(Reid, 1964)(Holland et al, 1965)(Holland et 
al, 1965)(Lambert et al, 1970). An increase in bronchitic symptoms has been shown to 
relate to an increase in pollution (Waller, 1978), and studies in Canada, USA, and Japan 
have confirmed the relationship between pollution and bronchitis (Service, 
1967)(Oshima et al, 1964).
The precise factor or factors in atmospheric pollution responsible for the effects remain 
unknown. Animal models have demonstrated that many of the features of chronic 
bronchitis can be mimicked after exposine to tobacco smoke (Lamb et al, 1969)(Jeffery 
et al, 1981) and inhalation of sulphur dioxide (Lamb et al, 1968). Smoke may be the 
most important as the two great London smogs of 1952 and 1962 were both associated 
with a rise in bronchitis mortality (Reid, 1964). However although the sulphur dioxide 
concentrations were similar' in both year's, the smoke concentration was much lower in 
1962 as was the associated mor-tality (Reid, 1964).
Since the introduction of the Clean Air Act, there has been substantial reduction in 
smoke levels and lesser reductions in sulphur dioxide in Britain (Waller, 
1978)(Economics, 1977). In Sheffield where there has been a substantial decrease in 
pollution, a study showed that patients during the later, less polluted period, had less 
productive cough, fewer winter illnesses, less severe breathlessness, and only a third of 
the rate of decline in FEVi compared with those who were studied in the earlier highly
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polluted period (Howard, 1974). Recent studies in the USA have also shown a persisting 
increased mortality from non malignant cardiopulmonaiy disease (although not 
specifically chronic bronchitis mortality) associated with urban air pollution (Dockery et 
al, 1993) although lower than 30 years earlier when pollution was higher.
1.2.1.5.3 Infection
Childhood infections
Evidence relating childhood respiratory infection and chronic respiratory symptoms in 
adult life was published by Colley (Colley et al, 1973) who showed that chronic winter 
cough was more common at the ages of 20 and 25, both for smokers and non smokers, 
who had a lower respiratory tract illness before the age of 2. Similarly in Arizona, 
Lebowitz and Burrows (Lebowitz et al, 1977) found a significant relationship between 
poor respiratory function and a history of childhood respiratory illness or recurrent 
respiratory infections in adult life. Nevertheless caution should be employed in assuming 
that the association between childhood respiratory infections and adult chionic 
bronchitis is causal as both may relate to poor social circumstances or a genetic 
predisposition.
Exacerbations
Both virus (Grist, 1967)(Buscho et al, 1978) and bacterial infection have been 
implicated in exacerbations of chronic bronchitis (Turk et al, 1967)(May et al, 
1973)(Stuart-Harris, 1968)(Tager et al, 1975). Long term studies in England by Fletcher 
(Fletcher et al, 1977) and in Canada by Bates (Bates, 1973) found that deterioration in 
lung function occurred independently of respiratory infections. Fletcher and Peto
25
(Fletcher et al, 1977) in their 8 year prospective study of working men in London found 
that broncho-pulmonary infection caused an acute decline in lung function but that 
recovery was complete. Although these authors found an association between mucus 
hypersecretion, increased frequency of infection and lower absolute levels of FEV] they 
concluded that neither mucus hypersecretion nor bronchial infection caused FEV] to 
decline more rapidly, as after adjustment for age, smoking and FEVi left no independent 
correlation between indices of mucus hypersecretion or bronchial infection and ammal 
decline in FEV;, The epidemiological data, however, that indicated a lack of effect of 
broncho-pulmonary infections and an accelerated decline in FEV i was derived from men 
with mild airflow obstruction and few individuals with severe obstruction. Once 
obstruction has developed hypersecretion and/or infections may therefore accelerate the 
subsequent decline in FEVi. This was demonstrated by a large community study in 
Copenliagen (Lange et al, 1990) in which hypersecretion was associated with a relative 
risk of death from chronic bronchitis of 1.2 if the FEVi was 80% predicted but a risk of
4.2 if the FEVi was 40% predicted. With the known potential for an infection to cause 
lung tissue damage, it seems surprising that bronchial infection does not cause the FEV j 
to decline more rapidly and further studies are clearly indicated.
1.2.1.5,4 Genetic factors
Preliminary studies from Eriksson in 1964 confirmed that pulmonary emphysema was 
related to homozygous PiZ alpha-1-antitrypsin deficiency (Eriksson, 1964) and that 
clii'onic bronchitis was common with reported prevalences from 20-59% (Eriksson, 
1965)(Brantly et al, 1988)(Tobin et al, 1983). The role of alpha-1-antitrypsin deficiency 
in the pathogenesis of lung disease is discussed in greater detail later.
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Alpha-1-antitrypsin deficiency however accounts for less than 1% of cases of chi'onic 
bronchitis in the USA (Bresnitz, 1997). Other genes, however, may influence the 
development of chronic bronchitis and the susceptibility to develop lung disease with 
smoking or other environmental factors is likely to depend on the coincidence of several 
gene polymorphisms that act together.
Few polymorphisms have been studied in patients with chronic bronchitis, although both 
polymorphism in the 5' promoter region of the tumour necrosis factor-alpha (TNF-a) 
gene (Huang et al, 1997) and the microsomal epoxide hydrolase gene (Smith et al, 1997) 
have been found to be more prevalent in patients with chronic bronchitis and 
emphysema. The polymorphism of the TNF-a gene would result in an increased 
transcription of TNF-a on activation (Wilson et al, 1997)(Kioeger et al, 1997) and 
increase in TNF-a concentrations (Louis et al, 1998), which may be a mechanism to 
promote neutrophil influx in such patients. The polymorphism of the microsomal 
epoxide hydrolase gene results in a slow metabolising form of the enzyme (Hassett et al, 
1994) that metabolises highly reactive epoxide intermediates that may be formed in 
cigarette smoke, and such patients may thus be more susceptible to the effects of 
cigarette smoke.
Recent data by Silverman and colleagues demonstrated that after adjusting for age and 
pack-years of smoking, odds ratios for reduced FEV; and chronic bronchitis were 
increased in current or ex-smoking first-degree relatives of early-onset probands with
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clii'onic bronchitis, suggesting that other non identified genetic factors are likely to be 
important (Silverman et al, 1996)(Silverman et al, 1998).
1.2.1.5.5 Occupation
A recent population based study in New Zealand found that chionic bronchitis and 
airway obstruction were significantly associated with working with vapours, gases, dust, 
or fumes (Fishwick et al, 1997). Elevated odds ratios for the development of chronic 
bronchitis were found in specific occupational groups including bakers, chemical 
processors, and spray painters. Hendrick (Hendrick, 1996), in a recent review of the 
occupational lung disease literature, concluded that employment in certain occupations 
was likely to influence the development of chi'onic bronchitis, possibly due to complex 
adverse interactions with smoking and other environmental agents.
1.2.1.5.6 Airway hyper-responsiveness
This is known to be a risk factor for accelerated rate of decline in FEV, (Silverman et al, 
1996) but its role in the development of chronic bronchitis is unclear. Prospective data 
from a 24 years follow up of a cohort of more than 2600 adults in the Netherlands 
showed that increased airways hyper-responsiveness was a positive predictor of the 
development of chronic respiratory symptoms including cough, phlegm, dyspnoea, 
asthma attacks, and persistent wheeze, and was a negative predictor of the remission of 
these symptoms (Xu et al, 1997).
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1.2.2 Pathogenesis of chronic bronchitis
1.2.2.1 Pathology
There Is airway wall inflammation (Mullen et al, 1985) associated with hypersecretion 
of mucus, goblet cell hyperplasia, enlargement of tracheo-bronchial submucosal glands, 
and a disproportionate increase in acidic mucus (Reid, 1954)(Wright et al, 
1983)(Thurlbeck, 1990)(Jeffery, 1997), The mucus gland size can be assessed by 
measining the thickness of the gland layer in histological sections compared to that of 
the bronchial wall (Reid index) (Reid, 1960) or alternatively by measurement of the 
absolute gland area or by the volume proportion of the glands, both of which correlate 
better with ante-mortem sputum production than the Reid index (Jamal et al, 1984). The 
mucus secreting goblet cells are increased in the bronchi and bronchioles (readily 
blocked by their secretions) but not in the terminal or respiratory bronchioles 
(Thurlbeck, 1976)(Lumsden et al, 1984). Other epithelial changes may include atrophy, 
focal squamous metaplasia, ciliary abnormalities, and decreases in both ciliated cell 
number and mean ciliary length (Jeffery, 1998).
1.2.2.1.1 Cellular changes
Early studies have shown that the inflammatory process present in the bronchial mucosa 
of subjects with chronic bronchitis is characterised predominantly by macrophages and 
activated T lymphocytes (Mullen et al, 1985)(Fournier et al, 1989)(011erenshaw et al,
1992)(Saetta et al, 1993). Such patients had an increased number of cells expressing 
interleukin-2 receptor and very late activation antigen-1, representing T lymphocytes at 
different stages of activation (Saetta et al, 1993). Bronchial biopsies have shown that this
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inflammatory process may persist even after smoking cessation, in subjects who 
continue to have symptoms of chi'onic bronchitis (Turato et al, 1995).
The T lymphocytes that were increased in patients with chionic bronchitis were CD3+ 
(Saetta et al, 1993) with no significant differences in CD4+ and CD8+ T lymphocytes in 
the lamina propria. A further study by O'Shaughessy and colleagues (O'Shauglmessy et 
al, 1997), however, have shown that compared to non smoking controls, patients with 
clu'onic obstructive bronchitis had increased numbers of macrophages, and CD3+ and 
CD8+ T lymphocytes in the lamina propria, and that the CD8+ T lymphocytes 
negatively correlated with FEVi (% predicted) (O'Shaughnessy et al, 1997).
The influence of airflow obstruction, was addressed by comparing patients with chronic 
bronchitis with and without airflow obstruction, showing that patients with chronic 
bronchitis with airflow obstruction have greater number of macrophages and T 
lymphocytes (CD3+ cells) and that the T lymphocytes negatively correlated with FEV] 
(Di Stefano et al, 1996). Di Stefano and colleagues studied smokers with chronic 
bronchitis with a wider range of airflow limitation and found that patients with chronic 
bronchitis with severe airflow limitation (FEVi <50% predicted) had increased numbers 
of neutrophils, macrophages, and NK lymphocytes in the lamina propria and that FEV] 
inversely correlated with the numbers of neutrophils, macrophages, and NK 
lymphocytes (Di Stefano et al, 1998). The authors postulated that neutrophils may be of 
importance in disease progression (Di Stefano et al, 1998).
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1.2.2.1.2 Adhesion molecules
Adhesion molecules are critical in the process of neutrophil migration from the vascular 
space into the lung. It has been shovyn that in patients 'with chronic bronchitis with 
airway obstruction, there is an increased vascular expression of adhesion molecules E- 
selectin on submucosal vessels, ICAM-1 on bronchial epithelium (Di Stefano et al,
1994), and increased beta-2-integrin (Mac-1) up-regulation on sputum neutrophils 
(Maestrelli et al, 1996). In addition Mac-1 negatively correlated with FEViA^C ratio, 
and the authors suggested that Mac-1 expression on sputmn neutrophils represented a 
marker for smokers who develop chronic airflow obstruction (Maestrelli et al, 1996). In 
addition further studies by Riise and colleagues foimd that patients with chronic 
bronchitis had increased levels of circulating ICAM-1 both in serum and in bronchial 
lavage, and higher circulating E-selectin in serum (Riise et al, 1994), the latter correlated 
significantly with FEV] (% predicted) (Riise et al, 1994). These studies suggest the 
involvement of these adhesion molecules may be of importance in the pathogenesis of 
chi'onic bronchitis.
1.2.2.1.3 Exacerbation
This cellular profile may change during exacerbations, and bronchial biopsies taken 
during such episodes show a marked eosinophilia and a milder increase in the number of 
neutrophils, activated CD3+ T lymphocytes, and TNF-a positive cells (Saetta et al,
1994).
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1.2.2.2 Bronchial and bronclioalveolar lavage data
Bronchial lavage and bronchoalveolar lavage fluid from patients with clnonic bronchitis 
recovers increased numbers of neutrophil granulocytes (Spurzem et al, 1991)(Thompson 
et al, 1989). Further studies have confirmed not only the increased activity of neutrophils 
but also demonstrated an increase of eosinophils in patients with clnonic bronchitis, 
although the importance of the eosinophils in the pathogenesis of bronchial disease has 
yet to be established (Riise et al, 1995)(Pesci et al, 1998). Balbi and colleagues 
demonstrated increased number of neutrophils and eosinophils in bronchoalveolar 
lavage specimens during exacerbations of chi'onic bronchitis (Balbi et al, 1997).
1.2.2.2.1 Association with airflow obstruction and progression
Early studies postulated that airway inflammation may play a pathogenetic role in
airway obstruction in patients with chronic bronchitis, since all spirometric 
measurements of airway obstruction were significantly lower in clnonic bronchitic 
patients with neutrophilia (Thompson et al, 1989). Similai’ly sputum induction studies 
have demonstrated that the % neutrophils negatively correlated with the FEV] (% 
predicted) (Keatings et al, 1997). Further studies have shown that increased neutrophils 
in the airways are related to the progression of airflow obstruction (Stanescu et al, 1996).
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1.2.3 Neutrophil migration into the lung
These studies highlight the importance of the neutrophil in the pathogenesis of chronic 
bronchitis, but to have this effect the neutrophils have to migrate into the lung. Because 
mature neutrophils cannot divide, the neutrophils in lung tissues are derived directly 
from the blood. A variety of integrated processes results in movement of neutrophils 
from the circulation to sites of inflanunation. These involve adherence to the vascular 
endothelium, diapedesis between the endothelial cells, and migration tlirough the 
connective tissue in the interstitial space to the site of the chemoattractant release within 
the airways. At present it is unloiown whether these processes are directly applicable to 
both the bronchial and pulmonary circulation and whether differences exist between the 
two.
1.2.3.1 Cell differentiation and release
The neutrophil is the most abundant leukocyte in the body (numbers in the circulation 
normally exceed 5 x 10^*). The normal neutrophil differentiates in the bone marrow, 
from pluripotent stem cells and is released into the circulation as a mature cell (Bainton 
et al, 1971).
It is thought to differentiate thi'ough several distinct stages; myeloblast, promyelocyte, 
myelocytes, metamyelocyte, band cells and finally to mature neutrophils (the azurophil 
granules are synthesised and the enzymes packaged at the promyelocyte stage (Bainton 
et al, 1971)). This differentiation process takes between 10-14 days and these mature 
cells remain in the marrow for approximately 2 days before being released in to the 
circulation, where they do not survive long, half life about 8 hours (Bainton et al, 1971).
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About half of the neutrophils are freely circulating but the rest are marginated on the 
endothelium (Abramson, 1993). The marginated cells can be mobilised rapidly and thus 
provide an immediately available source of extra cells which may be required during 
episodes of acute inflammation (during episodes of infection, the increased 
granulopoiesis along with mobilisation of neutrophils, results in neutrophilia to combat 
infections (Athens et al, 1965)).
1.2.3.2 Neutrophil rolling, triggering and strong adhesion
1.2.3.2.1 Neutrophil adhesion to endothelium
A critical step in cell migration is the adherence of freely circulating neutrophils to 
specific areas of endothelial cells near- the tissues that have become inflamed. This 
involves the specialised adhesion molecules that are expressed on the surface of both the 
neutrophil and the endothelial cells.
Adhesion of circulating neutrophils to the endothelial cells is necessary for subsequent 
trans-endothelial migration and involves 3 stages: neutrophil rolling, triggering and 
strong adhesion (Adams et al, 1994)(Springer, 1994).
Neutrophil rolling is the first crucial step in halting the progress of neutrophils through 
the circulation and is brought about by at least 3 different cell surface receptors called 
selectins (Bevilacqua et al, 1993)(Tedder et al, 1995)(Symon et al, 1996). Neutrophils 
express L-selectin constitutively (McEver et al, 1995)(Von Andrian et al, 1992)(Tedder 
et al, 1995) and the counter receptors are expressed on endothelial cells.
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Several studies have shown that neutrophil rolling on endothelial cells is L-selectin 
mediated (von Andrian et al, 1993, von Andrian et al, 1991, Von Andrian et al, 1992) 
and the rapid binding of this adhesion molecule to endothelial cells is believed to allow 
the slow rolling of neutrophils along venular walls at the shear force rates exerted by 
flowing blood (Von Andrian et al, 1992) (Symon et al, 1996).
Endothelial cells express 2 selectins, E-selectin and P-selectin (Albelda et al, 1994). P- 
selectin is stored within the Weibel-Palade bodies in endothelial cells and translocates 
rapidly to the plasma membrane under the influence of inflammatory mediators, 
including thrombin, histamine, complement fragments, oxygen derived free radicals and 
cytokines (Springer, 1994)(Tedder et al, 1995). In contrast E-selectin is not pre-stored, 
but is synthesised rapidly by endothelial cells and transported to the plasma membrane 
in response to inflammatory cytokines including Interleukin-1 (IL-1), Interleukin 8 (IL8) 
and tumour necrosis factor-a (TNF-a) (Albelda et al, 1994). Thus wealc selectin 
mediated attachment of neutrophils to endothelium occurs selectively at sites where 
these inflammatory mediators are being expressed.
Neutrophil rolling on endothelial cells at the very early stages of an inflammatory 
response, are dependant initially on L-selectin followed by P or E selectin (Wardlaw, 
1990)(Hogg et al, 1995)(Tedder et al, 1995).
The importance of the selectin mediated neutrophil rolling is seen in leukocyte adhesion 
deficiency II which is characterised by a failure to express sialyl Lewis X, the counter
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receptor for E and P selectin. This leads to a failure of neutrophil migration to 
inflammatory foci resulting in recunent bacterial infection (Etzioni et al, 1992)(von 
Andrian et al, 1993).
The interactions of the selectins with their counter receptors are not strong, and a second 
step of triggering and strong adhesion is required.
1.2.3.2.2 Triggering and strong adhesion
Neutrophils rolling has the effect of bringing the cells into close contact with endothelial 
cells at regions of inflammation, and consequently into contact also with factors that 
trigger or activate the neutrophil receptors-integrins, responsible for strong adhesion 
(Von Andrian et al, 1992).
The integrins are a family of trans-membrane glycoproteins. They are heterodimeric 
proteins, each consisting of one a-subunit and one p subunit, which are bound non- 
covalently. Subfamilies of integrins share common p subunits and different subfamily 
members have distinct a-subimits (Montefort et al, 1991)(Wardlaw, 1990)(Osborn, 
1990)(Albeida et al, 1994).
The most important neutrophil integrin (p2 integrin) is Mac-1 or CR3 (CDllb/CD 18) 
(Anderson et al, 1985). Another p2 integrin LFA-1 (CD 11 A/CD 18) is expressed by 
neutrophils but is probably less important than Mac-1 for strong binding (Anderson et al, 
1985).
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Strong adhesion appears to be primarily mediated by the p2 integrins LFA-1 and Mac-1. 
This is emphasised in the leukocyte adhesion deficiency syndrome I where patients have 
an autosomal recessive genetic defect in the P2 integrin subunit CD 18 (Osborn, 1990) 
causing reduced or absent expression of all the p2 integrins (Anderson et al, 1985). The 
neutrophils in these patients have an inability to adhere and migrate to the site of 
inflammation, and thus such patients suffer from recurrent infections (although the 
neutrophils demonstrate normal effector functions).
Once the p2 integrins have been activated, firm adhesion of neutrophils is dependant on 
their subsequent binding to one of their counter receptors the intercellular adhesion 
molecules (ICAMs) on the surface of the endothelium. Mac-1 binds to ICAM-1 (CD54) 
and LFA-1 binds to ICAM-1, ICAM-2, and ICAM-3 (Springer, 1994). One amino acid 
sequence known to be recognised by Mac-1 and LFA-1 is Arg-Gly-Asp (Ruoslahti et al,
1987), which is found on several proteins including C3bi (Mac-1 also has a binding site 
for bacterial lipopolysacchaiide (Wright et al, 1989)).
Another family if integrins, the Pi integrins (Wardlaw, 1990) is also present on 
neutrophils, known as the “very late antigens” VLA-5 & VLA-6. VLA-5 binds to 
fibronectin and VLA-6 to laminin (Wardlaw, 1990). These adhesion proteins have been 
thought to be important in the migration of leukocytes (principally eosinophils, 
monocytes, and lymphocytes) through the endothelium and the extracellular matrix 
(Montefort et al, 1991).
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The expression of integrins and ICAMs is modulated by a variety of pro-inflammatory 
factors. Integrin adhesiveness is increased on neutrophils by factors including host cell 
derived cytokines such as IL8, and compounds derived from micro-organisms such as 
N-formyl-methionyl-leucyl-phenylalanine (fMLP) and other formulated peptides. 
Similarly endothelial cells respond to pro-inflammatory agents. Whereas ICAM-2 
appears to be constitutively expressed (Abramson, 1993) by endothelial cells and 
synthesis is not believed to be regulated, ICAM-1 expression can be increased. 
Endothelial expression of ICAM-1 is upregulated by cytokines such as IL-1, TNF-a and 
by bacterial lipopolysaccharide (Biunett, 1997)(Klrair et al, 1994), again factors likely to 
be released at sites of inflammation. Thus strong adhesion of neutrophils to endothelial 
cells, thr'ough integrin-ICAM interactions and associated changes in neutrophil shape 
(flattening and spreading), is regulated by common pro-inflammatory factors, ensuring 
that this process is confined to areas of tissue where the cells are required.
Interestingly adhesion molecule expression has been shown to be down regulated on 
neutrophils that have migrated in response to a chemotactic signal in vitro (Harvath et al,
1995) which might represent the breakdown of cell adhesion in order for migration to 
occur.
1.2.3.2.3 Transmigration
The final step from tethering and rolling, firm adhesion involves transmigration. 
Transmigration into tissues is a process that requires both a chemotactic stimuli and 
engagement of adhesion receptors. Although inflammatory mediators can augment
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leukocyte adhesion to the endothelium, transmigration requires a chemotactic gradient. 
Studies have implicated PECAM-1, a member of the Immunoglobulin (Ig) superfamily 
to be one of the major molecules involved in transmigration (Albelda et al, 1994). If 
devoid of PECAM, there is a reduced migration rate (Kim et al, 1998) of up to 70-90% 
(Muller, 1993).
1.2.3.3 Chemoattractants
Neutrophils are recruited from the circulation to the lung in response to a chemotactic 
signal. Blood neutrophils are not homogeneous with respect to their chemotactic 
responses. There appears to be two subpopulation, one responsive, and the other not 
(Harvath et al, 1982) although the implications are currently unknown.
The chemotactic signal will be greatest at the point of release and decreases as it diffuses 
away. The exquisite sensitivity of the cell to a changing concentration gradient results in 
movement up the gradient towards the source of the signal, but the rate of movement 
will decrease after the optimum concentration is encoimtered. Thus neutrophils will 
accumulate at or near the origin of the signal. The cell will only then continue 
directional movement if the concentration changes, or in response to a different 
chemotactic signal (Foxman et al, 1997).
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1.2.3.3.1 Interleukin 8
Interleukin 8 (IL8) is present in patients with chronic lung disease, where it is thought to 
play a key role in neutrophil recruitment (Richman-Eisenstat et al, 1993)(McElvany et 
al, 1992). Recent data confirms that IL8 levels are raised in patients with chronic 
bronchitis (Riise et al, 1995)(Pesci et al, 1998)(Richman-Bisenstat et al,
1993)(Yamamoto et al, 1997), and correlates with myeloperoxidase (Riise et al,
1995)(Pesci et al, 1998)(Yamamoto et al, 1997) (a maiker of neutrophil influx). This 
relationship supports the concept that IL8 is an important lung chemoattractant for 
neutrophils.
IL8 is a 16kDa protein that is a member of the C-X-C family of cytokines. It is made and 
released by bronchial epithelial cells (Nakamura et al, 1992), monocytes/macrophages 
(Standiford et al, 1992), and even the neutrophils themselves (McCain et al, 1994).
The regulation of IL8 production in the lung is complex but recent studies have started 
to determine the processes involved. It is known that tumour necrosis factor-a (TNF-a) 
can increase the expression of the ILS gene (Khair et al, 1994), and certainly lung 
secretions contain TNF-a (Keatings et al, 1997). In addition bacteria can also induce IL8 
expression by epithelial cells (Khair et al, 1994)(Inoue et al, 1994). At present it is 
uncertain however whether the effect o f bacterial products on IL8 expression is direct or 
via TNF-a.
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1.2.3.3.2 Leukotriene B4
Leukotriene B4 (LTB4) is a biologically active fatty acid synthesised in myeloid cells 
from arachidonic acid. LTB4 was isolated and purified in 1978 from neutrophils 
(Borgeat et al, 1979), but subsequently it was chemically synthesised and its ability to 
activate neutropliils was identified in 1980 (Ford-Hutchinson et al, 1980). LTB4 is now 
known to be a major chemotactic product of activated neutrophils (Ford-Hutchinson et 
ai, 1980) and macrophages (Hubbard et al, 1991).
Leukotriene B4 induces recruitment and activation of neutrophils as well as monocytes, 
eosinophils, and lymphocytes. LTB4 promotes both neutrophil adherence to venule 
walls (via the integrin Mac-1 and ICAM-1) as well as the chemotactic process (Crooks 
et al, 1998).
Synthesis of LTB4 from arachidonic acid (Figure 1-2) is catalysed by 5-lipoxygenase 
and leukotriene A4 hydroxylase and is increased by inflammatory mediators including 
endotoxin, complement fragments, TNF-a, and interleukins such as IL8 (Crooks et al,
1998). 5 lipoxygenase activating protein, is an 18 kDa nuclear membrane protein, which 
is an essential co-factor for 5-lipoxygenase pathway degradation (Crooks et al, 1998).
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5-Hpoxygenase + FLAP
\
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Leukotriene B4
Figure 1-2: The pathway of LTB4 production from membrane phospholipid. 5 
lipoxygenase activating protein (FLAP) is an essential cofactor for 5 lipoxygenase.
1.2.3.3.3 Role of IL8 and LTB4
The exact role of these chemoattractants in lung disease is currently uncertain. As 
described above IL8 was thought to be the major chemoattractant in bronchial disease 
(Ricliman-Eisenstat et al, 1993)(McElvany et al, 1992). On the other hand Hubbard et al 
described studies that indicated that LTB4 was the major lung chemoattractant in alpha- 
1-antitrypsin deficiency (Hubbard et al, 1991). The LTB4 was thought to be released 
from macrophages as a direct effect of elastase activity, which was not inactivated in the
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lung because of the alpha-1-antitrypsin deficiency. There was, however, no information 
in these studies of the initial chemoattractant involved in recruitment of the neutrophils 
that would release the elastase to generate the LTB4.
Studies by Mikami et al (Mikami et al, 1998) have provided some clarification of the 
role of ILS and LTB4 in bronchiectasis indicating that they both play a significant role in 
neutrophil chemotaxis. The authors demonstrated that up to 43% of the chemotactic 
activity was dependant on IL8 and 27% was dependant on LTB4. In addition it was 
shown that the chemoattractants worked in an additive way for neutrophil recruitment 
(Mikami et al, 1998). However these workers also emphasised that some of the 
chemotactic activity of the lung secretion was due to an, as yet, unidentified protein.
1.2.3.3.4 Other potential chemoattractants
There are a vai'iety of other chemoattractants that could play a role in the airways 
including:
i. C5a generated from complement activation (Pick et al, 1986).
ii. modified apha-1 -antitrypsin (Stockley et al, 1990).
iii. leukocyte elastase-inhibitor complexes (Banda et al, 1988).
iv. protein and peptide components of damaged extracellular matrix, such as collagen 
(Senior et al, 1989) and laminin (Bryant et al, 1987).
V. antigen-antibody complexes (Boyden, 1962).
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vi. factors including the formyl peptides such as fMLP from micro-organism (Casale 
et al, 1992) as well as lipopolysacchaiide or endotoxin which can prime neutrophil 
functions including the chemotactic responses (Young et al, 1990).
1.2.3.3.5 Chemoattractants- summary
In summary a significant proportion of the chemotactic activity of lung secretions can be 
attributed to IL8 and LTB4. This is particularly true in patients with bronchiectasis, who 
usually have marked bronchial inflammation associated with significant neutrophil 
influx. Other potential chemoattractants listed above may also play a role and cells 
migrating in tissues may thus encounter multiple chemoattractant signals. Foxman et al 
(Foxman et al, 1997) have demonstrated that neutrophils can migrate “down” a local 
chemoattractant gradient in response to a distal gradient of a different chemoattractant. 
In addition cells can migrate effectively to a secondary distant agonist after migrating up 
a primary gradient into a saturating non-orienting concentration of an initial attractant. 
These mechanisms to navigate from one gradient to another in complex chemoattractant 
fields are likely to be necessary for successful localisation within sites of inflammation 
(Foxman et al, 1997).
1.2.3.3.6 Hierarchy of chemoattractants
The hierarchy of chemoattractants has been shown to be influenced by the quantity and 
type of chemoattractant present but also the barrier through which the neutrophil must 
migrate (Casale et al, 1992). These authors demonstrated that LTB4 was more potent 
than fMLP which was more potent than platelet activating factor (PAF) for migration
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tluough endothelial cells but fMLP>LTB4>PAF for migration through epithelial cell 
barriers. Further studies have demonstrated the dominance of end target derived 
chemoattractants (C5a, fMLP) over regulatory cell derived chemoattractants (IL8, 
LTB4) (Campbell et al, 1997)(Kitayama et al, 1997). This supports a concept of 
hierar chy of chemoattractants and further studies have demonstrated that neutrophils can 
migrate away from a local IL8 or LTB4 source towards fMLP or C5a although not vice- 
versa (Foxman et al, 1997).
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1.2.4 Role of proteinases and anti-proteinases
The neutrophil plays a key role in the pathogenesis of chi’onic bronchitis which is likely 
mediated tlii’ough the neutrophil products released. In particulai' in vitro and in vivo 
studies have shown that neutrophil elastase can reproduce many of the features of 
chronic bronchitis, when an imbalance occurs in the airways between the enzyme and its 
inhibitors (Stockley, 1994).
1.2.4.1 Proteinases
1.2.4.1.1 Neutrophil Elastase
Proteolytic enzymes have been implicated in the pathogenesis of both chronic bronchitis 
and emphysema. Early studies by Gross and colleagues (Gross et al, 1964) revealed that 
a proteolytic enzyme (papain) was capable of producing lesions in experimental animals 
similar to the pathological changes in human emphysema. Subsequent studies have 
concentrated on the effects of relevant serine proteinases, especially human neutrophil 
elastase. This enzyme is produced during the early stages of neutrophil differentiation 
and stored within the azuropliil granules (Sandborg et al, 1988). The enzyme is released 
when the neutrophil is activated, and can be rapidly neutralised by proteinase inliibitors 
such as alpha-1-antitrypsin (AAT) (Baumstark, 1967) and secretory leukoprotease 
inhibitor (Morrison et al, 1987).
When neutrophil elastase is instilled into the lungs of experimental animals, it produces 
lesions similar to human emphysema with enlargement of peripheral airspaces (Janoff et 
al, 1977), as a result of degradation of lung elastin (Kuhn et al, 1980).
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In addition, in vitro and in vivo work have demonstrated that neutrophil elastase can 
cause epithelial damage (Amitani et al, 1991), reduce ciliary beat frequency (Smallman 
et al, 1984), produce mucus gland hyperplasia (Snider et al, 1985), stimulate mucus 
secretion (neutrophil elastase being the most potent secretogogue studied to date) 
(Sommerhoff et al, 1990), and inactivate many critical lung host defences (Solomon, 
1978)(Tosi et al, 1990). Thus neutrophil elastase can produce pathological processes 
similar* to both chronic bronchitis (Figure 1-3) and emphysema found in humans.
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Figure 1-3: The potential damage from neutrophil elastase causing many of the 
features of chronic bronchitis. Amplification can be caused by neutrophil elastase 
inhibiting production of the proteinase inhibitor secretory leukoprotease inhibitor 
(SLPI) (Sallenave et al, 1994), stimulating the release of the chemoattractants [IL8 
by epithelial cells (Nakamura et al, 1992) and LTB4 by macrophages (Hubbard et 
al, 1991)], and finally bacterial proliferation itself stimulating further IL8 release 
by epithelial cells (Khair et al, 1994). The symbol indicates an amplification 
loop. Ig's = Immunoglobulins.
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1.2.4.1.2 Other proteolytic enzymes
There are other proteolytic enzymes tliat could play a role in the pathogenesis of chr onic 
bronchitis and emphysema. These include: 1) serine proteinases such as cathepsin G and 
proteinase 3 which are components of the azurophil granule of the polymorphonuclear 
phagocyte (Sandborg et al, 1988) and likely to be released at the same time as neutrophil 
elastase; 2) Cysteine proteinases such as Cathepsin B which has been identified within 
the human macrophage (Burnett et al, 1983) and epithelial cells (Howie et al, 1985); 3) 
Metalloproteinases such as the human collagenases (D'Armiento et al, 1992) and 
bacterial enzymes (Kilian et al, 1980), Despite this wide range of proteinases and their 
different classes, few have been studied in depth.
In experimental animals proteinase 3 (Kao et al, 1988), cathepsin B (Lesser et al, 1992), 
and collagenase (D'Armiento et al, 1992) have been shown to cause emphysema 
whereas cathepsin G (Sommerhoff et al, 1990)(Lucey et al, 1985) and bovine cathepsin 
B (Cardozo et al, 1992) cause mucus gland hyperplasia and hypersecretion. Cathepsin B 
is present in lung secretions as the pro-enzyme which can be cleaved by neutrophil 
elastase releasing active cathepsin B (Buttle et al, 1991) suggesting that if it plays a role 
in human disease it may be secondai'y to elastase release. Although neutrophil elastase 
remains the most potent secretagogue in the airways, more recent studies have shown 
that Proteinase 3 is also a potent secretagogue in the airways (Witko-Sarsat et al, 1999), 
and may play a role in the pathogenesis of bronchial disease.
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1.2.4.1.3 Summary
Several proteinases may play a role in the pathogenesis and features of bronchial 
disease. However the evidence to date suggests that neutrophil and its enzyme neutrophil 
elastase is likely to be a major mediator of bronchial disease and the mechanisms that 
summarise this processes of importance are shown in Figure 1-3.
50
1.2.4.2 The anti-proteinase screen
For neutrophil elastase to have these effects, it has to overcome the anti-elastases that 
protect the tissues. Several potent inhibitors of neutrophil elastase are present in lung 
secretions and are believed to play a major role in the protection of lung tissue from the 
destructive effects of these enzymes.
1.2.4.2.1 AIpha-1-antitrypsin
Alpha-1-antitrypsin (AAT) is secreted by hepatocytes and cells of the monocytic lineage 
(Perlmutter et al, 1989). Although alveolar macrophages are able to produce AAT 
(Barbey-Morel et al, 1987) most of the lung AAT is believed to be derived from plasma 
by simple transudation.
Lung AAT has been considered to be the most important of the lung anti-elastases 
particularly in the lower airways, since patients with AAT deficiency are particulai'ly 
prone to develop severe emphysema at a younger age than non deficient subjects whom 
ai’e susceptible to cigarette smoke (Tobin et al, 1983).
Structure
Alpha-1-antitrypsin is a 52 kDa glycoprotein consisting of a folded polypeptide chain of 
394 amino acids, with tluee carbohydrate side chains accounting for 12% of the total 
molecular mass (Carrell et al, 1982). Alpha-1-antitrypsin belongs to the seipin family 
because it is an inhibitor of serine proteases (Carrell, 1986).
The seipins share the unusual property of being able to change from one conformational 
form to another (Carrell et al, 1994) which has enabled them to evolve and become the
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most effective protease inliibitors in human plasma. The advantage that this molecular 
mobility of the serpins provides in higher organisms is that it allows the inliibitor not 
only to snare its target protease but also to tightly entrap it thereby effectively 
inactivating both proteins. The formation of a tight complex between a protease and its 
inliibitor is a physiological requirement as the complex may circulate for minutes or 
even hours before it is catabolically removed from the bloodstream and it would be 
detrimental to release the active enzyme again (Laurell et al, 1963). A disadvantage of 
having a mobile molecular mechanism however is that it makes the serpins more 
vulnerable to dysfunctional mutations (Stein et al, 1995).
The serpin molecule is made up of nine helices and three p pleated sheets; the dominant 
feature of the molecule being the five stranded A sheet and the reactive centre loop of 
the molecule arising from it.
AAT Variants
Alpha-1-antitrypsin is a polymorphic protein with over 100 phenotypes described to 
date. Most of these occur because of single amino acid substitutions although these do 
not usually affect protein concentration or function. The variants have different 
electrophoretic properties because of these amino acid differences that are detectable by 
isoelectric focussing (Hoffmann et al, 1977). The position of the isoelectric points of the 
variants identifies its phenotype which is described alphabetically. Alpha-1-antitrypsin is 
codominantly expressed with both alleles usually producing protein identifiable in the 
serum (Fagerhol et al, 1981)(Brantly et al, 1988). The most common phenotype is
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referred to as M (approximately 92% in England) (Fagerhol et al, 1981), and has at least 
four subtypes, although none are thought to be directly responsible for ill health. The 
other common variants are the S and Z phenotypes (approximately 5% and 2% in 
England) (Fagerhol et al, 1981), which are readily distinguished by iso-electric focussing 
and often by reduced serum concentration.
The AAT gene locus is located on chromosomal segment 14q 32.1 (Darlington et al, 
1982) and the variants arise from genetic coding errors which lead to a variety of 
changes including single amino acid substitutions in the primary chain, such as (a) 
glutamine to lysine at position 342 in the Z variant (Yoshida et al, 1976) and (b) 
glutamine to valine at position 264 in the S variant (Owen et al, 1976). Some 
abnormalities of the AAT gene totally prevent any production and secretion of AAT 
(Null genes) although these variants are rare (<1% of the population) (Fagerhol et al, 
1981)(Talamo et al, 1973)(Garver et al, 1986).
Effects of Z variant
The commonest deficiency associated with a tendency to develop lung disease is the Z 
mutation identified by its low concentration (<20% normal) and retarded mobility in iso­
electric focussing (Fagerhol et al, 1981), The homozygous Z variant results in normal 
synthesis of AAT (Bathhurst et al, 1983) but only 15% is secreted into the circulation. 
The remaining 85% is blocked in the hepatocyte secretory pathway (Forman et al, 1984) 
and most of this blocked AAT is degraded intracellulai'ly. However some accumulates 
and is recognised as the classical large intracellular inclusions seen as PAS positive 
bodies on liver biopsy.
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The Z variant of antitrypsin has a mutation at the hinge of the reactive loop that 
facilitates entry of the loop into the A sheets. This results in the loss of the constraints 
that hold the reactive loop in its external position and facilitates transition of the 
molecule to the partially incorporated locking form (Stein et al, 1995), These 
intermediate forms are susceptible to intracellular catabolism (Le et al, 1990) and also to 
extended linkage, forming long polymers that prevents protein secretion (Lomas et al, 
1992). This explains why the majority of the Z protein accumulates in the liver and it is 
the formation of tangles of these polymers, visible on electron microscopy, that form the 
characteristic liver inclusions.
Inlreritance
Initial clinical studies suggested that the inlreritance of AAT deficiency behaved as an 
autosomal recessive condition (Eriksson, 1964). Whereas this may be true for the 
clinical phenotype, the genetic components (alleles) are co-dominantly expressed so that 
each allele contributes to the total AAT serum concentration (Lieberman et al, 1972). 
The mean alpha-1-antitryspin concentration expressed as percentage predicted of the 
normal level (MM=100%) of the common phenotypes are MM=100%, MS=75%, 
MZ=57%, SS-52%, SZ=37%, and ZZ=16% (Lieberman et al, 1972). However the 
phenotype is dependant on iso-electric focusing of the plasma protein. Since null genes 
do no contribute to the phenotype it has become convention to described the phenotypes 
PiM, Pis or PiZ for cases which are apparently homozygous but where the null gene has 
not been excluded. In reality more than 95% of patients with severe AAT deficiency are
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PiZ homozygotes, and have serum AAT levels of 2.5 to 7 pM (mean 16% of normal) 
(Society, 1995).
Role of AAT
Alpha-1-antitrypsin (52 kDa) in serum is capable of inactivating a variety of serine 
proteinases (neutrophil elastase, cathepsin G, and proteinase 3) providing about 90% of 
the inliibitory capacity of serum against such enzymes (Baumstark, 1967).
Most lung AAT is derived from plasma by simple diffusion (Stockley et al, 1979), and 
AAT is present in both the bronchial (Stockley et al, 1979) and broncho-alveolar regions 
(Olsen et al, 1975) of the Imig. The concentration of AAT in sputum is 1-2% of that 
found in plasma (Stockley et al, 1990) approximately 0.3 pM and values in epithelial 
lining fluid are calculated to be l-3pM (Morrison et al, 1987). However unlike plasma 
AAT, airways protein is not fully active as a proteinase inhibitor being about 30% active 
in non-infected mucoid sputum (Morrison et al, 1986) and 50% active in lavage fluids 
(Morrison et al, 1987) although some workers have suggested that it is fully active in 
epithelial lining fluid (Gadek et al, 1979).
Inactivation of AAT in sputum secretions and lavage fluids is the result of several 
mechanisms:
1) about 20% is enzyme/inliibitor complexes in sputum (Monison et al, 1986) and 
lavage (Stockley et al, 1984) and at least some of this is likely to be with neutrophil 
elastase (Stockley et al, 1979).
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2) proteolytic cleavage near the active site accounts for a further 20% in sputum 
(Morrison et al, 1986) and is also seen in lavage (Stockley et al, 1984). AAT can be 
inactivated by a variety of enzymes that cause limited cleavage at or near the active 
site including enzymes from bacteria (Morihara et al, 1979), the macrophage (Banda 
et al, 1985), and also by neutrophil elastase itself (Stockley et al, 1984).
3) the remaining 60% in sputum was present as its native molecular size although a 
portion remained inactive as an inliibitor, probably due to oxidation at the active site 
methionine (Morrison et al, 1986). Again similar results have been identified in 
lavage fluids from patients (Stockley et al, 1984).
4) The form and frinction of lung AAT harvested by bronchoalveolar lavage has 
however been the subject of much debate. Early studies suggested that cigarette 
smoke decreased AAT function by 40% (Gadek et al, 1979) although this has not 
been confirmed by others (Stone et al, 1983)(Boudier et al, 1987)(Afford et al, 1988). 
Furthermore these other studies have found a degree of inactivation of AAT in 
healthy non-smokers and as little as 40% of the protein may remain active as an 
inhibitor (Afford et al, 1988). The nature of the inactivation has yet to be defined as 
most of the AAT was the same size as the native protein and there was little evidence 
of oxidation of the active site (Afford et al, 1988).
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Acute phase response CPiMf
Some serum proteins including AAT, alpha-1-antichymotrypsin, and C reactive protein 
(CRT) demonstrate acute phase responses in the presence of inflammatory processes. 
For instance following surgery in PiM individuals, AAT concentration rapidly rise to a 
maximum value after 1-4 days, rising on average by 120% although tlie range was wide 
(17-300%) (Crockson et al, 1966). C reactive protein rose within 24 hours also reaching 
its highest concentrations between 1-4 days later (mean 2 days) with an average increase 
of approximately 3000% (range= 33-7900%) (Crockson et al, 1966). Further studies 
assessing the acute phase response in surgical trauma confirmed that the response was 
rapid and the GRP and alpha-1-antichymotrypsin begin to rise within 8 hours, although 
AAT rose only after 24 hours (Aronsen et al, 1972).
Other studies have confirmed that AAT concentration can rise in PiM individuals, on 
average up to two fold, following typhoid vaccination (Kueppers, 1968) or after 6 
months of oral contraceptive therapy (Laurell et al, 1967). In addition serum AAT levels 
increase thioughout pregnancy, in a linear fashion until it reaches about twice the normal 
value at the time of parturition (Gam*ot et al, 1967). Six weeks after parturition, the 
serum AAT concentration returns to normal (Gamot et al, 1967).
Acute phase response (PiMZ & PiZ)
Patients with heterozygous (PiMZ) AAT deficiency show an acute phase response in 
AAT following stilboestrol therapy (Lieberman et al, 1973), pregnancy (Gamot et al, 
1967), and typhoid vaccination (Kueppers, 1968). The serum concentrations rise 2 fold 
and probably reflects the activity of the normal M gene. The mean percentage increase
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and time course was identical to that seen in normal subjects who were homozygote for 
the M allele. However the absolute concentration reached at the peak of the response 
was lower in heterozygote patients than in the PiM patients.
Nevertheless although patients with partial deficiency have a demonstrable acute phase 
response, initial studies with stilboestrol and typhoid vaccination indicated that patients 
with PiZ AAT deficiency had a much reduced response. Some fiirther insight has been 
gained from the treatment of PiZ patients with danazol therapy, an impeded androgen, 
which induces the hepatocytes to increase the production of AAT (Gadek et al, 1980). 
The authors foimd that 53% of patients had a greater than 20% rise in serum AAT levels 
with a mean percentage rise of 52% for the group classified as responders (Wewers et al, 
1986). However, not all the patients responded and again the peak concentrations 
achieved were much lower than patients with partial deficiency or normal AAT.
Lung AAT
Most lung AAT is derived from plasma by simple diffusion (Stockley et al, 1979). The 
concentration of AAT in the lung is therefore partially dependent upon the plasma 
concentration of AAT as well as the degree of airways inflammation (Stockley, 1984). 
As AAT is an acute phase protein, the lung concentrations of AAT will be higher during 
episodes where there is an acute phase response, as may occur in the presence of 
infection irrespective of inflammation (Stockley et al, 1979). However when the lung is 
inflamed, further protein leakage will occur due to airway vascular injury and these 2 
processes will have an additive effect on the concentration of lung AAT. This is likely to 
be critical in the protection of the lung since such episodes are likely to be associated
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with increased neutrophil influx and hence elastase release. Failure of an appropriate 
acute phase response might therefore enhance the degree of elastase induced lung 
damage.
Prevalence of PiZ AAT deficiency
The prevalence of PiZ AAT deficiency varies throughout the world and is thought to be 
rare in Black or Asian populations (Pierce et al, 1975)(Lieberman et al, 1976). The 
highest prevalence has been found by screening Swedish new-born infants (one in 
1,670) (Sveger, 1976). In the UK, estimates vary from one in 2,047 to one in 3,450 
(Cook, 1975)(Blundell et al, 1975)(Arnaud et al, 1979) whereas in the USA the 
prevalence is even more variable, with figures as low as one in 5,097 found fi’om 
screening 100,000 new-born infants in Oregon (O'Brien et al, 1978) and 1 in 2,857 from 
screening blood donors in St Louis (Silverman et al, 1989).
Clinical manifestations and natural history of PiZ AAT deficiency 
The current knowledge regai'ding the clinical manifestations and natural history of AAT 
deficiency is unclear as less than 5% of expected number of patients with PiZ AAT 
deficiency have been identified (Silverman et al, 1989)(Organisation, 1996). Once 
identified patients with AAT deficiency have a reduced life expectancy. Larsson 
(Larsson, 1978) reported a greatly reduced survival following an 11 year follow up of 
PiZ patients and in addition smoking PiZ individuals had an even lower life expectancy 
than non-smoking PiZ individuals. This study was supported by Brantly and colleagues 
(Brantly et al, 1988) who studied 120 PiZ patients with AAT deficiency and reported 
that the actuarial survival to age 60 was 16% compared with an expected age-matched
59
u s  survival of 85%. In both these studies, whilst referral bias may have effected 
mortality rates, the presence of PiZ AAT deficiency appears to be a significant factor 
determining survival.
More recent studies by Seersholm and colleagues (Seersholm et al, 1994), however, 
have indicated that differences exist between index cases (identified because of the 
presence of lung disease) and non-index cases (identified through family studies). The 
overall median life expectancy was 54.5 years. However, the median survival of the 
index cases (49.4 years) was significantly less than the non index cases (69.3 years) 
regardless of smoking history. In addition the authors found that life expectancy of the 
non-index subjects who had never smoked was similar to that of the normal Danish 
population (Seersholm et al, 1994) indicating that deficiency alone has a relatively good 
prognosis.
Effect of smoking in patients with PiZ AAT deficiency
Cigarette smoking is known to have a major adverse effect on subjects with AAT 
deficiency (Eriksson, 1965) and this has been confirmed by several other studies 
(Brantly et ai, 1988)(Kueppers et al, 1974)(Tobin et al, 1983)(Black et al, 1978)(Janus et 
al, 1985). In addition, Larsson (1978) showed not only that the median age of onset of 
dyspnoea was younger in PiZ smokers (40 years) compared to non smokers (53 years), 
but that smoking PiZ individuals had a significantly lower life expectancy than PiZ non- 
smokers (Larsson, 1978).
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In a recent study of 225 PiZ never smokers, Piitulainen and colleagues (1997) concluded 
that some individuals showed a significant decline in lung function, after 50 years of 
age. The authors found that additional risk factors that determined the development of 
airflow obstruction were male gender, previous asthmatic symptoms, and a history of 
occupational exposure to airway irritants. However this study also confirmed that a 
significant proportion of patients had well preseiwed lung function even into old age 
(Piitulainen et al, 1997).
Chronic bronchitis and emphysema in PiZ AAT deficiencv
Studies of the patients indicate that chronic bronchitis and emphysema is the most 
prevalent clinical disorder and liver disease is the second most prevalent (Organisation, 
1996). The relationship between AAT deficiency and lung disease is becoming clarified. 
Although early studies suggested it was a common association (Tobin et al, 1983), other 
studies however have now indicated that this may reflect a selection bias (Seersholm et 
al, 1994) in which studies have focused on index cases. Nevertheless there remains a 
general belief that AAT deficiency is a risk factor for the development of emphysema.
Emnhvsema in PiZ AAT deficiencv
Preliminary studies from Eriksson in 1964 described pulmonary emphysema as a 
common complication of PiZ AAT deficiency (Eriksson, 1964). In the archetypal case 
of emphysema, patients had an insidious onset of progressive shortness of breath 
between the ages of 25 and 40, associated with increasing evidence of airflow 
obstruction (Hutchison, 1988)(Brantly et al, 1988). Radiologically the striking feature is 
the predominant destruction of the lower zones of the lungs (Eriksson, 1964)(Kueppers
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et al, 1974)(Tobin et al, 1983) which occurs in over 90% of those with an abnonnal 
chest radiograph (Gishen et al, 1982). This is in contrast to the upper zone or more 
uniformly distributed emphysema found in patients with normal AAT phenotype.
Pathologically, the emphysema has been described as panacinar or bullous as opposed to 
the centrilobular emphysema found more commonly in patients with emphysema 
without AAT deficiency (Eriksson, 1964)(Thurlbeck et al, 1970)(Orell et al, 1972). 
Histological examination of post mortem specimens indicated that chronic bronchitis 
was common being present in 11/17 cases and 4/6 pathological specimens had 
cylindrical bronchiectasis (Orell et al, 1972).
The pathogenesis of emphysema is becoming clarified. Initial lavage studies revealed 
that PiZ patients had increased numbers of neutrophils in the lower airways, suggesting 
a greater potential elastase burden, compared with smoking subjects with emphysema 
who have normal levels of AAT (Morrison et al, 1987). In addition patients with PiZ 
AAT deficiency have reduced levels of immunoreactive AAT in both sputum (Morrison 
et al, 1987) and lavage fluids (Morrison et al, 1987)(Gadek et al, 1981). Therefore the 
mechanism for the development of lung disease was initially thought to be 
predominantly due to the low AAT in the presence of an increased neutrophil burden 
and that the development of lung disease was a direct consequence of poorly controlled 
neutrophil elastase activity.
As neutrophils migrate from the vasculai* space into the airways in response to 
chemoattractants such as LTB4 (Hubbar d et al, 1991), they must pass tlirough a compact
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interstitium of connective tissue. In order to achieve this migration it is believed that the 
cells need to digest a path creating a natural hole tlirough the matrix as has been 
elegantly demonstrated for eosinophils (Okada et al, 1997). Studies by Campbell and 
colleagues have shown that when neutrophils are in close contact with connective tissue 
they are able to digest matrix proteins even in the presence of super-normal 
concentrations of proteinase inhibitors (Campbell et al, 1982) which suggests the 
importance of the ability of these cells to digest connective tissue in order to migrate. It 
is believed that AAT acts as an inliibitor that prevents destruction of connective tissue 
beyond the limits of the cell and its close contact with the substrate.
Studies with AAT isolated from deficient subjects (PiZ) have shown that Z AAT has a 
reduced ability to inhibit connective tissue degradation by neutrophils compared to the 
M protein even at equivalent concentrations. This difference has been attributed to the 
slightly lower association rate constant of PiZ AAT (1.2 ± 0.2 x 10  ^M'' s'^  versus 5.3 ± 
0.1 X 10  ^M'^ s'^  for normal AAT (PiMM)) (Llewellyn-Jones et al, 1994). This provides 
one explanation for excessive connective tissue destruction by migrating neutrophils in 
subjects with AAT deficiency thereby leading to the development of extensive 
emphysema.
However more recently studies by Liou and Campbell, both on theoretical (Liou et al, 
1995) and experimental grounds (Liou et al, 1996), have emphasised that the azurophil 
granule contains exceedingly high concentrations of neutrophil elastase (5.33 mM). As 
these granules are exocytosed (when the cell is activated), the elastase would start to
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diffuse away from the granule leading to a gradual drop in concentration until it equals 
the physiological concentration of the inhibitors surrounding them. At this point 
connective tissue degradation would cease. Studies predict and show that the area of 
enzyme activity is well restricted until the concentration of suiTounding AAT falls below 
lOpM. At this point there would be, and is, an exponential rise in the area of persistent 
activity of neutrophil elastase. The implications of this observation are that for subjects 
with PiZ AAT deficiency where the concentration is less than lOpM (average ai’ound 
5pM), each neutrophil that enters the interstitium of the lung would produce an 
excessive area of connective tissue degradation, due to the inability of the critically low 
concentration of AAT to prevent elastase activity for a wide area around the activated 
neutrophil.
The above studies have provided an understandable mechanism which explain how 
emphysema can develop excessively in subjects with AAT deficiency. The addition of 
cigarette smoking is likely to enhance this process since the lungs of smokers contain 
more neutrophils than non smokers (Reynolds et al, 1974) that will have migrated 
through the interstitium causing some connective tissue degradation.
Other factors, however, are also likely to be important. Silverman et al (Silverman et al, 
1989) and Larsson (Larsson, 1978) identified lower respiratory tract infection as a risk 
factor for clii'onic airflow obstruction in adults with PiZ AAT deficiency, again a 
situation where neutrophil migration is likely to increase. In addition it is likely that 
there is some other familial component or risk factor involved in the development of
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iung disease, and a histoiy of COPD or asthma in a parent may be important suggesting 
a genetic tendency (Silverman et al, 1989). 4
Bronchial disease in PiZ AAT deficiencv
The prevalence of chronic bronchitis as defined by the Medical Research Council (1965) S
V
is variable affecting from 20 - 59 % of patients (Eriksson, 1965)(Brantly et al, I1988)(Tobin et al, 1983). Early pathological studies demonstrated the presence of $
bronchiectasis in patients with AAT deficiency (Orell et al, 1972) and more recently a 
study by King and colleagues revealed 6 out of 14 PiZ patients had a diagnosis of 
bronchiectasis identified by computed tomography (King et al, 1996). Further studies are 
needed with larger cohorts of deficient patients to determine whether bronchiectasis is Ireally associated more frequently with PiZ AAT deficiency.
The pathogenesis of emphysema related to PiZ AAT deficiency is now better 
understood, but there remains a paucity of information about bronchial disease in such
patients apart from prevalence figures quoted above.
.......................................................................The bronchial disease is responsible for a significant proportion of the morbidity of |
I:'patients with COPD, especially during acute exacerbations (Seemungal et al, 1998). IAgain there is little data in subjects with AAT deficiency, even though it is recognised 'I
that lower respiratory tract infection is a risk fector for the development of chronic 
airflow obstruction in such patients (Larsson, 1978). It is possible therefore to .i:hypothesise that during infections, such patients may be particularly susceptible to lung 
damage by proteinases due to the low baseline concentration of AAT, and the absence of
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a physiologically important acute phase response (Kueppers, 1968) resulting in 
excessive neutrophil mediated lung injury.
1.2.4.2.2 Other proteinase inhibitors
Although AAT is the main serum inliibitor of neutrophil elastase, secretory 
leukoprotease inhibitor (SLPI) is thought to be the major bronchial inhibitor of this 
enzyme (Morrison et al, 1987).
Secretory leukoprotease inhibitor
Studies in the 1970's identified a low molecular mass (12 kDa) inhibitor of neutrophil 
elastase that was in bronchial secretions, subsequently called secretory leukoprotease 
inliibitor. In addition to its anti-elastase function, SLPI may also have a broad spectrum 
antibiotic functions that include anti-retroviral, bactericidal, and antifungal activity 
(Toniee et al, 1998). SLPI is not glycosylated, and is produced locally in the lung by 
epithelial cells (Maruyama et al, 1994), and is present in serous glands (De Water et al, 
1986)(Mooren et al, 1983) and clara cells (Sallenave et al, 1993).
Regulation of the production of SLPI is only partly understood. Early studies suggested 
it was constitutionally expressed and that its production was constant (Dijkman et al, 
1986). However, more recent studies have shown that corticosteroids increase its 
concentration in the bronchial secretions in vivo (Stockley et al, 1986) and its production 
by epithelial cells in vitro (Abbinante-Nissen et al, 1995). Fmthermore, its secretion may 
actually decrease during infection (Piccioni et al, 1992) suggesting negative control, and
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recent studies have confirmed that neutrophil elastase can reduce SLPI secretion by 
epithelial cells (Sallenave et al, 1994).
Because it is the major inhibitor of neutrophil elastase in bronchial secretions 
(accounting for up to 90% of all inhibition (Morrison et al, 1987)) it is probably the most 
important inhibitor protecting the upper airways from neutrophil elastase. The role of 
this protein in the lower airways however has been more controversial. Early studies 
suggested that the only inhibitor of neutrophil elastase in the peripheral aii-ways was 
AAT (Gadek et al, 1981). This observation is at variance with other studies that have not 
only demonstrated the presence of SLPI in the lower airways (Boudier et al, 1983), but 
shown that it is functionally active (Boudier et al, 1983)(Afford et al, 1988) and can be 
produced by type II pneumocytes (Sallenave et al, 1994). These data suggest that SLPI 
is likely to have a role at the alveolar level. Furthermore SLPI may be secreted from the 
basolateral surface of epithelial cells (Dupuit et al, 1993) and can be identified in the 
lung interstitium (Willems et al, 1986), suggesting it may also have a protective role at 
that site as well as in the airways.
Other elastase inliibitors
Other protease inhibitors have been identified in the lung with the ability to inhibit 
neutrophil elastase although their role is less clear. These inhibitors include elafin 
(Sallenave et al, 1992) a 7kDa inhibitor produced locally in the lung by type II 
pneumocytes (Sallenave et al, 1994) and az macroglobulin which is a serum derived 
inhibitor of neutrophil elastase although its large mass (725 kDa) largely prevents its
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diffusion into lung secretions in effective amounts unless the lung is also inflamed 
(Stockley et al, 1979). Furthermore, even when present, az macroglobulin contiibutes 
little to the overall lung antineutrophil elastase screen (Stockley, 1986).
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1.2.5 Influence of bacterial colonisation
The normal bronchial tree is kept sterile through a sophisticated system of defence 
which consists of primary and secondary mechanisms. Patients with chronic bronchitis, 
however, are frequently colonised by bacteria even in the stable clinical state (Monso et 
al, 1995), but little is known how this influences the bronchial inflammation or natural 
history.
The complex interactions between bacteria and the lung and host defences can result in 
several distinct clinical situations.
1) If the bacterial load is low, the primary defences can sterilise the bronchial tree 
without activation of the secondary host defences. This has been shown in animal 
models revealing the primary host defences are able to cleai* bacterial loads of up to 
2x10^ colony forming units per ml (cfu/ml) (Onofrio et al, 1983) with little or no 
activation of the secondary host defences.
2) Bacteria may cause acute infections probably due to a higher bacterial load. In this 
instance the primary host defences become overwhelmed, and the secondary defences 
are activated. The net effect of these processes results in sterilisation of the bronchial 
tree and the process resolves. The processes involved in the secondary host response are 
currently poorly understood but may consist of 3 distinct phases.
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Initiation:
It is plausible that airway bacterial load can initiate the secondary host response, as 
bacterial products may stimulate bronchial epithelial cells to secrete interleukin 8 
(Bedard et al, 1993)(Khair et al, 1994) and activated alveolar macrophages by the 
phagocytic process may be a source of interleukin 8 (Standiford et al, 1992) and 
leukotriene B4 (Bigby et al, 1987)(Hubbard et al, 1991). Both these chemoattractants ai'e 
thought to be of major importance in neutrophil recruitment (Mikami et al, 1998), but in 
addition further neutrophil migration will be further enhanced by stimulation of 
endothelial adhesion molecules by the pro inflammatory cytokines (Khair et al,
1994)(Wardlaw, 1990). In addition to the neutrophil, monocytes recruited to sites of 
inflammation may also play an important role in the inflammatory process. A 
subpopulation (20-30%) of circulating monocytes have neutrophil-like pro inflammatory 
properties (P phenotype), including avid adherence to the extracellular matrix, the ability 
to produce reactive oxygen species, high neutrophil elastase content, and proteolytic 
activity against elastin and fibronectin (Owen et al, 1994). These pro inflammatory 
monocytes have considerably higher phagocytic activity than other monocytes and also 
lack the HLA-DR antigen, which means they camiot participate in specific immune 
responses. It is this neutrophil like pro inflammatory subpopulation that is recruited 
rapidly by chemoattractants to sites of inflammation (Owen et al, 1994), where they can 
eitlier promote resolution of inflammation or contribute to tissue injury in a similar way 
to the neutrophil. Finally the inflammatory response that forms a key part of this 
secondary defence system results in leakage of additional proteins, such as 
immunoglobulins and complement factors from the circulation which will also facilitate 
bacterial phagocytosis and death (Stockley, 1995).
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Amplification
Activation of neutrophils following migration results in the release of further 
chemoattractants including both LTB4 (Ford-Hutchinson et al, 1980) and IL8 
(Takahashi et al, 1993) which will add to the chemoattractant concentration in the 
airway. In addition the release of neutrophil elastase from activated neutrophils has been 
reported to increase IL8 production by epithelial cells (Nakamura et al, 1992) and 
induces production of LTB4 by alveolar macrophages (Hubbai'd et al, 1991) again 
adding to the chemoattractant gradient, further increasing neutrophil influx.
Infection related indirect mechanisms may also amplify and perpetuate neutrophil influx, 
including: 1) chemoattractants and active leukocyte elastase released from neutrophils 
(Takahashi et al, 1993)(Doerfler et al, 1989)(Nakamura et al, 1992); 2) leukocyte 
elastase-inhibitor complexes (Banda et al, 1988); and 3) products of local extracellular 
matrix degradation (Senior et al, 1980).
Resolution of the inflammatorv response
The mechanisms involved in switching off the secondary host defences have been least 
studied but may involve some of the mechanisms described below.
a) As the bacterial load is reduced, this would be expected to decrease the bacterial 
stimulus to the inflammatory processes (reducing release of the chemoattractants 
IL8, LTB4, and other factors such as TNF-a and neutrophil elastase). These 
changes would reduce neutrophil recruitment and this down-regulation may also
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be facilitated by the release of anti-inflammatory cytokines such as interleukin 1 0  
(Poulter, 1997).
b) The acute phase response may also be important with serum AAT levels 
increasing up to threefold as part of the systemic effect of lung inflammation 
(Crockson et al, 1966). This along with increased lung endothelial and epithelial 
permeability, would result in major leakage of this proteinase inliibitor into the 
lung which will tend to reduce the amount of free neutrophil elastase (Stockley,
1995). Such a change would potentially reduce IL8 and LTB4 production.
c) Other acute phase proteins such as alpha-1-chymotrypsin rises several fold within 
8  hours (Aronsen et al, 1972). This protein is thought to be a major inliibitor of 
neutrophil chemotaxis (Lomas et al, 1995), which could “down-regulate” the 
inflammatory process by a direct effect on reducing neutrophil influx.
d) Apoptosis represents a granulocyte fate which by a number of mechanisms would 
tend to limit inflammatory tissue injury and promote resolution rather than 
progression of inflammation: apoptosis is responsible for macrophage recognition 
of senescent neutrophils with retention of the integrity of the plasma membrane; 
the apoptotic neutrophil loses its cytotoxic and secretory capacity; the macrophage 
possesses a huge phagocytic capacity for apoptotic neutrophils which it rapidly 
ingests and degrades without disgorging neutrophil contents; and the macrophage 
utilizes a novel phagocytic recognition mechanism which fails to trigger the
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release of pro-inflammatory macrophage mediators during the phagocytosis of 
apoptotic neutrophils (Haslett et al, 1994), The release of pro-inflammatory 
cytokines Interleukin 6  (IL6 ) (Afford et al, 1992) and TNF-a (Hachiya et al, 1995) 
may paradoxically promote apoptosis, leading to phagocytosis of the neutrophils 
by resident macrophages (Haslett et al, 1994).
3) All these and, almost certain, other processes result in a return of the lung to its 
normal sterile state. However in some patients sterilisation does not occur and persistent 
colonisation is the result. In such patients there is a balance between the efficacy of the 
host defence mechanisms and bacterial replication which achieves a position of stability. 
This usually occurs in patients with an abnormal host defence e.g. patients where 
mucociliary clearance may be impaired as in patients with chronic bronchitis (Monso et 
al, 1995) where bacteria may be permanently present in the secretions even in the stable 
clinical state. Little is known, however, how this influences the bronchial inflammation 
or natural history in such patients.
The bacteria isolated are thought to be of low pathogenicity (non-typeable Haemophilus 
influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus 
parainfluenzae) but may themselves facilitate the process of colonisation by interfering 
with host defence. For instance bacterial products can interfere with neutrophil 
chemotactic responses inhibiting neutrophil migration and therefore down-regulating the 
inflammatory response (Cundell et al, 1993). In addition bacteria may generate features
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of chronic bronchitis and impair other features of the primary host defences, thus 
facilitating bacterial persistence in the airways. The processes involved may include:
i. Interference with ciliary function via cilia toxins such as pyocyanin and 
hydroxyphenazine (Wilson et al, 1987).
ii. The generation of excess mucus production (Li et al, 1997).
iii. The production of epithelial damage (Amitani et al, 1991).
iv. Damage to immunoglobulin A (IgA) by specific proteases (Kilian et al, 1980).
V. Change their antigenic response to avoid the immune response (Groeneveld et al, 
1988), thus facilitating their survival.
4) Finally in some instances colonisation is associated with a major degree of 
inflammation which may be detrimental and produce a vicious circle (Figure 1-4) of 
ongoing bronchial inflammation, further facilitating bacterial persistence. In this 
situation there is usually an overactive response of both the immune system and 
inflammatory response.
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Figure 1-4; The vicious cycle of bronchial inflammation and bacterial colonisation.
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Immune system
Patients who are chronically colonised often have increased serum immunoglobulin 
concentrations with increased immunoglobulins in their secretions (Bilton et al, 1992) 
(including both the IgAi and IgAi subclasses (Burnett et al, 1987)). The lung tissues 
contain increased numbers of T lymphocytes, predominantly with CD8 + cell population 
(Lapa e Silva et al, 1989), In some patients the host immune response may be made less 
efficient by the production of the wrong subclass of antibodies that prevent effective 
phagocytosis thus protecting the important clearance mechanisms (Pick et al, 1986).
Inflammatorv response
Activation of secondary host defences and the development of inflammation should 
result in clearance of the bacterial load. However, if this secondary response fails to 
sterilise the bronchial tree continued bacterial proliferation can occur despite a marked 
inflammatory response (Stockley, 1995) thereby resulting in a vicious circle of tissue 
damage (Figure 1-4). In this vicious circle (Figure 1-4), both the bacteria (described 
earlier) and the inflammatory response itself (thought to be mediated by neutrophil 
elastase) may play a role in the persistence of bacterial colonisation by reducing the 
efficacy of the host defences in the respiratory tract whilst perpetuating the 
inflammation.
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In particular neutrophil elastase can (Figure 1-3):
i. lead to excess mucus production (Sommerhoff et al, 1990).
ii. cause mucus gland hyperplasia (Snider et al, 1985).
iii. cause bronchial epithelial damage (Amitani et al, 1991).
iv. reduce ciliary beating (Smallman et al, 1984).
V. decrease phagocytic clearance by cleavage of immunoglobulins preventing
opsonisation (Doring et al, 1986).
vi. destroy phagocytic receptors on the neutrophil itself (C3bi) thereby reducing 
opsonophagocytosis (Tosi et al, 1990).
vii. stimulate epithelial cells to produce 1L8 (Nakamura et al, 1992) and 
macrophages to produce LTB4 (Hubbard et al, 1991) thus amplifying the 
neutrophil response.
viii. Peipetuate its own function by decreasing the concentration of SLPI (Sallenave 
et al, 1994).
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1.3 AIMS OF THESIS
The aims of the thesis were several fold;
1. To examine the interrelationship of sputum inflammatory markers in patients with 
chronic bronchitis in a stable clinical state including;
a) the relationship of myeloperoxidase (a measure of neutrophil influx) to elastase 
activity (a measure of the potential damage).
b) the relationship of the neutrophil chemoattractants interleukin 8  and leukotriene 
B4 to both myeloperoxidase and elastase activity.
c) the relationship of elastase activity to its major bronchial inhibitor secretory 
leukoprotease inhibitor, and airway epithelial leakage (as assessed by the 
sputum/serum albumin ratio %).
d) the relationship between FEVi (% Predicted) and inflammation as reflected by 
neutrophil numbers (myeloperoxidase) or protein leak.
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2. To investigate the relationship between bacterial colonisation and upper airways 
inflammation from patients with chronic bronchitis in a stable clinical state to 
determine:
a) whether patients who are colonised have more upper airways inflammation than 
those not colonised.
b) whether there is a threshold effect between bacterial load and recruitment of the 
secondary host defences.
c) whether different bacteria have a similar effect on upper airways inflammation.
3. To study upper airways inflammation from patients with clironic bronchitis in a
stable clinical state and investigate:
a) whether alpha-1 -antitrypsin deficiency influences upper airways inflammation.
b) whether any effect is influenced by smoking.
c) whether bacterial colonisation has an influence in patients with and without 
homozygous PiZ alpha-1-antitrypsin deficiency.
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4. Finally 1 wished to study upper airways inflammation during exacerbations in 
patients with chronic bronchitis with and without alpha-1 -antitrypsin deficiency:
a) to determine whether upper airways inflammation in PiZ alpha-1-antitrypsin 
deficiency is greater than patients without deficiency.
b) to study airways inflammation during an exacerbation and compare this to the 
stable state in patients with PiZ alpha-1-antitrypsin deficiency.
c) to study the acute phase response of alpha-1 -antitiypsin during the acute 
exacerbation in patients with PiZ alpha-1-antitrypsin deficiency.
d) to study the time course to recovery in patients with PiZ alpha-1-antitrypsin 
deficiency.
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2. GENERAL METHODS
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2.1 ETHICAL APPROVAL AND CONSENT
All studies reported in this thesis had ethical approval from the local ethics committee at 
the Queen Elizabeth Hospital, Birmingham. All patients gave signed consent.
2.2 SAMPLE COLLECTION & ANALYSIS
2.2.1 Sputum and serum collection
Patients provided a sputum sample that had been collected into a sterile container during 
the four hours following rising from bed. Patients delivered the sputum sample or the 
sputum was collected and processed within 2 hours. Serum was obtained at the time of 
sputum collection.
2.2.2 Sputum characteristics
Each sputum was assigned a value based upon its colour, by visual comparison with a 9 
point chart (Bronkotest, Heredilab, Inc., Salt Lake City, USA). Available integers were 0 
(water clear) to 8  (conesponding to the deepest green colour observed in cystic fibrosis) 
(0-2 = Mucoid, 3-5 = Mucopurulent, 6 - 8  = Purulent) (a copy of the colour chart is in the 
diary card at the end of the thesis).
2.2.3 Quantitative sputum bacteriology
A portion of the sputum collected was immediately removed for determination of the 
number of viable organisms present as described previously (Pye et al, 1995), Results 
are expressed as colony forming units per millilitre of sputum (cfu/ml). For each sample, 
the predominant organism present was determined (Pye et ai, 1995).
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2.2.4 Sputum and serum processing
The remaining sputum sample was ultracentrifuged at 50,000 x g for 90 minutes at 4°C. 
The sol phase was removed and stored at -70°C until it was analysed. Venous blood was
collected into a plain vacutainer tube, allowed to clot and then centrifuged at 1500 x g
0 0 for ten minutes at 25 C. The serum was then stored at "70 C until analysis.
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2.3 BIOCHEMICAL ASSAYS
2.3.1 Myeloperoxidase from sputum sol phase
Measurement of sputum myeloperoxidase activity (MPO) was used as an assessment of 
neutrophil influx. MPO activity was measured from sputum sol phase by chromogenic 
substrate assay relative to a preparation of lysed neutrophils. Ten microlitres of standard 
or sample were added to the wells of a microtitre plate, followed by 150 microlitres of 
1 mg/ml (w/v) 0-dianisidine dihydrochloride, 0.01% (v/v) 30% H2O2 in 50mM K3HPO4 
and 0.5% w/v hexadecyl trimethyl ammonium bromide (pH 6 ) (Sigma Aldrich Co. Ltd.
Poole, Dorset, UK). The plate was then incubated for 15 minutes at 25 C and the 
absorbance was then measured at 450nm using a Dynatech MR 5000 (Dynatech 
Corporation, Burlington, VT) and the MPO concentration interpolated from the standard 
cm’ve and expressed as Units/ml.
The standards, sample dilution used, and the lower detection of the assay is illustrated in 
Table 2-1. The standard curve is shown in Figure 2-1. The inter-assay coefficient of 
variation (standard deviation/mean (%)) was less than 1 0 %.
Standards Typical Sample Dilution Lower Limit of Detection
0.0976 - 50 Units/ml 1 in 5 - 1 in 500 0.1 Units/ml
Table 2-1: The standards, sample dilution used, and the lower limit of detection for 
the myeloperoxidase assay is illustrated.
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Myeloperoxidase (Units/ml)
Figure 2-1: Standard curve for myeloperoxidase.
2.3.2 Neutrophil elastase activity from sputum sol phase
Neutrophil elastase standard was purified from empyema pus according to the method of 
Baugh and Travis (Baugh et al, 1976). The activity of the elastase standard was 
determined by active site titration using published kinetic constants (Nakajima et al, 
1979). Neutrophil elastase activity present in the samples was measured 
spectrophotometrically using the synthetic substrate Succinyl-ala-ala-ala- 
paranitroanilide. 30pi of standard or sample were added to wells of a microtitre plate 
(Life Technologies, Ltd., Paisley, UK), followed by 150pl of Img/ml (w/v) Succinyi- 
ala-ala-ala-paranitroanilide (Sigma-Aldrich Company Ltd., Poole, Dorset, UK) in 0.0IM 
Tris-HCl, 0.5M NaCl, and 0.1% Triton X-100 (pH 8 .6 ). The plate was then incubated
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for 30 minutes at 37 C, following which the absorbance 410nm was measured and the 
elastolytic activity obtained by interpolation from the standard curve.
The standards, sample dilution used, and the lower detection of the assay is illustrated in 
Table 2-2. The lower limit of detection was 10 nM, and samples with less than this 
activity were considered to be zero for statistical purposes. The standard curve is shown 
in Figure 2-2. The inter-assay coefficient of variation was less than 1%.
Standards Typical Sample Dilution Lower Limit of Detection
0.8 iiM - 0.1 pM i in 10 - 1 in 50 0.01 pM
Table 2-2: The standards, sample dilution used, and the lower limit of detection for 
the elastase assay is illustrated (Substrate Succinyl-ala-ala-ala-paranitroanilide).
y = 8.4894X - 0.0043 
= 0.9996
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Figure 2-2: Standard curve for elastase.
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Later studies used the substrate methoxysuccinyl-ala-ala-pro-val-paranitroanilide 
(MeOSAAPVpNa) (Sigma-Aldrich Company Ltd., Poole, Dorset, UK) which was more 
sensitive at the bottom range of the assay. For this assay 20pi of standard or sample 
were added to wells of a microtitre plate (Life Technologies, Ltd., Paisley, UK), 
followed by MeOSAAPVpNa (0.3mM) in phosphate buffer (0.2M, pH 8.0). The 
reaction was allowed to continue for one hour at 37°C and then stopped by the addition 
of 200pl of 1 N acetic acid. The absorbance was read at 410nM and the elastolytic 
activity obtained from the standard curve by interpolation.
The standards, sample dilution used, and the lower detection of the assay is illustrated in 
Table 2-3. The inter-assay coefficient of variation was less than 1% and the lower limit 
of detection was 0.8 nM (samples with less than this activity were considered to be zero 
for statistical purposes).
Standards Typical Sample Dilution Lower Limit of Detection
0.8 nM " 0.1 pM Pure sample - 1 in 5 0.8 nM
Table 2-3: The standards, sample dilution used, and the lower limit of detection for 
the elastase assay is illustrated (Substrate MeOSAAPVpNa).
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2.3.3 Chemoattractants from sputum sol phase
2.3.3.1 Interleukin 8
IL8  was measured by ELISA using a commercially available Quantikine kit (R&D 
Systems Europe Ltd, Abingdon, UK). One-hundred microlitres of assay diluent RDI- 8  
were added to each well, followed immediately by 50pi of standard or sample (dissolved 
in calibrator diluent RD5P). One-hundred microlitres of IL8  conjugate were then added 
to each well. The wells were covered with an adhesive strip and the plate was incubated 
for 2.5 hours at 25°C. Twenty millilitres of wash buffer concentrate were dissolved in 
480 ml of distilled water to produce 500ml of wash buffer. Each well was washed six 
times with wash buffer. Two hundred microlitres of substrate solution (equal volumes of 
colour reagents A and B) were then added to each well and the plate was incubated for 
30 minutes at 25”C. The reaction was stopped by using 50 pi of IM sulphuric acid. The 
absorbance at 450mn with a 570nm correction was measured using a Dynatech MR 
5000 microplate reader, and the IL8  concentration calculated by inteipolation from the 
standard curve.
The standards, sample dilution used, and the lower detection of the assay is illustrated in 
Table 2-4. The standard curve is shown in Figure 2-3. The inter-assay coefficient of 
variation was 7%, and samples spiked with pure IL8  resulted in greater than 85% 
recovery Figure 2-4.
Standards Typical Sample Dilution Lower Limit of Detection
0.004 - 0.25 nM 1 in 100- 1 in 500 0.008 nM
Table 2-4: The standards, sample dilution used, and the lower limit of detection for 
the interleukin 8 assay is illustrated.
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Figure 2-3: Standard curve for interleukin 8.
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Figure 2-4: The optical density of the ELISA reaction (vertical axis) is plotted 
against the IL8 concentration (horizontal axis). The open circles are 4 sample 
results and the closed circles are spiked with known amounts of IL8. Results lie 
close to the line of the standard curve indicating good recovery of the sample spike.
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2.3.3.2 Lenkotriene B4
LTB4 was measured by ELISA using a commercially available kit (Amersham 
International pic, Buckinghamshire, UK). One-hundred microlitres of assay buffer were 
added to the non-specific-binding wells, followed immediately by 50 pi of standard or 
sample. Fifty microlitres of LTB4 antiserum was then added to all wells except the non­
specific-binding wells and the plate covered with an adhesive strip. The plate was the 
incubated for 2 hours at 25°C whilst shaking at 150 rpm on a rotary shaker (Fisher 
Scientific, Loughborough, UK). Fifty microlitres of LTB4 peroxidase conjugate was 
then added to every well and the plate covered with an adhesive strip and the plate was 
then further incubated for 1 hour at 25°C whilst shaking at 150 rpm on a rotary shaker 
(Fisher Scientific, Loughborough, UK). Each well was washed four times with 370pl of 
wash buffer. One-hundred microlitres of substrate solution was then added to each well 
and the plate covered with an adhesive strip. The plate was incubated for 20 minutes at 
25°C whilst shaking at 150 rpm on a rotary shaker (Fisher Scientific, Loughborough, 
UK). The reaction was then stopped by using 100 pi of IM sulphuric acid. The 
absorbance at 450nm with a 570mn correction was measured using a Dynatech MR5000 
microplate reader and the LTB4 concentration calculated by interpolation from the 
standard curve.
The standards, sample dilution used, and the lower detection of the assay is illustrated in 
Table 2-5. The standard curve is shown in Figure 2-5. The inter-assay coefficient of 
variation was <6 %, and samples spiked with pure LTB4 resulted in greater than 85% 
recovery (Figure 2-6).
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Standards Typical Sample Dilution Lower Limit of Detection
0.028 - 0.9 nM 1 in 30 - 1 in 50 0.17 nM
Table 2-5: The standards, sample dilution used, and the lower limit of detection for 
the lenkotriene B4 assay is illustrated.
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Figure 2-5: Standard curve for LTB4. The bound/total bound LTB4 (horizontal 
axis) is plotted against the LTB4 concentration (vertical axis).
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Figure 2-6: The bound/total bound LTB4 (horizontal axis) is plotted against the 
LTB4 concentration (vertical axis). The open circles are 4 sample results and the 
closed circles are spiked with known amounts of LTB4. Results lie close to the line 
of the standard curve indicating good recovery of the sample spike.
2.3.4 Elastase inhibitors from sputum sol phase
2.3.4.1 Secretory leukoprotease inhibitor
SLPI was measured by ELISA using a commercially available Quantikine kit (R&D 
Systems Europe Ltd, Abingdon, UK). One-hundred microlitres of assay diluent RDIQ 
were added to each well, followed immediately by 100pi of standai'd or sample. The 
plate was covered with an adhesive strip and incubated for 2 hours at 25^0. Twenty 
millilitres of wash buffer concentrate were dissolved in 480 ml of distilled water to 
produce 500ml of wash buffer. Each well was then washed four times with 370 pi of 
wash buffer. Two-hundred microlitres of SLPI conjugate were then added to each well, 
the wells covered with an adhesive strip, and the plate was incubated for 2  hours at
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25^C. Each well was washed four times with 370 pi of wash buffer. Two hundred 
microlitres of substrate solution (equal volumes of colour reagents A and B) were then 
added to each well and the plate was incubated for 20 minutes at 25°C. The reaction was 
stopped by using 50 pi of IM sulphuric acid. The absorbance at 450nm with a 570nm 
correction was measured using a Dynatech MR 5000 microplate reader, and the SLPI 
concentration calculated by interpolation from the standard curve.
The standards, sample dilution used, and the lower detection of the assay is illustrated in 
Table 2-6. The standard curve is shown in Figure 2-7. The inter-assay coefficient of 
variation was <10%, and samples spiked with pure SLPI resulted in greater than 85% 
recovery (Figuie 2-8).
Standards Typical Sample Dilution Lower Limit of Detection
8  - 333 pM 1 in 1 0 , 0 0 0  - 1 in 1 0 0 ,0 0 0 1,125 pM
Table 2-6: The standards, sample dilution used, and the lower limit of detection for 
the SLPI assay is illustrated.
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Figure 2-7: Standard curve for SLPI.
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Figure 2-8: The optical density of the ELISA reaction (vertical axis) is plotted 
against the SLPI concentration (horizontal axis). The open circles are 6 sample 
results and the closed circles are spiked with known amounts of SLPI. Results lie 
close to the line of the standard curve indicating good recovery of the sample spike.
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2.3.4.2 Alpha-1 -antitrypsin
AAT was measured by ELISA relative to a commercially available serum standard (The 
Binding Site Limited, Birmingham, UK). Two hundred microlitres of goat antihuman 
AAT antibody (The Binding Site Limited, Birmingham, UK) in 0.05M sodium 
carbonate / bicarbonate pH 9.6 was added to a MAXISORP (Nunc) microtitre plate and
incubated overnight (4 °C). The plate was then washed three times with PBS containing 
1% (v/v) Tween 20. Two hundred microlitres of standard or sample were added to the
plate followed by a 60 minute incubation at 37 °C. The plate was then washed thi'ee 
times with PBS containing 1% (v/v) Tween 20. Two hundred microlitres of goat 
antihuman AAT antibody peroxidase conjugate (The Binding Site Limited, Birmingham, 
UK) in PBS containing 1% (v/v) Tween 20 was then added to each well, the plate was
then incubated for 60 minutes at 37 °C. Each well was then washed three times with PBS 
containing 1% (v/v) Tween 20 (Sigma). Two hundred microlitres of 1 mg/ml O- 
phenylamine dihydrochloride (Sigma-Aldrich Company Limited, Poole, Dorset, UK), 
0.01% H2O2 in 1 volume O.IM citric acid (Sigma-Aldrich Company Limited, Poole, 
Dorset, UK)) / 2 volumes O.IM Na2HP0 4  pH 5 was then added to each well followed by
an incubation for 10 minutes at 25 ”c . The reaction was then stopped with 50p,l of 0.5M 
citric acid. The plate was then read at 450nm and the AAT concentration calculated from 
the standard curve by interpolation.
The standards, sample dilution used, and the lower detection of the assay is illustrated in 
Table 2-7. The standard curve is shown in Figure 2-9. The inter-assay coefficient of 
variation was less than 5%.
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Standards Typical Sample Dilution Lower Limit of Detection
0.001 - 1.08 nM 1 in 500 - 1 in 100,000 1.68 nM
Table 2-7: The standards, sample dilution used, and the lower limit of detection for 
the alpha-l-antitrypsin assay is illustrated.
^  0 v>
g  -0.1 
Ü5 -0.2
I  .0 .3
o -0.4 
D)O -0.5
- 0.6
y = 0.6351x-0.8056 
= 0.9909
0 0.5 1
Log AAT (ug/L)
1.5
Figure 2-9: Standard curve for alpha-l-antitrypsin.
2.3.5 Protein leakage
The ratio of sol/serum albumin and sol/serum AAT was obtained for each patient sample 
and multiplied by 100 for convenience as described previously (Stockley, 1984). This 
value was used as a measure of protein transudation from plasma indicating the degree 
of lung airway leakage.
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2.3.5.1 Measurement of albumin from sputum sol phase
Albumin from the sputum sol phase was measured by radial immunodiffusion using a 
commercially available kit (The Binding Site Limited, Birmingham, UK). Five 
micro litres of standard or sample was added to each well, and the plate was incubated 
for 72 hours at 25°C. The ring diameters were then measured using an eye piece 
graticule and the albumin concentration present in the samples calculated by 
interpolation from the standard curve.
The standards, sample dilution used, and the lower detection of the assay is illustrated in 
Table 2-8. The inter-assay coefficient of variation was less than 5%.
Standai'ds Typical Sample Dilution Lower Limit of Detection
16 - 160 mg/1 Pure to lin  20 1 0  mg/1
Table 2-8: The standards, sample dilution used, and the lower limit of detection for 
the sputum albumin assay is illustrated.
2.3.5.2 Serum albumin assay
Serum albumin was measured by radial immimodiffiision using a commercially 
available kit (The Binding Site Limited, Birmingham, UK). Five microlitres of standard 
or sample was added to each well, and the plate was incubated for 72 hours at 25°C. The 
ring diameters were then measured using an eye piece graticule and the albumin 
concentration present in the samples calculated by interpolation from the standard curve.
The standards, sample dilution used, and the lower detection of the assay is illustrated in 
Table 2-9. The inter-assay coefficient of variation was less than 3%.
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Standards Typical Sample Dilution Lower Limit of Detection
500 - 5,000 mg/1 1 in 2 0 300 mg/1
Table 2-9: The standards, sample dilution used, and the lower limit of detection for 
the serum albumin assay is illustrated.
2.3.6 Acute phase proteins
2.3.6.1 Serum Alpha-l-antitrypsin assay
AAT was measured by radial immunodiffusion using a commercially available kit (The 
Binding Site Limited, Birmingham, UK). Five microlitres of standard or sample was 
added to each well, and the plate was incubated for 72 hours at 25°C. The ring diameters 
were then measured using an eye piece graticule and the AAT concentration present in 
the samples calculated by interpolation from the standard curve.
The standards, sample dilution used, and the lower detection of the assay is illustrated in 
Table 2-10. The inter-assay coefficient of variation was less than 2%.
Standards Typical Sample Dilution Lower Limit of Detection
5.4-53.8 pM Pure 1.9 pM
Table 2-10: The standards, sample dilution used, and the lower limit of detection 
for the serum alpha-l-antitrypsin assay is illustrated.
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2.3.6.2 Serum C reactive protein assay
Serum C reactive protein was measured by radial immunodiffusion using a 
commercially available kit (The Binding Site Limited, Birmingham, UK). Five 
microlitres of standai'd or sample was added to each well, and the plate was incubated 
for 72 hours at 25°C. The ring diameters were then measured using an eye piece 
graticule and the C reactive protein concentration present in the samples calculated by 
interpolation from the standard curve.
The standards, sample dilution used, and the lower detection of the assay is illustrated in 
Table 2-11. The inter-assay coefficient of variation was less than 2.5%.
Standards Typical Sample Dilution Lower Limit of Detection
5.2 - 52.0 mg/1 Pure 2  mg/1
Table 2-11: The standards, sample dilution used, and the lower limit of detection 
for the serum C reactive protein assay is illustrated.
2,4 Lung function testing
Full lung function testing including FEVi, FVC, VC, TLC, RV, kCO and reversibility 
following nebulised p2 agonist (salbutamol 5mg) were carried out in the stable clinical 
state (Society et al, 1994). They were expressed as % predicted for the patients age, sex, 
and height (Society et al, 1994).
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3. THE INTERRELATIONSHIP OF SPUTUM INFLAMMATORY 
MARKERS IN PATIENTS WITH CHRONIC BRONCHITIS
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3.1 INTRODUCTION
The neutrophil and more specifically elastase released from its azurophil granules has 
been implicated as a major mediator of bronchial disease (Stockley, 1994). This serine 
proteinase is capable of generating many of the features of chronic bronchial disease 
including epithelial damage (Amitani et al, 1991), reduced ciliary beat frequency 
(Smallman et al, 1984), mucus gland hyperplasia (Snider et al, 1985), mucus secretion 
(Sommerhoff et al, 1990), and also to inactivate many of the critical lung host defences 
(Solomon, 1978)(Tosi et al, 1990). These latter effects may facilitate bacterial 
colonisation, which is often present in patients with chronic bronchitis (Monso et al, 
1995).
However, for neutrophil elastase to have these effects, it has to overcome the anti- 
elastases that protect the tissues. SLPI is thought to be the most critical anti-elastase 
protecting the airways (Morrison et al, 1987) whereas alpha-l-antitrypsin is thought to 
be less important at this site, although critical at the alveolar level protecting against the 
development of emphysema (Gadek et al, 1981).
There have been few studies assessing the complex interplay of inflammatoiy cells and 
appropriate mediators in established lung disease. Recent limited studies have indicated 
that neutrophils are increased in the airway of patients with chronic bronchitis (Riise et 
al, 1995)(Pesci et al, 1998), and that the degree of neutrophil recruitment is related to the 
severity of airflow obstruction (Keatings et al, 1997), although separation of cause or 
effect has not been possible. The neutrophils or their product MPO is related to the
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presence of a single chemoattractant, IL8 (Riise et al, 1995)(Pesci et al, 
1998)(Yamamoto et al, 1997). Although these studies have suggested that IL8 may be 
the major factor influencing neutrophil recruitment, there are clearly other 
chemoattractants that may also play a role (Mikami et al, 1998). This concept is of 
importance since in vitro studies have indicated that chemoattractants may interact in an 
additive way (Mikami et al, 1998) and in addition there may be a hierarchical response 
influencing the cell and its migration pattern (Foxman et al, 1997).
Furthermore studies of the relationship between chemoattractants and neutrophils may 
be finther complicated, although most of this concept is based on in vitro studies. 
Neutrophil activation can lead to the release of the chemoattractants ÏL8 (McCain et al, 
1994) and LTB4 (Ford-Hutchinson et al, 1980) that could result in further neutrophil 
recruitment. Release of elastase from the neutrophil may stimulate production of IL8 
from epithelial cells (Nakamura et al, 1992) and LTB4 from alveolar macrophages 
(Hubbard et al, 1991), and at the same time reduce production of its own natural 
inhibitor, SLPI (Sallenave et al, 1994) thereby perpetuating its function. Furthermore 
impairment of host defences by elastase could facilitate bacterial colonisation and 
endotoxin release from bacteria also provides a further potential mechanism for 
neutrophil recruitment by stimulating production of IL8 by epithelial cells (Khair et al,
1994).
The purpose of the present study was to investigate patients with chi'onic bronchitis and 
a wide spectrum of neutrophil influx to assess the interrelationship of the inflammatory 
markers: neutrophil influx (as reflected by the sputum MPO concentration) and the
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chemoattractants (ILS and LTB4); active neutrophil elastase to the chemoattractants, its 
own inhibitor SLPI, and bronchial protein leak (sputum/serum albumin ratio); FEVi (% 
Predicted) and MPO, elastase activity, ILS, LTB4, SLPI, and protein leak.
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3.2 METHODS
3.2.1 Patient selection
Patients with a history of chronic bronchitis, as defined by the Medical Research 
Council (Medical Research Council, 1965), were studied in the stable clinical state. 
Patients that had an infection within the preceding 2 months of the study were excluded.
3.2.2 Processing of samples and lung function testing
The sputum and serum processing, the measurements of MPO, elastase activity, IL8, 
LTB4, SLPI, and protein leakage (sputum/serum albumin ratio; %) is described in the 
general methods (Chapter 2). All subjects underwent standardised lung function testing 
(Society et al, 1994) at the time of the study.
3.2.3 Statistical analysis
Values are reported as mean (± standard error). Correlations between the inflammatory 
markers were assessed by the Spearman correlation coefficient (2 tailed). Samples were 
subdivided into 4 groups: those with no detectable elastase activity (Group A); those 
with small amounts of elastase activity (l-50nM) as Group B; those with a moderate 
level of elastase activity (50-100nM) as Group C; and those with high levels of elastase 
activity (>100nM) as Group D. The Ki'uskal-Wallis test was used to compare results 
between samples grouped by their elastase activity and where significant the Mann- 
Whitney U test for non paired data (2 tailed) was used to compare individual groups. A p 
value < 0.05 was considered to be significant.
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3.3 RESULTS
The patients that entered the study included 101 samples from 55 subjects with chronic 
bronchitis (without alpha-l-antitrypsin deficiency), 61 samples from 40 patients with 
clii’onic bronchitis with homozygous (PiZ) alpha-1 -antitrypsin deficiency, and 64 
samples from 43 patients with idiopathic bronchiectasis diagnosed by high resolution 
computed tomography or bronchogram. Table 3-1 reveals the characteristics of the study 
population and the major results section reflects analysis of all samples as individual 
data points.
Chi’onic bronchitis Alpha-l-
antitrypsin
deficiency
Bronchiectasis
Number of patients 55 40 43
Mean age (years) 65.0 48.7 65.2
Range (42-79) (33-62) (36-82)
Gender (M/F) 38/17 28/12 14/29
Current smoker 30 9 3
Ex- smoker 25 31 19
Never smoker 0 0 21
Mean FEV i (% Predicted) 62.6 + 3.0 
(13.6-113,9%)
30.2 + 2.5 
(12-56%)
69.0 + 3.8 
(28.0-133.5%)
Table 3-1: Characteristics of the study population.
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3.3.1 Sputum MPO and elastase activity
Myeloperoxidase activity was detectable in all but one sample and 147 samples (65.0%) 
had detectable elastase activity > 1 nM. The relationship between these two factors is 
summarised in Figure 3-1.
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Figure 3-1: The relationship between sputum MPO (Units/ml) and elastase activity 
(pM) is shown on logarithmic scales. Each circle represents the data from an 
individual sample (r= 0.68, n= 226, p< 0.001). Samples where elastase was not 
detected are shown as O.OOOSpM (arrowed).
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3.3.2 Sputum chemoattractants and MPO
All samples (226) contained detectable amounts of both chemoattractants (range = 0.05- 
87.38 nM for IL8 and 0.34-263.34 nM for LTB4). Figure 3-2 and Figure 3-3 show the 
relationship between the levels of the chemoattractants IL8 and LTB4 and neutrophil 
influx (MPO). The overall data revealed a positive correlation between both 
chemoattractants and MPO activity (IL8; r= 0.52, p< 0.001 and LTB4; r= 0.41, p< 
0.001). Similar correlations were present even when the outlying samples (MPO >10 
Units/ml) were excluded (see Figure 3-2 and Figure 3-3).
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Figure 3-2: The relationship between sputum MPO (Units/ml) and the 
chemoattractant IL8 (nM) is shown (r= 0.52, p< 0.001). Each circle represents the 
result from a single sample (open circles represent samples with an MPO value <10 
Units/ml and closed circles represent samples with an MPO value >10 Units/ml). 
After excluding these latter samples the relationship persisted (r= 0.40, p< 0.001).
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Figure 3-3: The relationship between sputum MPO (Units/ml) and the 
chemoattractant LTB4 (nM) is shown (r= 0.41, p< 0.001). Each circle represents 
the result from a single sample (open circles represent samples with an MPO value 
<10 Units/ml and closed circles represent samples with an MPO value >10 
Units/ml). After excluding these latter samples the relationship persisted (r= 0.43, 
p< 0.001 respectively).
108
3.3.3 Sputum chemoattractants and elastase activity
The overall data revealed a positive correlation between both IL8 and LTB4 and elastase 
activity (IL8 r= 0.55, p< 0.001 and LTB4 i -  0.41, p< 0.001). However, in view of the 
wide scatter of elastase activity (range 0-8,564 nM), the samples were fuither subdivided 
into 4 groups based on the activity. Those with no detectable elastase activity were 
classified as Group A (n=79); those with small amounts of elastase activity (l-50nM) as 
Group B (n=92); those with a moderate level of elastase activity (50-100nM) as Group C 
(n=14); and those with high levels of elastase activity (>100nM) as Group D (n=41). 
The mean ± SE levels of free elastase in each of the groups were; zero for Group A; 21.7 
±1.4 iiM for Group B; 71.1 ±4 .7  nM for Group C and 1739.7 ± 330.4 nM for Group D. 
Figure 3-4 demonstrates the average Interleukin 8 levels (± SE) and Lenkotriene B4 for 
the four sample groups (A-D). Low concentrations of IL8 and LTB4 were found in 
patients with no detectable elastase (IL8 5.61 nM ± 0.67; LTB4 9.09 nM ± 1.47). 
However in the presence of elastase activity (Group B) greater amounts of these 
chemoattractants were found (p< 0.001 for IL8 and p< 0.005 for LTB4). The highest 
levels were found in patients in Group D (elastase activity > 100  nM) with an average 
ILS concentration of 25.61 nM ± 2.48 and 36.51 nM ± 8.80 for LTB4 (both p< 0.001 
compared with Group A).
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Figure 3-4: The relationship between the sputum chemoattractants (IL8 (nM) and 
LTB4 (nM)) and elastase activity (nM) is shown. Samples are grouped into those 
with no elastase activity, elastase activity between 1-50 nM, elastase activity 
between 50-100 nM, and those with elastase activity greater than 100 nM (see text). 
The histograms represent the mean ± SE bar. The asterisks indicate values that are 
significantly greater than samples with no elastase activity (*  p< 0.005;** p< 0.001).
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3.3.4 Sputum elastase activity and SLPI
SLPI was detectable in all samples (range 0.04-14.26 pM). There was a negative 
correlation between the SLPI concentration and elastase activity (r= -0.49, p< 0.001). 
Separation of samples into their elastase ranges indicated that SLPI concentrations were 
unaltered in samples with absent or low concentrations of elastase (Groups A&B). 
However the average concentration was reduced (p< 0.005) from 3.78 pM ± 0.51 
(Group A) to 1.35 pM ± 0.41 in samples where elastase activity ranged from 50-100nM 
(Group C) and reduced further (p< 0.001) in samples containing >100nM elastase 
activity (0.66 pM ± 0.16). These results are summarised in Figure 3-5.
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Figure 3-5: The relationship between sputum SLPI levels (pM) (mean ± SE) and 
elastase activity (nM) is shown. The asterisks indicate group values that are 
significantly greater than those with no elastase activity (* p< 0.005;** p< 0.001).
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3.3.5 Sputum elastase activity and protein leakage
Protein leakage (as assessed by the sputum/serum albumin ratio) showed a positive 
correlation with elastase activity (r= 0.36, p< 0.001). In samples where elastase activity 
was undetectable (Group A) the degree of leakage was low (1.02% ± 0.14). Protein 
leakage was also low in Group B (1.08% ± 0.10), but increased in samples with elastase 
activity between 50 and 100 nM (Group C: 2.02% ± 0.51, p< 0.05). Protein leakage was 
greatest (2.54 % ± 0.42) in samples containing greater than lOOnM elastase (p< 0.005 
compared with Group A).
3.3.6 Effect of treatment
Patients with chronic lung disease are frequently treated with a variety of agents that 
may affect lung inflammation. No patients had taken oral steroids or antibiotic therapy 
within the preceding 2 months of sample collection. There were 90 of the 226 samples, 
however, were from patients on inhaled steroids with or without theophylline therapy. 
Exclusion of these samples did not alter the results seen for the group as a whole (Table 
3-2).
MPC
&
Elastase
activity
MPO
&
IL8
MPO
&
LTB4
Elastase
activity
&
IL8
Elastase
activity
&
LTB4
Elastase
activity
&
Protein
Leak
Elastase
activity
&
SLPI
r= 0.52 r= 0.44 1- 0.34 r= 0.57 r= 0.38 r= 0.46 r= - 0.52
p< 0.001 p< 0.001 p< 0.001 p< 0.001 p< 0.001 p< 0.001 p< 0.001
Table 3-2: Correlations after excluding samples from patients on inhaled steroids 
with or without theophylline therapy.
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3.3.7 Influence of replicate samples
Some patients provided more than 1 sample (usually 2). These Avere treated as individual 
data points (see methods). Nevertheless since it is possible that this approach could bias 
the interrelationships, the data was reanalysed for single samples from each patient and 
this had no significant effect on the correlation or statistics (Table 3-3).
MPO
&
Elastase
activity
MPO
&
IL8
MPO
&
LTB4
Elastase
activity
&
ILS
Elastase
activity
&
LTB4
Elastase
activity
&
Protein
Leak
Elastase
activity
&
SLPI
r= 0.43 r= 0.32 r= 0.43 1= 0.40 r= 0.30 r= 0.49 1- - 0.62
p< 0.001 p= 0.001 p< 0.001 p< 0.001 p< 0.001 p< 0.001 p< 0.001
Table 3-3: Correlations after excluding replicate samples.
3.3.8 Relationship with FEVi (% Predicted)
There was no correlation between the severity of lung function and neutrophil influx 
(MPO) or protein leakage for the group as a whole. Subset analysis of the individual 
patient groups was undertaken since the data would be skewed by the patients with 
idiopathic bronchiectasis who usually have well preserved lung function despite marked 
bronchial inflammation.
When the patient groups were studied independently there was still no correlation 
between FEVi and either neutrophil influx or protein leakage in the patients with 
bronchiectasis or AAT deficiency. In patients with chronic bronchitis without AAT 
deficiency, however, there was a significant negative correlation between FEVi and
113
MPO, elastase activity, chemoattractants, and protein leakage (Table 3-4). This 
relationship was retained when the analysis was confined to a single result (mean of 
replicates) from each patient (Table 3-4), with the exception of LTB4. Figure 3-6 shows 
the relationship between FEV i (% Predicted) and protein leak (sol/serum albumin ratio 
(%)) is shown for patients with chronic bronchitis without AAT deficiency when the 
analysis was confined to a single result.
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Figure 3-6: The relationship between FEVi (% Predicted) and protein leak 
(sol/serum albumin ratio (%)) is shown for patients with chronic bronchitis without 
AAT deficiency. Each point represents a value for each patient (r= -0.54, p=0.01).
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Replicate samples Single samples
r value p value r value p value
MPO -0.37 <0.001 -0.31 <0.005
Elastase activity -0.23 0.01 -0.34 0.001
IL8 -0.27 < 0.005 -0.34 0.001
LTB4 -0,22 0.02 -0.16 0.1
SLPI -0.05 0.7 0.17 0.5
Albumin leakage -0.42 <0.01 -0.54 0.01
Table 3-4: Correlation with FEVi (% Predicted) and markers of bronchial 
inflammation for replicate and single samples (mean of replicates) from each 
patient.
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3.4 DISCUSSION
The current data spans a wide range of myeloperoxidase activity used as a marker of the 
presence of bronchial neutrophils (Riise et al, 1995)(Pesci et al, 1998)(Stockley et al,
1991). Activation of these cells (as would occur during the migration process) leads to 
both MPO and elastase release (Ohlsson et al, 1977) as both are derived from the same 
granule. Indeed the data shows a good correlation between the MPO activity and 
elastase over the wide range, although this is less apparent at the lower end where many 
samples with detectable MPO had no detectable elastase activity. This is to be expected 
since the presence of bronchial inhibitors such as SLPI and alpha-1-antitrypsin would be 
expected to inhibit the low concentrations of elastase released when neutrophil numbers 
are low. Elastase activity was used in this study as in vitro studies have suggested the 
effects of elastase on inflammation are dependent on its activity.
Neutrophil recruitment is dependent upon the chemoattractants being released. Studies 
have shown that IL8 and LTB4 (Mikami et al, 1998) are the major chemoattractants in 
patients with bronchial disease and indeed both correlate with the MPO activity as 
indicated here. The source of these 2 chemoattractants, however, is unknown. For 
instance, endotoxin and TNF-a (both of which are likely to be present in the airway) are 
known to increase IL8 production by epithelial cells (Khair et al, 1994). In addition, ILS 
is stored within the specific granules of a neutrophil and is also released from this cell on 
activation (Takahashi et al, 1993). Finally, it has been suggested that elastase itself when 
released from the neutrophil can lead to IL8 production by bronchial epithelial cells 
(Nakamura et al, 1992). Whatever the mechanism it would therefore be predicted that
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IL8 levels should correlate not only with neutrophils (as indicated by the MPO 
concentration) but also with the elastase activity. Although the IL8 levels measured here 
do correlate with MPO (as suggested by previous workers (Riise et al, 1995)(Pesci et al, 
1998)(Yamamoto et al, 1997)), the relationship is less robust than that for MPO and 
elastase activity, suggesting that the relationship is not a simple cause and effect but 
probably reflects multiple sources of ILS. However, even though there is a highly 
statistical relationship between IL8 and MPO and elastase, examination of the raw data 
suggests this may not be a simple linear relationship. Indeed the data would suggest that 
the relationship maybe curvilineai* with a tlireshold effect leading to rapidly increasing 
concentration of neutrophil MPO once the IL8 level exceeds approximately 10 nM 
(Figure 3-2).
The relationship with LTB4 on the other hand seems to be much more straightforward, 
although there was a wide scatter of values for both MPO and LTB4, the relationship 
tends to follow a general linear trend (Figure 3-3). However the dose relationsliip 
between MPO and LTB4 suggests either that the neutrophil itself may be the source of 
both proteins or that LTB4 is the major factor determining neutrophil recmitment in 
these samples.
However it has been shown that LTB4 and IL8 are additive in their effect on neutrophil 
recruitment in vitro (Mikami et al, 1998). It may well be therefore that at low levels of 
IL8, recruitment of small numbers of neutrophils leads to release of LTB4 from the 
activated cell. This may thereafter add to the chemoattractant gradient recruiting more 
cells in a linear fashion. However, once IL8 levels exceed 10 nM the inflammatory
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process may become excessive leading to much greater neutrophil recruitment (as 
indicated by MPO) than would be expected for LTB4 alone. This concept would be 
consistent with the potential curvilinear relationship between IL8 and MPO as well as 
the data points for MPO displaced from the LTB4 curve (see Figure 3-3). Again this 
concept would be consistent with a hierarchical organisation of chemoattractants 
(Foxmanetal, 1997).
Alternatively it is possible that other chemoattractants are involved in samples where 
neutrophil recruitment is excessive. The solid symbols in figures 3-2 and 3-3 represent 
samples where MPO exceeds 10 Units/ml. These samples appeal’ displaced from the 
relationship of both LTB4 and IL8 to MPO and this complex relationship needs further 
comment. Preliminary data indicated that of the 10 samples colonised with 
Pseudomonas aeruginosa, 1 were in this high MPO group of 17 samples. It therefore 
remains possible that the colonising organism may also influence cell migration and this 
point will be covered in the next chapter.
Studies of the relationships of the inflammatory process to elastase are worthy of further 
comment. When released from the neutrophil this enzyme would be rapidly inhibited by 
both alpha-1-antitrypsin and, in the airway, more particularly by SLPI. This study 
showed that there were low levels of SLPI associated with high levels of elastase 
activity. In vitro studies have indicated that elastase can adversely affect SLPI 
production by epithelial cells (Sallenave et al, 1994) thus it would be expected that an 
inverse relationship should exist. However, the data as presented here indicates that 
SLPI concentration does not decrease until the elastase activity of the samples is in
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excess of 50 nM. The relationship between SLPI and elastase therefore is not a simple 
linear one and the data presented here may indicate a threshold at which significant 
interference with epithelial cell metabolism or the development of epithelial damage 
occurs resulting in a reduction in SLPI secretion. At present whether this relationship 
reflects cause or effect is not known and interpretation will have to await intervention 
studies using specific anti-elastases. If the reduction in SLPI production is merely a 
reflection of the elastase activity in the airway, the introduction of an effective anti- 
elastase would be expected to lead to an acute rise in SLPI concentration. However if 
significant airway cell damage is responsible for the reduction in SLPI, a longer period 
of repair would be necessary before SLPI concentrations return to normal.
There is, however, a similar relationship between the elastase activity and inflammation 
in the airway as reflected in leakage of serum albumin. Protein leakage increased only 
when free elastase activity was >50 nM, and increased further when the elastase activity 
exceeded 100 nM. The exact mechanism for protein leakage is currently unknown. 
Previous studies in patients with bronchiectasis have shown antibiotic therapy reducing 
the bacterial load and hence neutrophil influx, results in a rapid reduction in protein 
leakage as sputum purulence and elastase activity disappear (Stockley et al, 1979). The 
rapidity of this response would suggest that airway leakage is not a direct effect of 
epithelial cell damage. The leakage may therefore reflect an effect of elastase on the 
tight junction between epithelial cells (Peterson et al, 1995), the simultaneous release of 
vasoactive mediators in the airway, and cleavage of cadherins that link endothelial cells 
(Carden et al, 1998). Once again interpretation of the associations will await studies with 
effective anti-elastases.
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The relationship between elastase and IL8 is of fuilher interest. As indicated above, 
studies have suggested that IL8 release by epithelial cells can be induced by the presence 
of free elastase (Nakamura et al, 1992). However, since both mediators can also be 
derived from the neutrophil (although from different cell granules) it would be expected 
that the two concentrations would be related. The data provided here shows that the 
relationship is present although weak and it is therefore unlikely that these 2 proteins 
directly represent a cause and effect. Also, as indicated above, the relationship between 
IL8 and myeloperoxidase does not appear to be linear across a wide range of 
inflammatory situations unlike results of previous more limited studies (Riise et al,
1995)(Pesci et al, 1998). However, it is also possible that the presence of additional (as 
yet uncharacterised) factors may play a role when inflammation is excessive.
Finally Keatings and colleagues showed that increased neutrophil influx was associated 
with worse lung function in patients with chronic bronchitis (Keatings et al, 1997) 
although separation of cause or effect has also not been possible. Similarly, the current 
study showed that both increased neutrophil influx (as assessed by the concentration of 
MPO), elastase activity, chemoattractants IL8 and LTB4, and protein leak were 
associated with worse lung function in patients with chronic bronchitis without alpha-1- 
antitrypsin deficiency. The relevance of this is currently uncertain as these correlations 
are weak and this study does not separate cause or effect. In addition there was no 
association in the other two patient groups (those with alpha-1-antitrypsin deficiency or 
bronchiectasis) although it should be noted that all patients with alpha-1-antitrypsin 
deficiency had an FEVi < 56% predicted which would tend to minimise the range of 
inflammation that might potentially be predicted. Thus in this group there was a limited
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spectrum of disease being assessed which might make any relationship more difficult to 
determine. The association is thus complex and further studies are required to determine 
whether the observation in chronic bronchitis without alpha-1-antitrypsin deficiency 
represents a true cause and effect.
In summary the inteiTelationship between the neutrophil and some of its products and 
the inflammatory process has been assessed in patients with different causes of bronchial 
disease to provide a wide spectrum of neutrophilic inflammation. Although relationships 
can be demonstrated it is clear that these are complex and understanding the inteiplay of 
various mediators will require the development of specific antagonists and appropriately 
designed intervention studies.
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4. AIRWAY BACTERIAL LOAD IN STABLE OBSTRUCTIVE
AIRWAYS DISEASE:
A POTENT STIMULUS FOR AIRWAY INFLAMMATION
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4.1 INTRODUCTION
As described in the general introduction chapter, the defence system of the lungs in 
patients with chronic bronchitis often fails to maintain sterility in the airways, leading to 
persistent lower airway colonisation with bacteria (Monso et al, 1995)(Murphy et al,
1992)(Stockley, 1998)(Pelaet al, 1998).
In animal models, small numbers of bacteria instilled into the airways can be cleared 
efficiently by the primary host defence mechanisms alone (Onoffio et al, 1983), 
However, as increasing numbers of organisms are instilled, secondary host defences are 
activated (Onoffio et al, 1983)(Vial et al, 1984) and this is likely to reflect the release of 
pro inflammatory mediators, resulting in an acute inflammatory response with 
predominant recruitment of neutrophils (Vial et al, 1984)(Toews et al, 1984). It is 
possible that persistent bacterial airway colonisation in humans with clironic airways 
diseases contributes in important ways to the morbidity of the disease. In particular, the 
chronic airway bacterial load may stimulate secondary host defences and lead directly to 
persistent airway inflammation even in the stable clinical state (Stockley, 1998)(Hill et 
al, 1986). This possibility has received little attention in clinical studies in man. For this 
reason, quantitative sputum bacteriology in patients with “stable” chronic bronchitis and 
its relationship of the acute inflammatory response in the lung was studied. This 
included the measurement of sputum colour assessed macroscopically, neutrophil influx 
(MPO), the neutrophil chemoattractants IL8 and LTB4, neutrophil elastase and its 
inliibitor SLPI, and finally airway protein leakage.
123
4.2 METHODS
4.2.1 Study Population
Thi'ee groups of patients with established bronchial disease and a history of chi’onic 
bronchitis, as defined by the Medical Research Council (Medical Research Council, 
1965), were studied in the stable clinical state. These included; 64 patients with clii'onic 
bronchitis with alpha-1-antitrypsin (AAT) deficiency, who had AAT levels < 1 1  pM 
(Silverman et al, 1989), and had the phenotype PiZ; 55 subjects with chronic bronchitis 
(without AAT deficiency); and 43 patients with idiopathic bronchiectasis diagnosed by 
high resolution computed tomography or bronchogram. None of the patients reported 
any change in respiratory symptoms (including sputum characteristics) within the eight 
weeks prior to the initial visit, and none were on oral steroids or antibiotics during the 
study.
4.2.2 Lung Function Testing
All subjects underwent standardised lung function testing (Society et al, 1994) at the 
time of the study.
4.2.3 Processing of samples
The sputum and serum processing, and assessment of sputum colour, MPO, elastase 
activity, IL8, LTB4, SLPI, and protein leakage (sputum/serum albumin ratio (%)) is 
described in the general methods (Chapter 2). In patients who provided more than one 
sample, the results from all sputum samples for the subject were averaged, and the mean 
result was used.
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4.2.4 Quantitative Bacteriology
Quantitative bacteriology was carried out on all spontaneously expectorated sputum 
samples as described in the general methods chapter. For data analysis, the bacterial load 
is expressed as the sum of all bacterial species present in that sample.
4.2.5 Statistical Analysis
Values ai’e reported as mean ± SE. The Ki'uskal-Wallis test was used to compare results 
at different bacterial loads, and if significant the Mann-Whitney U test for non paired 
data (one tailed) was used to compare individual groups. Correlations between the 
inflammatory markers were measured with the Spearman correlation coefficient (2 
tailed). A p value < 0.05 was considered to be statistically significant.
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4.3 RESULTS
The demographic information, smoking histories, and lung function measurements for 
the study population are shown in Table 4-1. The ages of the patients with chronic 
bronchitis without AAT deficiency and bronchiectasis were similar, while the mean age 
of the patients with AAT deficiency was lower (p< 0.005). Nearly half of the patients 
with bronchiectasis, but none of the patients with clnonic obstructive bronchitis or AAT 
deficiency, were lifelong non smokers. As in other reports (Brantly et al, 1988), few of 
the patients with AAT deficiency were current smokers.
Characteristic Chi'onic bronchitis AAT deficiency Bronchiectasis
Age (yr.) 67.4 ± 1.4 49.3 ±1.7 62.7 ± 2.6
range (51-78) (33-66) (36-82)
Gender (M/F) 38/17 49/15 15/28
Current smoker 30 9 4
Ex- smoker 25 55 18
Never smoker 0 0 21
FEVi (% Predicted) 36.0 ±4.5 26.7 ±3.1 63.8 ±4.9
FEVi/FVC 
(% Predicted)
49.3 + 2.9 38.4±3.1 70.5 ±3.3
Table 4-1: Mean ± SE demographics of the study group
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4.3.1 Sputum samples analysed
The subjects provided 336 sputum samples for analysis. These included 72 samples from 
55 subjects with chronic bronchitis without AAT deficiency, 179 samples from 64 
subjects with AAT deficiency, and 85 samples from 43 patients with bronchiectasis. 
Individual subjects provided up to 4 samples over as many as 12 weeks, whereas 74 
subjects provided a single sample only.
4.3.2 Bacterial Isolates
Among the 336 samples, 26% were classified as mixed normal flora (MNF) where no 
viable bacteria were cultmed or yielded only a sparse culture (< 10  ^cfu/ml) of normal 
oral commensals. Of the remaining samples, 5% yielded between 10  ^ and 10  ^ cfu/ml, 
8% yielded 10  ^and 10  ^cfu/ml, 13% yielded 10  ^and 10  ^cfu/ml, and 48% yielded > 10  ^
cfu/ml.
The overwhelming majority of the 'primary" (predominant) pathogens isolated were non 
typeable Haemophilus influenzae or Haemophilus parainfluenzae (grouped as 
Haemophilus species). Haemophilus species were often isolated in pure culture, 
particularly when the airway bacterial load was relatively low. Among the 45 samples 
with <10^ cfu/ml, 98% yielded Haemophilus species alone and the remaining sample 
yielded Streptococcus pneumoniae.
In the 42 sputum samples with 10^-10^ cfu/ml, the dominant organisms were 
Haemophilus species in 71%. In the remaining 12 samples, 4 grew coliforms, 4
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Staphylococcus aureus, 2 Proteus mirabilis, and one each of Streptococcus pneumoniae 
and Pseudomonas aeruginosa.
Among the 160 samples with the heaviest bacterial loads (> 10  ^cfu/ml), 69% contained 
Haemophilus species as the predominant organism. Among the remaining samples, 15% 
yielded Moraxella catarrhalis and 13% yielded Pseudomonas aeruginosa. Less 
common organisms included coliforms in 2, Streptococcus pneumoniae in 2, and one 
each of Acinetobacter Iwoffi and a Corynebacterium species.
In 20% of the samples, a secondary organism was isolated; however, in most of these 
samples (92%), the predominant isolate was already present at >10^ cfu/ml. These 
secondaiy organisms were present in minimally lower numbers in 48% of samples in 
which they were present, while their concentration was at least one order of magnitude 
lower in the remainder. The secondary pathogens were Haemophilus influenzae and 
Streptococcus pneumoniae in 69% and 15% of the samples, respectively. For data 
analysis, the bacterial load is expressed as the sum of all bacterial species present in that 
sample.
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4.3.3 Airway neutrophils
MPO concentration, as a measure of the number of airway neutrophils, coiTelated with 
airway bacterial load (r= 0.58; p< 0.0005). In samples with a low bacterial load, little 
MPO was present (Figure 4-1). However, samples that contained >10^ and <10^ cfu/ml 
had a highly significant increase in MPO (p < 0.01). Samples with > 10  ^ cfu/ml had an 
18 fold increase in MPO when compared with samples containing only MNF (p< 10’^ ).
MNF 10 10 10 
Airway Bacterial Load (cfu/ml)
>10
Figure 4-1: Relationship between sputum MPO (a measure of airway neutrophils) 
and airway bacterial load. MNF = mixed normal flora. Note the progressive 
increase in MPO with increasing bacterial load (from 10^  cfu/ml). The asterisks 
indicate significant differences when compared to samples containing only MNF (* 
p< 0.01 and **  p< 0.005). Histograms represent mean data ± SE bar lines.
Sputum colour, as an easily assessed visible surrogate for MPO, also correlated with 
airway bacterial load (r= 0.52; p< 0.0005). Using the nine-point scale, the average 
colour for samples containing only MNF was 2.8 ± 0.2, corresponding to a barely
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detectable yellow colour. In samples containing > 1 0 ^  cfii/ml, sputum colour was 
increased to an average of 4.2 ±0.1 (p< 0.0001 when compared with samples containing 
only MNF) (Figure 4-2).
10 ® 10® 10^ > 10 ' 
Airway Bacterial Load (cfu/ml)
Figure 4-2: Relationship between sputum colour and airway bacterial load. Note 
the progressive increase in colour with increasing bacterial load (from 10^  cfu/ml). 
The asterisks indicate signiBcant differences when compared to samples containing 
only MNF (* p< 0.05 and ** p< 0.005). Histograms represent mean data ± SE bar 
lines.
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4.3.4 Sputum chemoattractants
Immunoreactive IL8 and LTB4 were detectable in all samples, and both correlated with 
airway bacterial load (r= 0.67; p< 10'^ and r= 0.48; p< 0.0005 for IL8 and LTB4, 
respectively). Figui*e 4-3 demonsti*ates the relationship between IL8 and bacterial load 
and shows that sputum IL8 concentration increased significantly (p< 0.05) for samples 
containing >10^ and <10^ cfu/ml when compared to the results for MNF. Samples with > 
10® cfu/ml had a 5.3-fold higher IL8 concentration when compared to samples 
containing only MNF (p< 10'^). LTB4 was also significantly higher in samples 
containing >10^ and <10^ cfu/ml than in samples containing only MNF (Figure 4-4). 
Samples with >10® cfu/ml had a 5-fold higher LTB4 concentration when compared to 
samples containing only MNF (p< 10'^).
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MNF 10 10 10 
Airway Bacterial Load (cfu/ml)
>10
Figure 4-3: Relationship between sputum IL8 (nM) and bacterial load. Note that 
concentrations of IL8 increased progressively with increasing bacterial load (from 
10  ^ cfu/ml). The asterisks indicate significant differences when compared to 
samples containing only MNF (* p< 0.05 and **p< 0.005). Histograms represent 
mean data ± SE bar lines.
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Airway Bacterial Load (cfu/ml)
>10
Figure 4-4; Relationship between sputum LTB4 (nM) and airway bacterial load. 
Note that concentrations of LTB4 increased progressively with increasing bacterial 
load (from 10^  cfu/ml). The asterisks indicate significant differences when
compared to samples containing only MNF 
Histograms represent mean data ± SE bar lines.
(* p< 0.05 and ** p< 0.005).
133
4.3.5 Sputum leukocyte elastase activity
Leukocyte elastase activity in the samples also increased with increasing bacterial load 
(r= 0.43; p< 0.0005). Among 89 samples that contained only MNF, 29% contained 
detectable, but invariably low concentrations of leukocyte elastase activity (Figure 4-5). 
Elastase activity was present in 78% of the 27 samples containing 10^-10^ cfu/ml, with a 
significantly gi-eater mean value when compared with samples containing only MNF 
(Figure 4-5). However 87% of the 160 samples with > 10® cfu/ml had detectable elastase 
activity, and the mean value was 86-fold higher than samples containing MNF alone (p<
01
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Figure 4-5: Relationship between sputum leukocyte elastase activity (nM) and 
airway bacterial load. Note the progressive increase in leukocyte elastase activity 
with increasing bacterial load (from 10  ^ cfu/ml). The asterisk indicates significant 
differences when compared to samples containing only MNF (* p< 0.005). 
Histograms represent mean data ± SE bar lines.
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4.3.6 Sputum secretory leukocyte proteinase inhibitor
Levels o f SLPI correlated negatively with bacterial load (r= -0.52, p< 0.0001), Further 
examination of the data, however, revealed that the mean SLPI concentrations only fell 
at high bacterial loads (>10^ cfu/ml). In samples that contained only MNF, the mean 
SLPI concentration was 4.0 ± 0.6 pM whereas in samples with > 10  ^ cfu/ml, SLPI 
concentrations were reduced to 1.4 ± 0.2 pM (p< 0.0001 when compared with the MNF 
samples) (Figure 4-6).
Airway Bacterial Load (cfu/ml)
Figure 4-6: Relationship between sputum secretory leukoprotease inhibitor (pM) 
and airway bacterial load. Note the mean levels of SLPI do not change until 
bacterial loads >10® cfu/ml. The asterisk indicates a signiticant difference 
compared to samples containing only MNF (p< 0.001). Histograms represent mean 
data ± SE bar lines.
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4.3.7 Airway protein leakage
The sputum/semm albumin ratio showed a positive correlation with airway bacterial 
load ( i-  0.44, p< 0.0001). Samples colonised with 10  ^ and > 10® cfu/ml showed a 
greater sputum/serum albumin ratio (p< 0.005) compared to samples containing MNF 
alone Figure 4-7.
5 1.5
E 0.5
MNF 10 10 10 
Airway Bacterial Load (cfu/ml)
>10
Figure 4-7: Relationship of airway protein leakage (sputum/serum albumin ratio 
(%)) to aiiTvay bacterial load. Note the significant increase in samples containing 
10  ^ or more cfu/ml. Asterisks indicate signiticant differences compared to samples 
containing only MNF (p< 0.005). Histograms represent mean data ± SE bar lines.
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4.3.8 Effect of Type and Severity of Airflow Obstruction
Among the 43 patients with bronchiectasis, the airway bacterial load was > 10® in 70%, 
while only one patient was in the MNF group. The airway bacterial load in the other two 
patient groups was less intense than in the bronchiectasis group and there was no clear 
relationship between the airway bacterial load and the severity of airflow obstruction. 
For example even in the chronic bronchitis group, the FEVi (% predicted) was 28.2 ±
3.2 for those with MNF (n = 19) and 29.1 ±3.3 for those with >10® cfli/ml (n=17). 
Among the patients with AAT deficiency, those with MNF (n = 15) had a mean FEVi of
28.7 (± 4.6)% of predicted, and those with > 10® cfu/ml (n = 24) had an FEVi of 26.3 (± 
3.7)% of predicted.
4.3.9 Effect of bacterial species
When Pseudomonas aeruginosa was found, the bacterial load was always >10® cfu/ml 
(except one sample 10 -^10® cfu/ml). To determine the effect(s) of bacterial species 
alone, further analysis was confined to samples which: 1) contained only a single isolate; 
2) contained > 10® cfu/ml of that organism; and 3) were derived from subjects with 
bronchiectasis alone. This resulted in 5 samples colonised by Pseudomonas aeruginosa, 
17 colonised by Haemophilus sp., and 3 colonised by Moraxella catarrhalis.
Table 4-2 shows the results of the analysis of these 25 samples. Samples from which 
Pseudomonas aeruginosa had been isolated differed significantly from each of the other 
two groups in that: 1) there was a higher concentration of MPO; 2) a higher 
concentrations of active elastase; and 3) a greater airway protein leakage. There were
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however no significant differences in IL8, LTB4, or SLPI concentrations between the 
groups.
Organism Pseudomonas
Aeruginosa
Haemophilus
Sp.
Moraxella
catarrhalis
No. Samples 5 17 3
MPO (Units/ml) 38.76 ± 11.56 8.1+LL21** 4.59 ±2.93*
Leukocyte elastase (pM) 4.18 ±0.60 0.75 ±0.23** 0.11+0.06*
IL8 (nM) 21.87 + 4.41 30.99 ± 4.41 32.39 ± 24.00
LTB4 (nM) 14.71 ±3.20 33.09 ±7.21 19.35 ±12.08
SLPI (pM) 0.78 ± 0.53 1.47 ±0.41 1.91 ±1.01
Albumin ratio (%) 3.36 + 0.40 1.71 ±0.45* 0.82 ±0,17*
Table 4-2: Effects of bacterial species on airway inflammation. Results are means ± 
S.E. *p< 0.025 and **p< 0.005 when compared with Pseudomonas aeruginosa.
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4.4 DISCUSSION
Quantitative bacterial cultiue has been used to demonstrate a vride range of airway 
bacterial load among patients with daily productive cough in the stable clinical state. 
This study included three groups of patients to cover a wide range of airways 
colonisation with adequate numbers in each quintile of colonising load. Exclusion of 
patients with AAT deficiency or bronchiectasis did not influence the overall relationship 
between colonising load and airways inflammation (Hill et al, 2000). Increasing airway 
bacterial load was strongly related to: 1) the number of neutrophils (sputum colour and 
MPO); 2) the concentration of neutrophil chemoattractants IL8 and LTB4; 3) the 
concentration of active leukocyte elastase; and 4) the sputum/serum albumin ratio. 
Pseudomonas aeruginosa provoked a more intense inflammatory response than 
Haemophilus sp. and Moraxella catarrhalis, when present in comparable numbers and 
was associated with higher concentrations of active leukocyte elastase and more airway 
protein leakage.
Patients with current or recent exacerbations of lung disease were excluded, to avoid a 
potential dynamic state of both bacterial load (Monso et al, 1995) and airway 
inflammation (Anthonisen et al, 1987). These results challenge conventional thinking 
about bacterial “colonisation” of the airways in chronic bronchitis. Organisms such as 
non typeable Haemophilus influenzae are common colonisers of the normal upper 
respiratory tract, being present in up to 75% of healthy adults (Murphy et al, 1987). The 
lower airways of patients with chronic bronchitis are also commonly colonised with 
such bacteria although the subjects do not appear to be acutely ill (Murphy et al, 1992).
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Thus, the role of this airway bacterial load has been uncertain. The results presented 
here, however, indicate that the concentration of viable organisms, regardless of the 
bacterial species, can have an important influence on airway inflammation in "stable" 
patients.
It is plausible that airway bacterial load promotes airway inflammation because bacterial 
products may directly initiate and perpetuate lung inflammation through induction of the 
local secretion of IL8 (Bedard et al, 1993)(Khair et al, 1994). In addition alveolar 
macrophages activated by phagocytosis may be a source of the observed LTB4 (Bigby et 
al, 1987)(Hubbard et al, 1991). Other indirect mechanisms may also amplify and 
perpetuate neutrophil influx, including: 1) chemoattractants and leukocyte elastase 
released from activated neutrophils in the airways (Takahashi et al, 1993)(Doerfler et al, 
1989)(Nakamura et al, 1992); 2) leukocyte elastase-inhibitor complexes (Banda et al, 
1988); and 3) products of local extracellular matrix degradation (Senior et al, 1980).
Concentrations of the local proteinase inhibitor, SLPI, decreased when airway bacterial 
load > 10® cfu/ml. This may be a direct consequence of the effect of leukocyte elastase 
on the bronchial epithelium (Sallenave et al, 1994), or the result of bronchial epithelial 
injury (Amitani et al, 1991). Changes in SLPI are noteworthy because elastase-mediated 
acute airway injuiy would be enhanced, possibly increasing inflammation, when levels 
of SLPI are reduced. The increase in inflammation may be due, at least in part, by 
increased serine proteinase generation of the chemoattractants C5a (Brozna et al, 1977) 
and perhaps IL8 (Nakamura et al, 1992).
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Taken together, the data reported herein indicate that persistent bacterial colonisation of 
the airways may not be a benign process in patients with chronic bronchitis, even in the 
absence of an acute deterioration of symptoms.
It is of special interest that the concentration of leukocyte elastase varied by more than 
80-fold with changes in airway bacterial load. This enzyme has been shown to have 
important adverse effects the airways, including inducing mucus hypersecretion 
(Sommerhoff et al, 1990), impairment of ciliary function (Smallman et al, 1984), 
damage to immunoglobulins (Solomon, 1978), reduction in opsonophagocytosis (Tosi et 
al, 1990), and damage to epithelial tissue (Amitani et al, 1991). Thus, active leukocyte 
elastase may both cause airway pathology and also promote continued bacterial 
colonisation.
The bacterial species isolated from samples reported here are similar" to those from 
previous studies of sputum lower airway bacteriology. Since Haemophilus species, 
Streptococcus pneumoniae, and Moraxella catarrhalis are normal oropharyngeal 
commensals, non-quantitative sputum cultures may lead to confusion concerning their 
role because they cannot confirm a lower respiratory souree for the isolates (Murphy et 
al, 1992)(Monso et al, 1995). In the study reported here, quantitative cultures of 
expectorated sputum provides greater certainty of their source. Bacteria that were 
present at > 10  ^ cfu/ml were strongly associated with evidence of airway inflammation 
suggesting a cause and effect. In previous work by others, quantitative culture of the 
lower airways by means of the protected specimen brush (Monso et al, 1995) also 
demonstrated that lower respiratory colonisation was common in "stable" COPD (25%
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of cases had significant growth of > 1,000 cfu/ml and 5% had > 10,000 cfu/ml). 
However, airway inflammation was not studied, and this technique is not applicable to 
routine clinical testing.
Future studies of antibacterial intervention in stable patients with high airway bacterial 
loads, both at baseline and during exacerbations, can be expected to provide insights into 
the potential benefits and complications of reducing the bacterial load in these patients. 
Indeed, published studies of stable patients with bronchiectasis who produce pui'ulent 
sputum have indicated that clinical benefits and a reduction in airways inflammation can 
be obtained from antibiotic therapy both in the short and long term (Hill et al, 1986). It 
should be noted that, for infections of the uroepithelium, it has long been standard 
clinical practice to base therapeutic decisions upon both quantitative bacterial cultures 
and enumeration of inflammatory cells in urine specimens. The present results suggest 
that a similar strategy with respiratory secretions may improve the management of 
infection of the respiratory tract and provide more logical indicators of the need for 
antibiotic therapy.
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5. AIRWAYS INFLAMMATION IN CHRONIC BRONCHITIS: 
THE EFFECTS OF SMOKING AND ALPHA-l-ANTITRYPSIN
DEFICIENCY
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5.1 INTRODUCTION
Chi'onic bronchitis was first recognised as a disabling disorder in 1808 (Badham, 1808). 
It is often a feature of COPD, and recent studies have shown that airway neutrophils are 
increased in patients with clironic bronchitis (Raise et al, 1995) and that the degree of 
neutrophil recruitment is related to the severity of airflow obstruction (Keatings et al,
1997)(Di Stefano et al, 1998). Furthermore increased neutrophils in the airways are 
related to the rate of progi’ession of airflow obstruction (Stanescu et al, 1996). Smoking 
(the major risk factor in COPD) increases neutrophil recruitment to the lung (Keatings et 
al, 1997)(Hunninghake et al, 1983) possibly by inducing the bronchial epithelium to 
secrete the important neutrophil chemoattractant IL8 (Mio et al, 1997).
Neutrophils contain a serine elastase which has been shown to reproduce many of the 
features of clironic bronchitis and emphysema (Introduction chapter). For neutrophil 
elastase to have these effects, it has to overcome the anti-elastases that protect the 
tissues. SLPI is thought to be the most critical anti-elastase protecting the airways 
(Morrison et al, 1987), whereas alpha-1-antitrypsin (AAT) is thought to be less 
important at this site, although critical at the alveolar level protecting against the 
development of emphysema (Gadek et al, 1981).
Subjects with AAT deficiency (PiZ phenotype) have decreased circulating (about 15- 
20%) (Lieberman et al, 1972) and alveolar concentrations of AAT (Gadek et al, 1981) 
which facilitates the development of early onset and rapidly progressive emphysema 
(Brantly et al, 1988). 30-40% of these patients also have clironic bronchitis (Eriksson,
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1965)(Brantly et al, 1988) although the nature of the upper airways inflammation has not 
been studied in these patients.
The purposes of the study were to assess upper airways inflammation using sputum from 
patients with chi'onic bronchitis and airflow obstruction to determine the effect of 
continued smoking and, in particular, investigate the role of AAT in the bronchi by 
studying subjects with AAT deficiency.
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5.2 METHODS
5.2.1 Study population
The following patients were studied; 42 patients with chronic obstructive bronchitis 
(FEVi<70% Predicted) with normal AAT (PiM) referred as COB and 39 patients with a 
similar degree of airflow obstruction who had AAT deficiency of the PiZ phenotype. All 
patients had chionic bronchitis (Medical Research Council, 1965) and were studied in 
the stable clinical state at least 8 weeks after a clinical exacerbation and none had 
received oral steroids or antibiotics within that time period. More patients with AAT 
deficiency (26) received regular inlialed steroids than the COB group (18, p< 0.05) 
although all other therapy was similar.
5.2.2 Processing of samples and lung function testing
The sputum and serum processing, and assessment of sputum MPO, elastase activity, 
IL8, LTB4, SLPI, and protein leakage (sputum/serum AAT ratio (%)) is described in the 
general methods (Chapter 2). All subjects underwent standardised lung function testing 
(Society et al, 1994) at the time of the study.
5.2.3 Statistical Analysis
Values are reported as mean (± standard error). The Mann-Whitney U test for non paired 
data was used to compare different groups (AAT deficiency with COB, subgroups of 
patients colonised with an identifiable pathogen compared to patients not colonised, and 
finally COB patients who were current or ex smokers). A p value less than 0.05 was 
considered to be statistically significant.
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5.3 RESULTS
The mean age for the patients with COB was 67.1 years (SE ± 1.2), range 44-79 years 
and 15 were female. The patients with AAT deficiency were younger with a mean age of 
50 (± 1.5), range 33-66 years (p < 0.005) and 9 were female (p> 0.1). Average lung 
function for both groups is summarised in Table 5-1. Twenty of the patients in the COB 
group were ex-smokers and the remaining 22 were current smokers, whereas the 
majority of patients in the AAT deficiency group (34) were ex smokers with 5 current 
smokers.
COB PiZ AAT deficiency
Observed %Predicted Observed % Predicted
FEVi (L) 0.8 30.1 0.9 27.4
(0.1) (3.1) (0.1) (3.0)
FVC (L) 2.0 64.3 2.9 70.7
(0.2) (4.4) (0.2) (4.6)
FEVi/FVC (%) 36.4 46.3 29.9 36.5
(2.2) G2.8) (2.1) (2.5)
RV/TLC (%) 61.3 159.8 41.6 130.8
(1.7) (3.9) (2.4) (7.4)
kCO 0.8 51.4 1.0 53.3
(mmol/m/kPa/L) (0.1) (5.1) (0.1) 03.2)
Table 5-1; Average lung function data (± SE) is shown for the patients with COB 
and those with PiZ AAT deficiency. Values are also expressed as a percentage of 
that predicted for the patients age, height and sex (Society et al, 1994).
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Table 5-2 summarises the average sputmn values for all the patients in each group, as 
well as data for the current and ex-smokers in the COB group. The current smokers had 
slightly better lung function with an average FEV i (% predicted) for the patients age and 
height (Society et al, 1994) of 35.1 % (± 3.4) than the ex smokers (25.0 % + 1,8, p < 
0.05) although the ages were similar for both groups (current smokers 66.0 + 1,9 years 
and 68.8 ±1.5 years for ex smokers).
Mean ± SE COB COB PiZ AAT def.
Current smokers Ex- smokers
n=42 n=22 n= 20 n~39
Sputum 
MPO (Units/ml)
0.4 ±  0.1
****
0.5 ±  0.2
**** X
0.3 ±  0.1
***+
1.4 ±  0.4
Sputum 
Elastase (pM)
0.03 ± 0.01
**
0.05 ± 0.03
A
0.0210.01
A
0.18 + 0.09
Sputum 
IL8 (nM)
8.2 ±  1.2 10.4 ±  1.9
4)
6.9 ± 1 .7 11.2 ±  2.6
Sputum 
LTB4 (nM)
7.9 ±  1.4 8.3 ±  2.4
$
7.8 ±  1.7
H’
32.0 ±  8.7
Sputum 
SLPI (pM)
3.1 ±  0.5
*
2.1 ±  0.4 4.2 ±  0.9 2.4 ±  0.4
Sputum/Serum 
AAT Ratio
(%)
1.1 ±  0.2 
****
1.2 ±  0.3
****
0.6 ±  0.1
A
2.2 ±  0.3
Sputum 
AAT (pM)
0.3 ±  0.1 0.4 ± 0.10 0.2 ± 0.03
^
0.1 ±  0.01
Table 5-2; Data for the COB patients, and subset into COB current and ex­
smokers, and those with PiZ AAT deficiency. PiZ AAT def. = PiZ alpha-1- 
antitrypsin deficient patients. Values are the mean (standard error). Significant 
differences between the COB group and the group with PiZ AAT deficiency are 
indicated (* = p< 0.05, ** = p< 0.01, *** = p< 0.005, **** = p< 0.001). Significant 
difference between the COB current and ex- smokers (k = p= 0.06 and cj) = p< 0.05).
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All samples from the COB group contained measurable quantities of all proteins with 
the exception of elastase activity which was present in only 14 of the 42 patients. 
Subgroup analysis showed that the IL8 and MPO concentrations were lower in the ex 
smokers although the latter just failed to reach significance (Table 5-2).
The AAT deficiency group showed evidence of greater degree of bronchial 
inflammation compared to the COB group. The LTB4 and MPO concentrations were 
higher and elastase activity was detected in most samples (25/39) but the concentrations 
of its inhibitors SLPI and AAT were lower despite increased protein leakage of AAT. 
These differences were maintained even when the AAT deficient group was compared 
to the subgroups of patients with COB who were current or ex smokers (Table 5-2).
Quantitative bacterial culture indicated that some of the patients in both the COB and 
AAT deficient groups were colonised by bacteria despite being In a stable clinical state. 
Nineteen of the patients with COB had either no bacterial growth in their sputum or low 
numbers (<10^ colony forming units/ml [cfu/ml]) of mixed normal flora. However for 
the remainder the median bacterial load was 3x10® cfu/ml (range = 1 x 10  ^ - 5 x 10^). 
Of these patients 17 cultured Haemophilus sp., 4 Moraxella catarrhalis and 2 
Streptococcus sp. Sputum from thirteen patients with AAT deficiency grew no 
recognised organism or mixed normal flora. Twelve patients had <10^ cfu/ml of a single 
viable organisms in their sputum (all were Haemophilus sp.). The remaining 14 patients 
had organisms at > 10  ^ cfii/ml in their sputum with a median bacterial load of 8 x 10®
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(range = 2 x 10  ^ - 2 x 10^). Of the organisms grown, 11 were Haemophilus sp., 1 
Staphylococcus aureus, 1 coliform, and 1 Pseudomonas aeruginosa.
i
The presence of bacterial colonisation may influence the degree of bronchial L
inflammation (Hill et al, 1998) as discussed in the previous chapter. In view of this both |
the COB and AAT deficient groups were subdivided according to the results of bacterial I
culture. However in the COB group the identified pathogen load was >10^  cfu/ml
whereas the patients with AAT deficiency had a wider range of concentration of i:|
:li
colonising organisms (10^-10^). Therefore the groups were only compared for those 
subjects where either no pathogen was present or where the bacterial load was >10^
f /  I 'cfu/ml.
5.3.1 Mixed normal flora
The sputum MPO (Figure 5-1) and LTB4 concentration (Figure 5-2) were greater in 
subjects with AAT deficiency (there was no significant difference in IL8 concentration 
[Figure 5-2]). Samples from 9 of the 13 patients with AAT deficiency had low but 
detectable concentrations of elastase activity (mean -  0.02 pM ± 0.004) whereas f|
eighteen of the 19 samples from the COB patients had no detectable elastase activity (in 
the remaining subject the value was 0.03 pM, p < 0.0005) (Figure 5-3). Average protein 
leakage in the AAT deficient group (1.8% ± 0.5) was higher (p < 0.05) than the COB
■■/group (0.8% ±0.1) (Figure 5-4), whereas sputum AAT concentrations were lower in the
:AAT deficient group (0.08 pM ± 0.02, p < 0.005) than the COB group (0.24 pM ± 0.06) "I
which is consistent with the serum deficiency of this inhibitor (Figure 5-3). The f
I
concentrations of secretory leukoprotease inhibitor however were similar' in both the 
AAT deficiency (4.0 ± 0.7 pM) and COB patients (4.4 ±1.0 pM) (Figure 5-3).
4 1
3.5 4
1
3c 3
8} 2.5 (0 T31Q)CLO ^ 1.5
2  -
#(|)
9
COB PiZ
Mixed Normal Flora
COB PiZ
>10  ^cfu/ml
Figure 5-1: Sputum Myeloperoxidase (Units/ml) is shown for patients with COB 
and PiZ AAT deficiency. The data is separated into patients colonised (>10^ cfu/ml) 
or not colonised (mixed normal flora) with bacteria in the stable clinical state. The 
histograms represent mean results for the subgroup together with the standard 
error bar. The asterisks indicate a significant difference between COB and PiZ 
AAT deficiency (*** = p< 0.005; **** = p< 0.001), and the symbol (cp) significant 
differences within the COB and PiZ AAT deficiency patient groups related to 
bacterial load (9 = p< 0.05; cpcpcp = p< 0.005).
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Figure 5-2: The sputum concentrations of IL8 and LTB4 (nM) are shown for 
patients with COB and PiZ AAT deficiency. The data is separated into patients 
colonised (>10^ cfu/ml) or not colonised (mixed normal flora) with bacteria in the 
stable clinical state. The histograms represent mean results for the subgroup 
together with the standard error bar. The asterisks indicate a significant difference 
between COB and PiZ AAT deficiency (* = p< 0.05; ** = p< 0.01; **** == p< 0.001), 
and the symbol (cp) significant differences within the COB and PiZ AAT deficiency 
patient groups related to bacterial load (tpcpq) = p< 0.005).
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Figure 5-3: The sputum concentrations of SLPI, AAT, and Elastase (pM) are 
shown for patients with COB and PiZ AAT deficiency. The data is separated into 
patients colonised (>10^ cfu/ml) or not colonised (mixed normal flora) with bacteria 
in the stable clinical state. The histograms represent mean results for the subgroup 
together with the standard error bar. The asterisks indicate a significant difference 
between COB and PiZ AAT deficiency (* = p< 0.05; ** = p< 0.01; *** = p< 0.005; 
**** = p< 0.001), and the symbol ((p) significant differences within the COB and 
PiZ AAT deficiency patient groups related to bacterial load (cp = p< 0.05; cpcpcp = p< 
0.005; cpcpcp9 = p< 0.001).
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Figure 5-4; Sol to Serum AAT Ratio (%) is shown for patients with COB and PiZ 
AAT deficiency both with and without bacterial colonisation (mean ± SE). The 
asterisks indicate a significant difference between COB and PiZ AAT deficiency 
(*** p< 0.005), and the symbol (cp) significant differences within the COB and AAT 
deficiency patients related to bacterial load (cp p< 0.05).
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5.3.2 >10^ colony forming units/ml
The sputum MPO, LTB4, IL8, and elastase activity concentrations were increased in 
both the COB and AAT deficiency group colonised by >10^ cfu/ml compared to those 
not colonised (mixed normal flora) as shown in Figure 5-1, Figui'e 5-2, and Figure 5-3. 
Elastase activity was detectable in 7 of 23 samples from COB and 13 of 14 for AAT 
deficient patients (mean = 0.06 pM ± 0.02, p< 0.001 and mean -  0.46 pM ± 0.22, p< 
0.005 respectively). In addition protein leakage (COB 1.7% + 0.4 and AAT deficiency 
3.0% + 0.4) was greater in both patient groups (both p< 0,05) (Figure 5-4) and sputum 
AAT concentration (COB 0.45 ±0.13 pM and AAT deficiency 0.13 ± 0.02 pM) were 
increased (both p< 0.05) (Figure 5-3). On the other hand SLPI concentration (COB 2.2 ± 
0.5 pM and AAT deficiency 1.0 ± 0.4 pM) were reduced (p< 0.05 and p< 0.0005 
respectively) (Figure 5-3).
Comparison between patient groups colonised with >10^ cfu/ml showed that the AAT 
deficiency group had greater concentrations of MPO (p< 0.005) (Figure 5-1), LTB4 (p< 
0.005) and IL8 (p< 0.05) (Figure 5-2), elastase activity (p< 0.05) (Figure 5-3), and 
protein leakage (p< 0.005) (Figure 5-4) but lower concentration of AAT (p< 0.05) and 
SLPI (p< 0.01) (Figure 5-3).
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5.4 DISCUSSION
Present data shows evidence of upper airways inflammation in patients with chronic 
obstructive bronchitis with a wide range of neutrophil influx (as reflected in the MPO 
concentration) in response to the chemoattractants IL8 and LTB4 which are thought to 
play a key role in neutrophil recruitment (Mikami et al, 1998). Elastase activity was 
absent or low even though these samples are known to contain the enzyme (Stockley et 
al, 1979) probably due to inhibition by the natural inhibitors especially SLPI.
Comparison between current and ex smokers showed that the only differences were 
lower IL8 and MPO concentrations in the latter group. This did not reflect differences in 
therapy and the ex smokers had worse lung function which would, if anything, increase 
neutrophil numbers (Keatings et al, 1997)(Di Stefano et al, 1998). IL8 is thought to be a 
major airways neutrophil chemoattractant (Richman-Eisenstat et al, 1993) and is 
increased in healthy smokers (Keatings et al, 1997) and subjects with COPD (Keatings 
et al, 1997) although the effect of smoking cessation has not been assessed previously. 
The current data indicates that cessation of smoking in chronic bronchitis is related to a 
reduction in airways IL8 concentration which in turn would reduce neutrophil 
recruitment tliereby explaining the beneficial effect of smoking cessation on progression 
of lung disease. The effect may be due to loss of cigarette smoke induced epithelial 
production of IL8 (Mio et al, 1997).
SLPI is believed to be the major inhibitor of elastase in the airway. However the current 
data shows that airways inflammation is increased in the AAT deficient subjects despite
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more being on inhaled steroids (which would be expected to have a beneficial effect 
(Llewellyn-Jones et al, 1996)) and the subjects being younger (which would also reduce 
bronchial inflammation) (Meyer et al, 1996)(Meyer et al, 1998). MPO concentrations 
were higher, as was the chemoattractant LTB4. This suggests that LTB4 may be the 
major chemoattractant responsible for the increased neutrophil migration and is 
consistent with previous findings in bronchoalveolar lavage (Hubbard et al, 1991). The 
source of the LTB4 is uncertain although Hubbard et al. (Hubbard et al, 1991) suggested 
it was released from alveolar macrophages as a direct effect of uninhibited elastase due 
to alpha-1-antitrypsin deficiency. Indeed in the current study elastase activity was more 
readily detected in the alpha-1-antitrypsin deficient patients irrespective of bacterial 
colonisation and hence would support the suggestion that this may be responsible 
(Hubbard et al, 1991). The elastase activity that was more readily detected in the upper 
airways in alpha-1-antitrypsin deficiency is probably due to the combined effect of the 
lower concentrations of both AAT and SLPI. The mechanisms involved may be complex 
but free elastase activity can reduce secretion of SLPI (Sallenave et al, 1994) as well as 
increasing permeability of airway cells (Peterson et al, 1995). Despite the latter effect 
which accounts for an increase in AAT “leak” into the lung, the low AAT concentrations 
in these subjects may be critical in determining the overall changes suggesting that this 
inhibitor also has a major role in the airways.
Bacterial colonisation is clearly related to the degree of airways inflammation suggesting 
this may not always be a benign situation even though the patients were “clinically” 
stable. Controlling for airways colonisation, indicated the AAT deficient group still had 
increased airways inflammation which is likely to be responsible for or reflect the
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development of severe airflow limitation at an earlier age. It is of importance to note that 
these changes were present in ex smokers with AAT deficiency and would suggest that 
measures other than smoking cessation may be critical in stabilising lung disease in 
these patients, such as alpha-1-antitrypsin augmentation therapy, but this requires further 
studies.
In conclusion patients with chronic bronchitis have evidence of bronchial inflammation. 
The chemoattractant interleukin 8 plays a key role in neutrophil recruitment and the 
beneficial effects of smoking cessation may be mediated by reducing concentration of 
this cytokine. Patients with AAT deficiency have greater inflammation (probably related 
to increased LTB4 production) and this suggests AAT has an important role in 
protecting the airways from the inflammatory effects of elastase. Bacterial colonisation 
may play a major role in determining airways inflammation even in the stable state as 
shown in Chapter 4.
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6. BRONCHIAL INFLAMMATION DURING AN 
ACUTE EXACERBATION IN PATIENTS WITH 
PiZ ALPHA-l-ANTITRYPSIN DEFICIENCY
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6.1 INTRODUCTION
As discussed in the general introduction chapter, the lower respiratory tract is usually 
kept sterile by effective local host defences. However in the presence of established 
airways disease bacteria are often isolated from expectorated mucus even when the 
patient appears clinically stable. This presents problems in the determination of the 
cause of an acute exacerbation of airways disease and hence rationalisation of therapy. 
In a recent review these problems were highlighted although it was emphasised that 
when the bacterial load was low, the local host defences may be adequate (Stockley, 
1998). However as the bacterial load increases, recruitment of the secondary host 
defences would result in increased airways inflammation and neutrophil influx 
(Stockley, 1998). The resolution of such episodes requires a combination of effective 
therapy resulting in the loss of the inflammatory stimulus and an appropriate acute phase 
response (Stockley, 1998). In this respect AAT may play a critical role by inactivating 
elastase activity released by the activated airway neutrophils, both down-regulating 
inflammation and protecting airways tissue ftom enzyme induced damage (Stockley,
1998).
Subjects with AAT deficiency often have airways disease (Eriksson, 1965)(Brantly et al, 
1988) and hence will be susceptible to bacterial colonisation and acute bacterial 
infective exacerbations. However because of their deficiency such subjects will not have 
an appropriate AAT acute phase response which may therefore influence the degree of 
airways damage caused by such infections. The nature of the airway inflammation and 
its response to bacterial exacerbations have yet to be studied in AAT deficiency.
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The purposes of this study were two-fold. Firstly to assess the inflammatory nature of 
acute exacerbations in subjects with AAT deficiency and compare this to chionic 
bronchitic patients without deficiency. Secondly to monitor the inflammatory process 
and its resolution in patients with AAT deficiency following appropriate antibacterial 
therapy. Monitoring the inflammatory response included the following measurements: 
the recruitment of neutrophils (as reflected by MPO activity); the concentration of 
chemoattractants in the bronchial secretions (IL8 and LTB4); the concentration of active 
neutrophil elastase and its natural inhibitors (AAT and SLPI); protein leakage 
(sputum/serum albumin ratio) as a measure of airways inflammation. Finally the acute 
phase response of both C-reactive protein and AAT were measured in the serum.
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6.2 METHODS
11 patients with chronic bronchitis and homozygous AAT deficiency (PiZ) were studied. 
None of the patients had ever received AAT replacement therapy. The patients made 
contact and were seen in the clinic within 48 hours of the onset of new or worsening 
symptoms suggestive of an acute exacerbation of their disease. The presence of an 
exacerbation was based on the criteria suggested by Anthonisen (Anthonisen et al, 
1987), and included an increase in all 3 of the symptoms of breathlessness, sputum 
volume and sputum purulence.
6.2.1 Processing of samples
On the day of clinic visit the patients collected sputum over 4 hours from rising. The 
sputum characteristics, sputum and serum processing, assessment of sputum coloiu, 
MPO, elastase activity, IL8, LTB4, SLPI, protein leakage (sputum/serum albumin ratio 
(%)), and the acute phase response of serum AAT and CRP, was carried out as described 
in Chapter 2. All subjects underwent standardised lung function testing within 6 months 
of the study when patients were in a stable clinical state.
6.2.2 Treatment
After sample collection the patients were started on 14 days antibiotics (no patients 
received treatment before presenting with their exacerbation). They were commenced 
routinely on Amoxycillin SOOmg 3 times daily unless Moraxella catarrhalis was 
suspected on Gram stain, and such patients were started on Cefuroxime axetil SOOmg 
twice daily. These antibiotics were unchanged except in 1 patient where Cefuroxime was 
changed to Ciprofloxacin 750mg twice daily the following day as Pseudomonas
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aeruginosa was cultured in addition to Moraxella catarrhalis (the dominant organism). 
No patient received oral steroid therapy, and all other treatment (including inlialed 
steroids) remained constant tluoughout the study. The patients returned 1 ,3 ,5 ,7 ,1 4  and 
28 days after commencement of therapy and at these visits samples were collected and 
assessed as above except for follow up day 1 when semm alone was collected. Day 14 
was the end of antibiotic treatment and day 28 was 2 weeks later when patients were 
stable. All patients filled in a daily diary card recording morning and evening peak 
expiratory flow rates, as well as their symptoms. Finally the patients indicated the day 
they felt back to their stable clinical state (diary card at end of thesis).
6.2.3 Comparison with patients with chronic bronchitis without AAT deficiency
The data obtained on the day of presentation was compared to that from 11 control 
patients with chronic bronchitis who had normal AAT. These patients were chosen from 
a database of outpatients presenting with a similar acute exacerbation (increasing 
breathlessness, increasing sputum volume and pui'ulence) and were matched with the 
AAT deficient patients for stable state FEVi (% predicted) to ensure a comparable 
degree of lung flinction impairment. However complete samples for the control patients 
were only available for the day of presentation, day 5, and day 28 (stable clinical state) 
for comparison with the AAT deficient patients.
6.2.4 Statistical analysis
Values are reported as mean (± standard error). The Friedman test was used to compare 
the inflammatory markers throughout the exacerbation, and, where significant, the 
Wilcoxon Rank test for paired data was used to compare results from the start of the
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exacerbation to different points during the exacerbation. The Maim Wliitney U test for 
impaired data was used to compare data between patients with and without AAT 
deficiency. A P value <0.05 was considered to be statistically significant.
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6.3 RESULTS
Demographic details for the AAT deficient and control patients are shown in Table 6-1. 
Both groups were receiving similar therapy and, in particular, 8 of the AAT deficient 
group and 9 of the control group were on long term inhaled corticosteroids. No patients 
were on oral steroid therapy and neither group had evidence of bronchiectasis either 
clinically or visible on high resolution computed tomography of the chest. The results 
are shown for post bronchodilator FEVi, FEViA^C ratio, TEC and gas transfer (kCO) 
expressed as a % of the value predicted for the patients age, height, and sex (Society et 
al, 1994). Neither group had significant reversibility (>12% increase) to nebulised |32 
agonist (salbutamol 5mg). The average rise in FEVi was 55.0 mis (± 10.8) for the AAT 
deficient group and 65.0 mis (± 36.4) for the control group.
Mean ± SE Patients with 
AAT deficiency
Control patients without AAT 
deficiency
Age (years) 483 ±2.9* 67.6 ± 2.0
(range) (37-66) (58-79)
Sex (Male:Female) 8:3 7:4
Current Smokers 3 4
Ex Smokers 7 7
Non Smoker 1 0
Pack Years 32.0 ±5.9 48.1 ±8.9
FEVi (L) 1.3 ±0.3 1.4 ±0.3
(% Predicted) (36.3 ± 7.4) (38.0 ±5.7)
FEViA^C 44.3 ± 7.0 45.4 ±4.7
(% Predicted)
TEC 125.0 ±5.0 117.2 ±3.6
(% Predicted)
kCO 60.2 ±9.9 68.6 ± 4.9
(% Predicted)
Table 6-1: Demographics and lung function tests for the study. Mean values are 
shown (+ SE) for patient demographics features including lung function expressed 
as a % predicted for sex, age, and height. The asterisk indicates the only statistical 
difference between the two groups (p< 0.001).
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6.3.1 Bacteriology (Table 6-2)
All samples obtained at presentation had greater than 25 neutrophils (with < 10 epithelial 
cells) per high power field (x  100) on Gram stain. All 11 samples from the AAT 
deficient patients subsequently grew one or two bacterial pathogens (Table 6-2) with a 
median bacterial load of 6.6 x 10  ^ cfu/ml (range 2.7 x 10^- 5.4 x 10^). The sputum 
samples from the non AAT deficient patients also contained one or two bacterial 
organisms on quantitative cultui'c. The predominant species included non-typeable 
Haemophilus influenzae (n-6), Streptococcus pneumoniae (n=3), and Moraxella 
catarrhalis (n=2). The bacterial load was similar to that for the AAT deficient group 
(median 2.3 x 10  ^cfu/ml; range 1.2 x 10^ ~ 9.0 x 10 )^.
Patient Day 0 Day 14 Day 28 (Stable)
1 S. pneumoniae* 
7.9 X 10  ^cfu/ml
Mixed normal flora NTHI 
8.0 X 10  ^cfu/ml
2 NTHI 
9.1 X 10® cfu/ml
NTHI 
2.8 x 10® cfu/ml
NTHI 
3.2 X 10® cfu/ml
3 NTHI 
6.6 X 10® cfu/ml
NTHI 
2.1 X 10® cfu/ml
NTHI 
3.2 X 10® cfu/ml
4 H. para 
2.7 X lO’ cfu/ml
Mixed normal flora H. para 
5.0 X 10  ^cfu/ml
5 NTHI 
6.3 X 10® cfu/ml
Mixed normal flora Mixed normal flora
6 M. cat 
1.1 X lOYfu/ml
Ps. Aer 
6.4 X 10®cfu/ml
Mixed normal flora S. viridans 
8.4 X 1 o’ cfu/ml
7 M. cat 
2.6 X 10*cfu/ml
NTHI 
5.4 X 10® cfu/ml
Mixed normal flora Mixed normal flora
8 NTHI 
5.8 X 10®cfu/ml
Mixed normal flora NTHI 
1.5 X lO’cfu/ml
9 M. cat 
2.4 X 10®cfu/ml
Mixed normal flora Mixed normal flora
10 M. cat 
4.8 X lOYfli/ml
NTHI 
6.2 X 10®cfu/ml
NTHI 
3.9 X 10®cfii/ml
NTHI 
4.2 X lO^cfu/ml
11 S. pneumoniae 
2.2 X lO^cfu/ml
Mixed normal flora Mixed normal flora
Table 6-2: Sputum bacteriology in patients with AAT deficiency at the start of the 
exacerbation, end of treatment, and 2 weeks after treatment finished. *The 
organism is indicated together with the viable number in sputum (cfu/ml). S. 
Pneumoniae = Streptococcus pneumoniae'^ NTHI = Non typeable Haemophilus 
influenzae^ M. Cat = Moraxella catarrhalis; Ps. Aer = Pseudomonas aeruginosa; H. 
para = Haemophilus parainfliienzae; S. viridans = Streptococcus viridans.
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6.3.2 Sputum analysis at presentation (Table 6-3)
When first seen all patients with AAT deficiency had purulent sputum (see Methods) 
with a mean sputum coloui' value o f 4.6 (SE ±  0.3) which is consistent with the high 
sputum MPO level. In addition the sputum concentration of both the chemoattractants 
IL8 and LTB4 were high, and free elastase activity was present in 10 of the 11 sputum 
samples (range; 5-1,631 nM). Although the sputum SLPI concentration was low, the 
sputum AAT concentration was relatively high for this group consistent with increased 
protein leakage from serum. This increased leakage was supported by the high 
sputum/serum albumin ratio.
The control patients without AAT deficiency showed differences compared to the 
patients with AAT deficiency at presentation (Table 6-3). Although the average sputum 
MPO value was similar to that seen in the AAT deficient group (p= 0.17), the sputum 
elastase activity (detectable in 8/11 patients) was lower (p= 0.02) with a range from 0- 
166 nM in the non-deficient patients. In addition the average sputum concentrations of 
both IL8 and LTB4 were lower in the non deficient group (p= 0.01 and p= 0.02 
respectively) and the protein leakage was lower although this just failed to reach 
statistical significance (p= 0.06). The sputum concentrations of both SLPI and AAT 
were higher in the non-deficient group (p= 0.02 and p< 0.001 respectively).
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Controls without 
AAT deficiency
AAT Deficiency P value
Sputum MPO (units/ml) 1.0 ±0.3 1.4±0.4 0.17
Sputum Elastase (nM) 30.1 ±15.4 254.3 ± 147.2 0.02
Sputum IL8 (nM) 10.4 ±2.6 30.9 ±9.2 0.01
Sputum LTB4 (nM) 15.9 ±4.9 33.2 ±8.3 0.02
Sputum SLPI (pM) 1.9 ±0.6 1.0 ±0.4 0.02
Sputum AAT (pM) 0.91+0.14 0.25 + 0.09 <0.001
Sputum/Serum Albumin Ratio (%) 1.5 ±0.4 3.8 ± 1.8 0.06
Serum AAT (pM) 31.3 + 3.4 4.8+ 0.7 <0.001
Serum CRP (mg/L) 42.9 ±19.3 34.0 ±18.5 0.9
Table 6-3: Bronchial inflammation at the start of the exacerbation. * Average 
results (+ standard error) are shown for 11 patients with AAT deficiency and 11 
controls at the start of an exacerbation. The significance of any difference between 
the groups (p) is shown.
6.3.3 The effect of antibiotic therapy in patients with AAT deficiency
After 14 days of therapy the pathogen had been cleared in 8 of the 11 AAT deficient 
patients and the bacterial load was lower in the remaining three (Table 6-2). All patients 
improved clinically (as assessed by the symptom diary card) during antibiotic therapy. 
There was a reduction in sputum colour (p< 0.01), MPO (p< 0.005), ILS (p< 0.01), 
LTB4 (p< 0.005), and sputum elastase activity (p< 0.01) which fell in the 10 subjects 
where it was present at the start of the exacerbation becoming undetectable in 2. The 
sputum AAT fell (0.11 ± 0.04 pM, p< 0.005) and the SLPI concentration rose (p< 0.01). 
Finally there was a reduction in protein leakage in the airway as the sputum/serum 
albumin ratio fell (p< 0.01). These results are summarised in Figm'es 6-1 - Figure 6-7.
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Figure 6-1: Time course of response of sputum colour number following treatment. 
The average data + standard error is shown for samples at presentation, at 
different times during therapy up to day 14 and in the stable state 2 weeks after 
cessation of therapy. The asterisks indicate values that are significantly reduced 
compared to those at presentation (*p< 0.05; **p< 0.01).
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Figure 6-2: Time course of response of sputum myeloperoxidase following 
treatment. The average data + standard error is shown for samples at presentation, 
at different times during therapy up to day 14 and in the stable state 2 weeks after 
cessation of therapy. The asterisks indicate values that are significantly reduced 
compared to those at presentation (*p< 0.01; **p< 0.005).
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Figure 6-3: Time course of response of sputum interleukin 8 following treatment. 
The average data + standard error is shown for samples at presentation, at 
different times during therapy up to day 14 and in the stable state 2 weeks after 
cessation of therapy. The asterisks indicate values that are significantly reduced 
compared to those at presentation (*p< 0.01; **p< 0.005).
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Figure 6-4: Time course of response of sputum leukotriene B4 following treatment. 
The average data + standard error is shown for samples at presentation, at 
different times during therapy up to day 14 and in the stable state 2 weeks after 
cessation of therapy. The asterisks indicate values that are significantly reduced 
compared to those at presentation (*p< 0.05; **p< 0.005). Values for leukotriene 
B4 in the stable clinical state are significantly higher than at the end of treatment - 
day 14 (^p< 0.05).
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Figure 6-5: Time course of changes in sputum elastase activity. The asterisk 
indicates values for elastase that were significantly different from presentation (*p< 
0.05; **p< 0.01; ***p< 0.005).
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Figure 6-6: Time course of changes in sputum secretory leukoprotease inhibitor. 
The asterisks indicate values for SLPI that were significantly different from those 
at presentation (*p< 0.01;**p< 0.005).
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Figure 6-7: Sputum/serum albumin ratio is shown following presentation with the 
exacerbation (± standard error). The asterisks indicate values significantly lower 
than at presentation (*p< 0.05; **p< 0.01).
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6.3.4 Acute phase response
At presentation the serum CRP and AAT concentrations were raised to average values of 
34.0 mg/L (+ 18.5) and 4.8 pM (+ 0.7) respectively in patients with AAT deficiency 
(Figure 6-8 & Figure 6-9). The results for CRP were similai* to that for the non deficient 
subjects (42.9 ± 19.3, p= 0.9). On the other hand the control subjects had greater (p< 
0.001) serum concentrations of AAT (31.3 ±3 .4  pM) at the start of the exacerbation as 
would be expected.
By the end of therapy (day 14) the serum values for the AAT deficient subjects had 
fallen significantly (CRP: 8.9 mg/1 ± 3.9, p= 0.02; AAT 4.1 ± 0.5 pM, p= 0.03) and 
remained low when the patients were reviewed on day 28 whilst still clinically stable 
(CRP: 7.0 mg/1 + 2.9 and AAT 3.6 ± 0.5 pM). Similarly both the serum values of CRP 
and AAT were reduced at this stage in the non deficient subjects (CRP 7.0 mg/1 ± 2 .6  
and AAT 23.8 ± 2.2 pM, both p< 0.05).
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Figure 6-8: The average value for C-reactive protein is shown (+ standard error). 
Asterisk indicate values that are higher than in the stable clinical state (day 28) 
(*p< 0.01).
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Figure 6-9: The average value for AAT are shown (+ standard error). Asterisks 
indicate values that are higher than in the stable clinieal state (day 28) (*p< 0.05;
**p< 0.01).
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6.3.5 Time course of the response in patients with AAT deficiency
The patients showed a gradual improvement in symptoms and indicated a return to their 
stable clinical state (on the diary card), on average 13.2 (+ 2.1) days after the start of 
therapy. The biochemical response to antibiotic therapy, however, was generally rapid 
with a significant decrease in sputum colour number (p< 0.05) to 3.8 ± 0.2 by the third 
day of treatment. This was associated with a significant decrease in sputum MPO (p< 
0.01), IL8 (p< 0.005) and LTB4 concentrations (p= 0.02) by the third day of treatment. 
The lowest average concentrations of MPO, IL8 and LTB4 were found by the 5^*’, 7^  ^and 
14^ *^  day of therapy respectively (these results are summarised in Figure 6-2, Figure 6-3, 
& Figure 6-4). By the third day of treatment sputum elastase activity had decreased (p< 
0.01) (Figure 6-5) and the sputum AAT concentration had fallen (p< 0.005) to 0.17 pM 
(± 0.06). This latter effect was related to a rapid fall in protein leakage (p= 0.02) as 
shown in Figure 6-7. However, the sputum SLPI concentration rose (p< 0.005) to 2.9 ±
1.3 pM by the third day of treatment (Figure 6-6).
On the fifth day, the MPO, elastase activity, ILS, LTB4, and protein leakage remained 
low in the deficient subjects (Figures 6-2 - Figure 6-7). These results were similar to 
those observed in the non-deficient patients at this time with the exception that patients 
with AAT deficiency still had higher ILS concentration and elastase activity (AAT 
deficient patients:- IL8= 14.1 ± 2.8 iiM and elastase activity = 60.9 ± 44.0 nM; non- 
deficient patients:- IL8= 4.9 ± 1 .9  nM and elastase activity = 2.6 ± 1.7 nM: both p< 
0.005) and the sputum AAT concentration remained lower (p< 0.001) in the deficient 
patients compared to the controls (0.12 pM ± 0.04 and 0.48 pM ± 0.11 respectively).
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The serum acute phase response in patients with AAT deficiency was most obvious with 
CRP which peaked on the first day after presentation and fell significantly (p< 0.05) by 
the fifth day of treatment (Figure 6-8). The AAT response was small but peaked at day 
3, falling thereafter (average presentation = 4.8 ± 0.7 pM; day 3= 5.5 ± 0.7 pM; day 14= 
4.1 + 0.5 pM; and day 28= 3.6 ± 0.5 pM) (Figure 6-9).
6.3.6 Stable clinical state
When the AAT deficient patients were restudied 28 days after presentation (14 days 
after cessation of therapy), 7 were colonised with an identifiable organism (Table 6-2) 
although the viable bacterial load in these 7 subjects (median value on day 28 = 8.4 x 
10 ;^ range = 5.0 x 10  ^- 4.2 x 10^) was lower than that at presentation (median = 6.6 x 
10  ^organisms/ml; range = 2.1 x  10  ^- 5.4 x 10 :^ p< 0.05).
The continued well being of the patients was reflected in a persistently lower sputum 
colour compared to that at presentation (p< 0.01). The average sputum MPO and IL8 
concentration remained low (Table 6-4) although the sputum LTB4 concentration was 
higher (p= 0.02) than at the end of therapy (9.5 ± 2.6 nM) as summarised in Figure 6-4. 
Elastase activity became detectable in all but 1 patient by day 28 although the average 
value remained low (Figure 6-5). Finally sputum SLPI concentration remained high 
(Figure 6-6) and the sputum AAT concentration remained low (0.10 pM ± 0.03) 
consistent with a persistent reduction in protein leakage (Figure 6-7).
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The results obtained on day 28 were not significantly different to those obtained in the 
AAT deficient patients when they had been studied in the stable clinical state more than 
8 weeks prior to their exacerbation (Table 6-4).
Baseline Exaeerbation
Onset
Resolution 
(day 28)
P value 
Baseline- 
Exacerbation
Sputum MPO 
(units/ml)
0.5 ±0 .2 1.4 ± 0.4 0.6 ±0 .2 < 0.005
Sputum Elastase 
(nM)
28.0 ± 16.0 254.3 ± 147.2 25.0 ±8 .0 < 0.005
Sputum IL8 
(nM)
12.6 ±4.2 30.9 ±9.2 10.4 ±3.0 0.01
Sputum LTB4 
(nM)
17.2 ±8.2 33.2 ±8.3 16.5 ±3.5 < 0.005
Sputum SLPI 
(pM)
4.0 ± 1.4 1.0 ± 0.4 5,7 ±2.2 <0.005
Sputum AAT 
(pM)
0.07 ± 0.02 0.25 ± 0.09 0.10 + 0.03 0.01
Sputum/Semm 
Albumin Ratio (%)
0.6 ±0 .2 3.8±1.8 0.9 ± 0.2 <0.01
Serum CRP 
(mg/L)
6.3 ±4.3 34.0 ±18.5 7.0 ±2 .9 <0.01
1
I
Table 6-4: Average results of biochemical measurements (± SE) are shown for the 
AAT deficient patients. Results are shown for baseline (at least 8 weeks prior to the 
initial exacerbation), at the start of the exacerbation and 2 weeks after the cessation 
of therapy (Resolution- day 28). Significant differences are shown comparing 
baseline values with the start of the exacerbation.
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All non deficient patients improved with significant reductions in MPO (0.4 ± 0 . 1  
Units/ml, p= 0.02), elastase activity (1.7 ± 1.1 nM, p= 0,02), LTB4 (4.9 ±1.3 nM, p= 
0.01), sputum AAT (0.49 pM ± 0.10, p= 0.02), albumin leakage (0.6 ±0.1 %, p< 0.01) 
and C-reactive protein (7.0 mg/L ± 2.6, p= 0.04) by day 28 and the SLPI levels rose by 
day 28 (11.8 pM ± 6.5, p= 0.02). Comparison with the results obtained in the AAT 
deficient subjects on day 28 showed that some differences still existed as the MPO, 
LTB4, and elastase activity were all lower in the non deficient group (p< 0.001, p< 0.01 
and p< 0.001 respectively) whereas sputum AAT was higher (p< 0.001). However the 
IL8 (8.8 nM ± 2.9), SLPI, albumin ratio, C-reactive protein and the bacterial load (6 
were colonised with a median bacterial load of 5.5 x 10  ^cfu/ml (range= 3.0 x 10^- 1.7 x 
10  ^cfu/ml)) was similar to the AAT deficient subjects.
6.3.7 Peak expiratory flow rates
Peak flow rates were recorded throughout the exacerbation. In patients with AAT 
deficiency, the mean morning pre-bronchodilator peak expiratory flow rates at 
presentation with the exacerbation was 236.4 L/min + 41.4, which increased (p< 0.005) 
by day 14 to 261.8 L/min + 45.4 (11.9%). The mean evening post-bronchodilator peak 
expiratory flow rates at the start of the exacerbation was 260.0 L/min + 40.5 which also 
increased (p< 0.005) by day 14 to 278.6 L/min + 40.8 (10.2%). The mean morning and 
evening peak expiratory flow rates on day 28 were not significantly different from day 
14 (day 28; mean morning 265.5 L/min + 44.6; mean evening 285.5 L/min ±  43.6).
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The peak flow rates in the non deficient patients were not significantly different to the 
AAT deficient group throughout the study and followed a similar pattern. The mean 
morning pre-bronchodilator pealc expiratory flow rates at presentation with the 
exacerbation was 205.0 L/min + 32.7, which also increased (p< 0.005) by day 14 to
225.5 L/min + 32.2 (12.1%). The mean evening post-bronchodilator peak expiratory 
flow rates at the staid of the exacerbation was 216.8 L/min ± 30.6 which increased (p< 
0.005) by day 14 to 236.4 L/min + 31.7 (9.6%). The mean morning and evening peak 
expiratory flow rates on day 28 were not significantly different from day 14 (day 28: 
mean morning 223.6 L/min + 31.7; mean evening 237.3 L/min +31.0).
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6.4 DISCUSSION
In the present study all AAT deficient patients presented with an increase in symptoms 
and pui'ulent sputum production associated with the presence of a high bacterial load of 
a single or (in 3 cases) 2 bacterial pathogens. The exacerbations were characterised by 
high sputum colom' and MPO concentration consistent with the presence of a significant 
number of neutrophils which is probably a result (at least in part) of the high 
concentration of the two chemoattractants 1L8 and LTB4.
Elastase activity was present in most of the samples at presentation and may be expected 
to have a detrimental effect on airways host defences. The enzyme activity probably 
reflects several factors including increased neutrophil recruitment (as indicated by 
MPO), reduced SLPI concentration probably as a result of suppression of inhibitor 
release by elastase itself (Sallenave et al, 1994) and low AAT concentration (see results), 
despite a small acute phase response and increased protein leakage into the airways.
This latter concept is supported by comparison with subjects who had normal AAT. In 
these patients the severity of the exacerbation indicated by the acute phase protein CRP, 
influx of neutrophils (as assessed by MPO), and bacterial load was similar. However the 
activity of elastase in the sputum was much lower which probably reflects the greater 
influx of AAT. This inactivation of elastase would in tmm, prevent the effect on SLPI 
release accounting for the higher concentration of this protein which, in turn, would also 
facilitate elastase inactivation.
184
Of interest the subjects with A AT deficiency also had higher levels of the 
chemoattractants LTB4 and IL8 than the non deficient subjects at presentation. The 
exact soui'ce of these chemoattractants is uncertain since both can be derived from the 
activated neutrophils (Borgeat et al, 1979)(Takahashi et al, 1993). In addition the 
infection could stimulate epithelial cells to release IL8 (Khair et al, 1994). However both 
patient groups had a similar influx of neutrophils (MPO) and bacterial load suggesting 
this was not the case. Previous studies have suggested that macrophage release of LTB4 
is increased in AAT deficiency as a result of free elastase activity (Hubbard et al, 1991). 
In addition elastase has been reported to increase IL8 release from epithelial cells 
(Nakamura et al, 1992). Thus the greater elastase activity may explain the increases in 
both chemoattractants seen in AAT deficiency. Nevertheless it might be predicted that 
the greater concentration of chemoattractants should increase neutrophil recruitment 
(MPO) in the AAT deficient group and yet this was not the case (see results). However 
as seen in the interrelationships chapter the relationship between both IL8 and LTB4 and 
MPO is shallow. The differences in chemoattractant concentrations between these 2 
patient groups would only produce a predicted change in MPO equivalent to 0,5 
Units/ml which is unlikely to be detected in the relatively small group of patients studied 
here.
Following initiation of therapy in the AAT deficient group the inflammatory response 
reversed briskly in the group as a whole. Sputum colom*, MPO and the chemoattractants 
all fell, as did the elastase activity. This latter effect was probably enlianced by the rise 
in SLPI concentration (approximately 2pM), despite the slight fall in average sputum
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AAT concentration of 0.08 |_iM by day 3 (due mainly to decreased protein leakage). The 
sputum became sterile in the majority of subjects and the systemic acute phase response 
(both CRP and AAT) settled. These results provide an objective measure to support the 
patients subjective feeling of improvement and a return to their normal clinical state and 
is consistent with a resolution of the exacerbation and the associated inflammation.
Two weeks after the cessation of therapy the sputum remained sterile in 4/11 patients 
and in the other patients the bacterial load was less than at presentation. Inflammation 
remained low as indicated by the sputum colour, MPO, IL8, elastase activity (although 
the majority of samples had become positive), protein leakage and acute phase response, 
although the LTB4 concentration had risen (though less than at presentation). These 
results are however consistent with the patient’s usual clinical state, as confirmed by 
comparison with samples from the 11 patients studied at least 8 weeks prior to the 
clinical exacerbation (Table 6-4). In addition this extra data confirms that the change at 
the start of the exacerbation was major and indicated a clear pathological process 
associated with their clinical deterioration.
Of interest, however, the LTB4 concentration had risen in the whole group studied here 
2 weeks after treatment had ceased although the reasons are currently uncertain. It is 
unlikely that this change represents the early stages of relapse after antibiotic therapy 
since the results are similar to those obtained in the stable clinical state at least 8 weeks 
prior to the exacerbation (Table 6-4). Previous studies in AAT deficiency had identified 
high LTB4 concentrations in bronchoalveolar lavage. The authors argued that the source
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could be macrophages stimulated by neutrophil elastase as a result of the defective AAT 
inhibitory screen (Hubbard et al, 1991). Whether this mechanism is correct and
applicable to the airways, where SLPI is the major antielastase in the stable state
(Morrison et al, 1987), remains to be clarified.
However it should be noted that the elastase activity in these samples was not
significantly greater than at the end of treatment (day 14) although more samples were 
positive. In addition more samples had become colonised with bacteria and this could 
also have an effect by stimulating LTB4 release from airway phagocytes. Clearly this 
complex interrelationship requires further study.
Some differences were still observed between the AAT deficient and non deficient 
subjects by day 28. The non deficient patients had higher sputum AAT (as would be 
expected) but lower MPO, elastase activity, and LTB4. AAT deficiency is associated, 
therefore, not only with increased inflammation at the start of the exacerbation but also 
in the stable state. However several factors including lung function, smoking habit, 
airway bacterial load, and treatment such as inlialed corticosteroids can influence 
inflammation. For this reason both groups were matched for all these potential 
confounding factors as well as the severity of their exacerbation as indicated by the 
objective measurement of C-reactive protein. It is likely, therefore, that the results 
reported here reflect, predominantly, the AAT deficiency itself and increased upper 
airways inflammation as an ongoing phenomenon. Clearly further studies are indicated 
to clarify whether this alone determines the more rapid rate of progression of disease in 
AAT deficiency.
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Finally it is worth commenting on the acute phase response of serum AAT in the 
deficient subjects. Although basal levels are low in AAT deficiency, acute phase 
responses can be induced by Danazol (Wewers et al, 1986) and Tamoxifen (Wewers et 
al, 1987). This is the first report to my knowledge of the acute phase response in a 
naturally occurring infection in AAT deficiency. Unlike CRP where the response is early 
and marked, and resolution is rapid, the AAT response is minimal, slower (peaking on 
day 3) and falls slowly. The average increase is approximately 40% but it should be 
emphasised that the highest concentration (5.5 pM) is still well below normal plasma 
concentrations in the absence of an acute phase response or even the putative lung 
protective thi’eshold of 11 pM (Society, 1995). Thus despite the increase in protein 
leakage into the airway the ability of AAT to modulate the inflammatory process is still 
markedly impaired in AAT deficient subjects.
In conclusion acute exacerbations of chronic bronchitis in subjects with AAT deficiency, 
in the presence of bacteria in secretions, are associated with marked neutrophil influx. 
Although the specific nature of these episodes can only remain speculative the poor 
AAT acute phase response and the brisk response following commencement of 
antibiotic therapy suggests that such episodes are due to the bacteria and should he 
promptly treated to protect the airways tissues. Whether AAT deficiency makes patients 
more susceptible to bacterial colonisation of the airways bacteria remains to be 
determined. However the current study suggests that AAT replacement may play a role 
in modulation of elastase activity in the airway during acute exacerbations in deficient 
subjects.
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7. GENERAL DISCUSSION
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7.1 The interrelationship of sputum inflammatory markers in patients 
with chronic bronchitis
The neutrophil and in particular Its product neutrophil elastase has been implicated in the 
pathogenesis of chronic bronchitis. In vitro and in vivo work have demonstrated that 
neutrophil elastase can cause epithelial damage (Amitani et al, 1991), reduce ciliary beat 
frequency (Smallman et al, 1984), cause mucus gland hypeiplasia (Snider et al, 1985), 
cause mucus secretion (Sommerhoff et al, 1990), and has been shown to inactivate 
many of the critical lung host defences (Solomon, 1978)(Tosi et al, 1990). Thus 
neutrophil elastase can cause the typical features of chronic bronchitis including 
facilitating bacterial colonisation, another feature often seen in such patients.
The inflammatory process in the bronchial tree is complex and involves the release of 
many mediators including cytokines and chemoattractants that regulate adhesion 
molecules, the processes of cell migration, and their activation and degranulation. The 
summation of these processes in chr onic bronchitis is predominantly the recruitment of 
neutrophils and release of the neutrophil proteinase elastase. In order for the neutrophil 
elastase to have the effects in the airways, the elastase released from the activated 
neutrophil has to overcome the natuially occurring inliibitors such as secretory 
leukoprotease inhibitor and alpha-1 -antitrypsin (secretory leukoprotease inhibitor being 
thought to be the major anti-proteinase in the airways).
There have been many studies of the effects of elastase in isolation in vivo and, in 
addition, a multitude of in vitro experiments exploring the role of this mediator.
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However, there have been very few studies assessing the complex interplay of 
inflammatory cells and appropriate mediators in patients with chronic bronchitis.
Recent limited studies have indicated that neutrophils in the airway of patients with 
chronic bronchitis are increased (Riise et al, 1995)(Pesci et al, 1998) and that these cells 
or their product myeloperoxidase is related to the presence of a single chemoattractant, 
interleukin 8 (Riise et al, 1995)(Pesci et al, 1998)(Yamamoto et al, 1997). Other 
chemoattractants however may be of importance. For instance studies by Mikami et al 
(Mikami et al, 1998) revealed that both interleukin 8 and leukotriene B4 play a 
significant role in neutrophil chemotaxis (demonstrating that up to 43% of the 
chemotactic activity was due to interleukin 8 and 27% due to leukotriene B4), and that 
these chemoattractants work in an additive way for neutrophil recruitment. In addition 
these workers found that some of the chemotactic activity was not due to these two 
chemoattractants suggesting that others may also he involved. This is of importance 
since in vitro studies have indicated that chemoattractants may interact in an additive 
way (Mikami et al, 1998) and in addition there may be a hierarchical response 
influencing the cell and its migration pattern (Foxman et al, 1997). Thus simple 
associations between cell numbers and single chemoattractants do not indicate effect and 
cause.
Furthermore in vitro studies have shown the relationship between chemoattractants and 
neutrophils may be even more complex. Neutrophil activation can also lead to the 
release of both interleukin 8 (McCain et al, 1994) and leukotriene B4 (Ford-Hutchinson 
et al, 1980) that may result in further neutrophil recruitment. However this could also
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account, at least in part, for any correlation between neutrophils and the 
chemoattractants. Release of elastase from the neutrophil may have several effects 
possibly stimulating epithelial cells to produce more interleukin 8 (Nakamum et al, 
1992) and macrophages to release leukotriene B4 (Hubbard et al, 1991) whilst at the 
same time reducing production of its own natural inhibitor, secretory leukoprotease 
inliibitor (Sallenave et al, 1994) thereby perpetuating its own activity. Furthermore 
impairment of host defences by elastase could facilitate bacterial colonisation and 
endotoxin release from bacteria can also provide a further potential mechanism for 
neutrophil recruitment by stimulating production of interleukin 8 by epithelial cells 
(Khair et al, 1994).
Previous studies have provided some insight into the complex mechanisms involved in 
the bronchial inflammatory response, but have been limited by a small numbers of 
patients and the study of single and isolated interactions. The study in Chapter 3 
investigated a large cohort of patients with a wide spectrum of bronchial inflannnation to 
study the complex interrelationships of the inflammatory markers in more detail: 
neutrophil influx (as reflected by sputum myeloperoxidase concentration) and the 
chemoattractants interleukin 8 and leukotriene B4; active neutrophil elastase and the 
chemoattractants (interleukin 8 and leukotriene B4), its own inhibitor secretory 
leukoprotease inhibitor, and bronchial protein leak (leakage of albumin from serum into 
the airways); and finally FEVi (% predicted) and myeloperoxidase, interleukin 8 and 
leukotriene B4, secretory leukoprotease inhibitor, and bronchial protein leak.
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The degree of neutrophil influx as assessed by myeloperoxidase correlated well with 
elastase activity, although this was less apparent at lower concentration where many 
samples with detectable myeloperoxidase activity had no detectable elastase activity. 
This is to be expected since the presence of bronchial inhibitors such as secretory 
leukoprotease inliibitor and alpha-1-antitrypsin would be expected to inliibit the low 
concentrations of elastase released when neutrophil numbers are low.
Neutrophil recruitment is dependent upon the chemoattractants being released and 
studies have suggested that interleukin 8 and leukotriene B4 are the most important 
chemoattractants in patients with bronchial disease. In the cunent studies both 
interleukin 8 and leukotriene B4 correlated with neutrophil recruitment and elastase 
activity. Previous studies have suggested that the relationship between interleukin 8 and 
myeloperoxidase is linear but examination of the raw data in the current study suggests 
this may not be the case and the relationship appears curvilinear. The relationship with 
leukotriene B4 on the other hand does appear to follow a linear trend. It has been shown 
that leukotriene B4 and interleukin 8 are additive in their effect on neutrophil 
recruitment. It may well be therefore that at low levels of interleukin 8, recruitment of 
small numbers of neutrophils leads to release of leukotriene B4 from the activated cell. 
This may thereafter add to the chemoattractant gradient recruiting more cells in a direct 
mamier. However, once interleukin 8 levels exceed 10 nM the inflammatory process 
may become excessive leading to much greater neutrophil recruitment than would be 
expected for the leukotriene B4 concentration (Chapter 3, Figure 3-2 and Figure 3-3). 
This concept would be consistent with the potential curvilinear relationship between 
interleukin 8 and myeloperoxidase and would be consistent with a hierarchical
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organisation of chemoattractants with one superseding the other as inflammation 
increases. Alternatively it is possible that other chemoattractants are involved in samples 
where neutrophil recruitment is excessive and this requires further study.
Studies o f the role of elastase in the inflammatory process are complex. When released 
from the neutrophil this enzyme would be rapidly inhibited by both alpha-1 -antitrypsin 
and, in the airway, more particularly by secretory leukoprotease inhibitor. In vitro 
studies however have indicated that elastase can adversely affect secretory leukoprotease 
inhibitor release by epithelial cells and thus it would be expected that an inverse 
relationship should exist. However, the data indicates that secretory leukoprotease 
inhibitor concentration does not decrease until the elastase activity of the samples is in 
excess of 50 nM. The relationship between secretory leukoprotease inhibitor and 
elastase therefore is not a simple linear one and the data presented here may indicate a 
threshold at which significant interference with epithelial cell metabolism or epithelial 
damage occurs resulting in a reduction in secretory leukoprotease inhibitor secretion. At 
present whether this relationship reflects cause or effect is not known and interpretation 
will have to await intervention studies using specific anti-elastases. If the reduction in 
secretory leukoprotease inhibitor secretion is merely a reflection of the elastase activity 
in the airway, the introduction of an effective anti-elastase would be expected to lead to 
an acute rise in secretory leukoprotease inhibitor concentration. However if significant 
airway cell damage is responsible for the reduction in secretory leukoprotease inhibitor, 
a longer period of repair would be necessary before secretory leukoprotease inhibitor 
concentrations return to normal.
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There is, however, a similar relationship between the elastase activity and inflammation 
in the airway as reflected by leakage of serum albumin. Protein leakage increased only 
when free elastase activity exceeded 50 nM, and further increased as the elastase activity 
rise above 100 nM. The exact mechanism for protein leakage is currently unknown.
Protein leakage has been shown to be increased during exacerbations but to quickly 
resolve with antibiotic therapy (Stockley et al, 1979), and the rapidity of this response 
would suggest that airway leakage is not a direct effect of epithelial cell destruction. In 
vitro work has demonstrated that proteolytic enzymes and charge interactions are 
important in epithelial permeability, and that the leakage may reflect an effect of
Îinflammation on the tight junction between epithelial cells (Peterson et al, 1995), as 
opposed to epithelial cell destruction. In addition more recent studies have shown that 
elastase can proteolyse endothelial cell cadherins (endothelial junction proteins) (Carden 
et al, 1998). The net effect could account for the increased protein leakage and would fit 
with the rapid reversal with treatment. ; 
j
Studies have indicated that increasing neutrophil influx is associated with worse lung
ÎÎfunction in patients with chronic obstructive pulmonary disease (Keatings et al, 1997)
■f(Di Stefano et al, 1998). The current study showed that increased neutrophil influx, 
elastase activity, the chemoattractants interleukin 8 and leukotriene B4, and increased 
protein leak were associated with worse lung function in patients with chronic bronchitis 
without alpha-1-antitrypsin deficiency. However there was no association in the other 
two patient groups (those with alpha-1-antitrypsin deficiency or bronchiectasis). It 
should be noted however that all patients with alpha-1-antitrypsin deficiency had an 
FEVi < 56% predicted which would tend to minimise the range of lung function
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impairment which may explain the lack of association in this group. Clearly further 
studies are required to determine whether this observation in chronic bronchitis 
represents a true cause and effect.
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7.2 Influence of bacterial colonisation
Organisms such as non typeable Haemophilus influenzae are common colonisers of the 
upper respiratory tract, being present in up to 75% of healthy adults (Murphy et al, 
1987). The lower airways of patients with chronic obstructive pulmonary disease are 
also commonly colonised with such bacteria while they are not acutely ill (Murphy et al,
1992)(Monso et al, 1995). The role of this airway bacterial load, however, has been 
uncertain.
The study in chapter 4 examined the effect of bacterial colonisation in patients with 
clri'onic bronchitis in the stable clinical state, to determine whether the bacterial 
colonising load influenced the degree of bronchial inflammation, including whether 
there is a thi’eshold, and whether the bacterial species influenced the degree of bronchial 
inflammation.
In this study, quantitative bacterial cultures have heen used to demonstrate highly 
variable airway bacterial load among patients with chronic bronchitis. Increasing airway 
bacterial load was strongly correlated with the following in airway secretions: 1) 
increasing numbers o f neutrophils (yellow to green sputum and myeloperoxidase); 2) 
increasing concentrations of neutrophil chemoattractants interleukin 8 and leukotriene 
B4; 3) increasing concentrations of active leukocyte elastase; and 4) increasing evidence 
of airway injury (leakage of albumin into the airways). There appeared to be a threshold 
for neutrophil recruitment at > 10  ^colony forming units/ml (colonising bacterial loads 
below this had a similai’ degree of upper airways inflammation to patients that were
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colonised with mixed normal flora or where no pathogen was isolated). Pseudomonas 
aeruginosa provoked a more intense inflammatory response than Haemophilus sp. and 
Moraxella catarrhalis, and was associated with higher concentrations of active 
leukocyte elastase and more severe airway injury. These results, however, indicate that 
the concentration of viable organisms, regardless of the bacterial species, has an 
important influence on airway inflammation in "stable" patients.
It is plausible that airway bacterial load promotes airway inflammation because bacterial 
products may directly initiate and perpetuate lung inflammation through induction of 
local secretion of interleukin 8 (Bedard et al, 1993)(Kliair et al, 1994). In addition, 
alveolar macrophages activated by bacterial phagocytosis may be a source of the 
observed leukotriene B4 (Bigby et al, 1987)(Hubbard et al, 1991). Indirect mechanisms 
may also amplify and perpetuate the neutrophil influx, including: 1) chemoattractants 
and active leukocyte elastase released from neutrophils (Takahashi et al, 1993)(Doerfler 
et al, 1989)(Nakamura et al, 1992); 2) chemotaxis to leukocyte elastase-inhibitor 
complexes (Banda et al, 1988); and 3) chemotaxis to products of local extracellular 
matrix degradation (Senior et al, 1980).
Regai’dless of the mechanistic linlc between airway bacterial load and airway 
inflammation, this data shows that airway inflammation is associated with evidence of 
airway injury. Taken together, the data indicates that persistent bacterial colonisation of 
the airways may not be a benign process in patients with chronic bronchitis, even in the 
absence of an acute deterioration of symptoms.
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The bacterial species that this study isolated are similar to those in other previous studies 
of sputum and lower airway bacteriology. Since Haemophilus species, Streptococcus 
pneumoniae, and Moraxella catarrhalis are normal oropharyngeal commensals, non- 
quantitative sputum cultures potentially leads to confusion because they cannot confirm 
a lower respiratory source for the isolates (Muiphy et al, 1992)(Monso et al, 1995). In 
the present study, quantitative cultures of expectorated sputum removed this imceitainty 
as bacteria that were present at > 10  ^ cfu/ml were strongly associated with evidence of 
airway inflammation.
Further studies of antibacterial intervention are needed in such patients. However, 
published studies of stable patients with bronchiectasis who produce purulent sputum 
have indicated that clinical benefits can be obtained from antibiotic therapy both in the 
short and long term (Hill et al, 1986). It is noted that, for infections of the uroepithelium, 
it has long been standard clinical practice to base therapeutic decisions upon quantitative 
bacterial cultures and enumeration of inflammatory cells in urine specimens. The present 
results suggest that analogous practices with respiratory secretions may improve the 
management of infections of the respiratory epithelium and provide improved indicators 
of the need for antibiotic therapy.
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7.3 Role of aIpha-1-antitrypsin in protection of the airways in the 
stable state
Secretory leukoprotease is thought to be the most critical anti-elastase in the upper 
aiiways (Morrison et al, 1987), whereas alpha-1-antitrypsin is thought to be less 
important, although more critical at the alveolai* level protecting against the development 
of emphysema (Gadek et al, 1981).
The study in chapter 5 investigated the effects of continued smoking and the role of 
alpha-1-antitrypsin in the upper airways by comparing patients with chronic bronchitis 
with and without alpha-1-antitrypsin deficiency. Subjects with alpha-1-antitrypsin 
deficiency (PiZ phenotype) have decreased circulating (about 15-20% normal) 
(Lieberman et al, 1972) and alveolar concentrations of alpha-1-antitrypsin (Gadek et al, 
1981) which is believed to be central to the development of early onset and rapidly 
progressive emphysema (Brantly et al, 1988). 30-40% of patients with alpha-1- 
antitrypsin deficiency have chronic bronchitis (Eriksson, 1965)(Brantly et al, 1988) 
although the nature of the airways inflammation has not been studied in detail.
The current study revealed evidence of upper airways inflammation in patients with 
chronic bronchitis. There was a wide range of neutrophil influx as reflected in the 
myeloperoxidase concentration as a result of die chemoattractants interleukin 8 and 
leukotriene B4, which are thought to play a key role in neutrophil recruitment (Mikami 
et al, 1998). Elastase activity was low even though these samples are laiown to contain 
the enzyme (Stockley et al, 1979) probably due to inhibition by the natural inhibitors
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alpha-1-antitrypsin but particularly secretory leukoprotease inhibitor. Comparison 
between current and ex smokers showed that the only differences were lower interleukin 
8 and myeloperoxidase concentrations in the latter group. This did not reflect differences 
in therapy but the ex smokers had worse lung function which would, if anything, 
increase neutrophil numbers (Keatings et al, 1997)(Di Stefano et al, 1998). Interleukin 8 
has been suggested as the major neutrophil chemoattractant (Richman-Eisenstat et al,
1993) and airways interleukin 8 is increased in healthy smokers (Keatings et al, 1997) 
and subjects with COPD (Keatings et al, 1997) although the effect of smoking cessation 
has not been assessed previously. The cuiTent data indicates that cessation of smoking in 
chronic bronchitis is related to a reduction in airways interleukin 8 concentration which 
in turn would reduce neutrophil recruitment thereby explaining the beneficial effects of 
smoking cessation and progression of lung disease. The effect may be due to loss of 
cigarette smoke stimulation of epithelial production of interleukin 8 (Mio et al, 1997) 
although further studies will be necessary to confirm this.
Secretory leukoprotease inhibitor is believed to be the major inhibitor of elastase in the 
upper airway. However the current data shows that airways inflammation is increased in 
the alpha-1-antitrypsin deficient subjects despite being younger (Meyer et al, 
1996)(Meyer et al, 1998), including a greater proportion of ex-smokers and more being 
on inhaled steroids (Llewellyn-Jones et al, 1996) (all of which would tend to limit the 
degree of inflammation). Myeloperoxidase concentrations were higher, as was the 
chemoattractant leukotriene B4. This suggests that LTB4 may be the major 
chemoattractant responsible for the increased neutrophil migration and is consistent with 
previous findings in bronchoalveolar lavage (Hubbard et al, 1991). The source of the
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LTB4 is uncertain although Hubbard et al. (Hubbard et al, 1991) suggested it was 
released from alveolar' macrophages as a direct effect of uninhibited elastase due to 
alpha-1-antitrypsin deficiency. Indeed in the current study elastase activity was more 
readily detected in the alpha-1-antitrypsin deficient patients irrespective of bacterial 
colonisation and hence would support the suggestion that this may be responsible 
(Hubbard et al, 1991). The elastase activity that was more readily detected in the upper 
airways in alpha-1-antitrypsin deficiency is probably due to the combined effect of the 
lower concentrations of both alpha-1-antitrypsin and secretory leukoprotease inhibitor. 
The mechanisms involved may be complex but free elastase activity can reduce 
secretion of secretory leukoprotease inliibitor (Sallenave et al, 1994) as well as 
increasing permeability of airway cells (Peterson et al, 1995). Despite the latter effect 
which accounts for an increase in alpha-1-antitrypsin “leak” into the lung, the low alpha- 
1-antitrypsin concentrations in these subjects may be critical in determining the overall 
changes suggesting that this inhibitor also has a major role in the airways.
As demonstrated in Chapter 4, bacterial colonisation is clearly related to the degree of 
airways inflammation in patients with chronic bronchitis both with and without alpha-1- 
antutrypsin deficiency suggesting this may not always be a benign situation even though 
the patients were “clinically” stable. Despite airways colonisation, the alpha-1- 
antitrypsin deficient group still had evidence of increased airways inflammation and this 
is likely to be responsible for, or reflect, the mechanisms central to the development of 
severe airflow limitation at an earlier age. It is of importance to note that these changes 
were present in ex smokers and the majority of patients being on inhaled corticosteroids
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and would suggest that measures other than smoking cessation and long term inhaled 
steroids may be critical in stabilising lung disease in these patients.
.li
,
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7.4 Bronchial inflammation in alpha-1-antitrypsin deficiency in 
exacerbations
Alpha-1-antitrypsin has been shown to be an important anti-proteinase in the bronchial 
airways in the stable clinical state. It would also be expected to be of particular 
importance during exacerbations since alpha-1-antitrypsin is also an acute phase protein, 
and this together with increased protein leakage into the airways due to inflammation 
should be important in down-regulating the inflammatory response. Therefore patients 
with alpha-1-antitrypsin deficiency may be susceptible to neutrophil mediated lung 
damage particulaiiy during exacerbations as such patients have both a low baseline 
alpha-1-antitrypsin levels and fail to have an effective acute phase response.
Although basal levels are low in alpha-1-antitrypsin deficiency, acute phase responses 
can be induced by Danazol (Wewers et al, 1986) and Tamoxifen (Wewers et al, 1987). 
This is the first report of the acute phase response in a naturally occurring infection in 
alpha-1-antitrypsin deficiency. The alpha-1-antitrypsin acute phase response was 
minimal peaking on day 3, and falling slowly thereafter. The average increase was 
approximately 40% but the highest concentration (5.5 qM) is still well below normal 
plasma concentrations in the absence of an acute phase response or even the putative 
lung protective threshold of 11 juM (Society, 1995). Thus despite the increase in protein 
leakage into the airway the ability of alpha-1-antitrypsin to modulate the inflammatory 
process is still markedly impaired in alpha-1-antitrypsin deficient subjects.
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In patients with alpha-1-antitrypsin deficiency, elastase activity was present in most of 
the samples at presentation with the exacerbation. The enzyme activity probably reflects 
several factors including increased neutrophil recruitment (as indicated by 
myeloperoxidase), reduced anti-proteinases secretory leukoprotease inhibitor 
concentration and low alpha-1-antitrypsin concentration, despite a small acute phase 
response and increased protein leakage into the airways. In comparison with subjects 
who had normal alpha-1-antitrypsin, patients with alpha-1-antitrypsin deficiency had 
higher mean levels of elastase activity at the start of the exacerbation, reflecting the 
defective anti-proteinase screen.
Within 3 days of antibiotic therapy in the alpha-1-antitrypsin deficient group there was a 
reduction in upper airways inflammation in the gioup as a whole. Sputum colour, 
myeloperoxidase and the chemoattractants all fell, as did the elastase activity and protein 
leakage. The length of time antibiotic therapy is needed and how augmentation therapy 
with alpha-1-antitrypsin replacement therapy modulates the bronchial inflammatory 
response requires further study.
Two weeks after the cessation of therapy the degree of bronchial inflammation was 
similar to the end of treatment with the exception of the rise in leukotriene B4. These 
results are however identical to the patient’s usual clinical state, as confirmed by 
comparison with the results obtained at least 8 weeks prior to the clinical exacerbation. 
In addition this extra data confirms that the change at the start of the exacerbation was 
major and indicated a clear pathological process associated with their clinical 
deterioration.
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Some differences were still observed between the alpha-1-antitrypsin deficient and non 
deficient subjects by day 28 (stable state). These included not only sputum alpha-1- 
antitrypsin (as would be expected) but also myeloperoxidase, elastase activity, and 
leukotriene B4. This suggests that alpha-1-antitrypsin deficiency is associated not only 
with increased inflammation at the start of the exacerbation but also in the stable state 
(this was studied in more detail in chapter 5) demonstrating the importance of alpha-1 - 
antitrypsin in the upper airways both in the stable state and exacerbations.
In conclusion acute exacerbations of chionic bronchitis in subjects with alpha-1- 
antitrypsin deficiency, in the presence of bacteria in secretions, are associated with 
marked neutrophil influx. Although the specific nature of these episodes can only remain 
speculative the poor alpha-1-antitrypsin acute phase response and the brisk response 
following commencement of antibiotic therapy suggests that such episodes are due to 
the bacteria and should be promptly treated to protect the airways tissues. Whether 
alpha-1-antitrypsin deficiency makes patients more susceptible to bacterial colonisation 
of the airways bacteria remains to be determined. However the current study suggests 
that alpha-1-antitrypsin may play a role in modulation of elastase activity in the airway 
during acute exacerbations in deficient subjects. Further studies on the role of 
augmentation therapy with alpha-1-antitrypsin are required.
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7.5 FUTURE STUDIES
1. Studies have highlighted the importance of neutrophils in the pathogenesis of 
clironic bronchitis (Riise et al, 1995) and in particular the degree of neutrophil influx 
has been shown to be related to the severity (Keatings et al, 1997)(Di Stefano et al, 
1998) and rate of progression of airflow obstruction (Stanescu et al, 1996). The role 
of the eosinophils is less clear, but both eosinophils and eosinophil cationic protein 
have also been shown to be increased in patients with chronic bronchitis (Riise et al, 
1995). Whether the eosinophil migration is a non selective migratory response to 
interleukin 8 (Shute, 1994) and leukotriene B4 (Oliveira et al, 1994) is not clear and 
further studies are indicated: assess eosinophil chemotaxis to sputum; investigate the 
contribution of interleukin 8 and leukotriene B4 by inhibiting their activity using a 
monoclonal antibody to interleuldn 8 and a leukotriene B4 receptor antagonist 
(Mikami et al, 1998); measure the specific eosinophil chemoattractants (RANTES 
and Eotaxin) (Walsh et al, 1997).
2. The chemoattractants IL8 and LTB4 have been shown to be important in patients 
with chronic bronchitis. Other chemoattractants, for example C5a, may be important 
particularly where there is excess neutrophil influx and this requires further study. 
This could be clarified by measuring C5a in the samples and determining if 
chemotaxis could be reduced by a specific antibody as has been used for interleukin 
8 (Mikami, 1998).
207
“ r
«
I:
3, It has been well recognised that bacteria can colonise the bronchial tree in patients 
with chronic bronchitis whilst patients are apparently clinically stable. There is 
however little knowledge on how this influences bronchial inflammation, disease 
progression, frequency of exacerbations, or how it affects patients quality of life. 
Long term follow up of a cohort of patients comparing sputum colonisation and 
inflammation with decline in lung function may determine the role of bacteria in this 
process. The study reported in the thesis has highlighted that bacterial loads 
exceeding 10  ^ cfu/ml is associated with significant neutrophil influx. Further studies 
are required to determine whether antibiotic treatment in such patients to decrease 
the bacterial load or eradicate the bacteria will influence bronchial inflammation, 
disease progression, frequency of exacerbations, or affect patients quality of life.
I
4. The increased bronchial inflammation in patients with alpha-1-antitrypsin deficiency 
has highlighted the importance of alpha-1-antitrypsin as an anti-proteinase in the 
airways both in the stable state and during exacerbations. The increased bronchial 
inflammation in the stable state was present despite patients being younger, a greater 
number being on inhaled steroids, and the majority being ex- smokers which would 
all tend to minimise the degree of bronchial inflammation.
IThe therapeutic strategy that may influence this process might include alpha-1- antitrypsin augmentation therapy. A controlled trial with alpha-1-antitrypsin 
replacement therapy is needed to determine whether such an approach can modify 
the progression of both the airways disease and emphysema in such patients, and 
whether this could also modify bacterial colonisation. The increase in alpha-1-
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antitrypsin following therapy may decrease or remove elastase activity, which would 
in turn down regulate the inflammatory response (less interleukin 8 release from 
epithelial cells and less leukotriene B4 release from activated macrophages). In 
addition there may be less elastase to damage the primary host defences and 
therefore bacterial colonisation may be modified by replacement therapy. A study 
monitoring these factors before, during, and after augmentation therapy would 
determine whether this concept is true.
Alpha-1-antitrypsin may be particularly important in exacerbations as alpha-1- 
antitrpsin is an acute phase protein. However in patients with PiZ alpha-1-antitrypsin 
deficiency, such subjects will not have an appropriate alpha-1-antitrypsin acute 
phase response, which likely accounts for the excessive bronchial inflammation seen 
in such patients. Again a controlled trial with alpha-1-antitrypsin replacement 
therapy is needed to determine whether alpha-1-antitrypsin replacement therapy can 
reduce the number of exacerbations or speed the recovery of exacerbations.
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